Gentherm (THRM) 10-K 21 Feb 24 2023 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Feb. 15, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Trading Symbol	THRM
Entity Registrant Name	GENTHERM INCORPORATED
Entity Central Index Key	0000903129
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Common Stock, Shares Outstanding		31,544,181
Entity Shell Company	false
Entity File Number	0-21810
Entity Tax Identification Number	95-4318554
Entity Address, Address Line One	21680 Haggerty Road
Entity Address, City or Town	Northville
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48167
City Area Code	248
Local Phone Number	504-0500
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	MI
Security Exchange Name	NASDAQ
Title of 12(b) Security	Common Stock, no par value
Document Transition Report	false
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Public Float			$ 1,841,068,675
Document Annual Report	true
Auditor Firm Id	42
Auditor Name	ERNST & YOUNG LLP
Auditor Location	Detroit, Michigan
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the proxy statement for the 2024 annual meeting of shareholders are incorporated by reference into Part III of this Annual Report to the extent described herein.
Document Financial Statement Error Correction [Flag]	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 149,673	$ 153,891
Accounts receivable, net	253,579	247,131
Inventory, net	205,892	218,248
Other current assets	78,420	64,597
Total current assets	687,564	683,867
Property and equipment, net	245,234	244,480
Goodwill	104,073	119,774
Other intangible assets, net	66,482	73,933
Operating lease right-of-use assets	27,358	29,945
Deferred income tax assets	81,930	69,840
Other non-current assets	21,730	17,461
Total assets	1,234,371	1,239,300
Current Liabilities:
Accounts payable	215,827	182,225
Current lease liabilities	7,700	7,143
Current maturities of long-term debt	621	2,443
Other current liabilities	100,805	93,814
Total current liabilities	324,953	285,625
Long-term debt, less current maturities	222,217	232,653
Non-current lease liabilities	16,175	20,538
Pension benefit obligation	3,209	3,638
Other non-current liabilities	23,095	24,573
Total liabilities	589,649	567,027
Common Stock:
No par value; 55,000,000 shares authorized 31,542,001 and 33,202,082 issued and outstanding at December 31, 2023 and December 31, 2022, respectively	50,503	122,658
Paid-in capital		5,447
Accumulated other comprehensive loss	(30,160)	(46,489)
Accumulated earnings	624,379	590,657
Total shareholders’ equity	644,722	672,273
Total liabilities and shareholders’ equity	$ 1,234,371	$ 1,239,300

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common Stock, par value
Common Stock, shares authorized	55,000,000	55,000,000
Common Stock, shares issued	31,542,001	33,202,082
Common Stock, shares outstanding	31,542,001	33,202,082

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Product revenues	$ 1,469,076	$ 1,204,656	$ 1,046,150
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Cost of sales	$ 1,117,452	$ 931,006	$ 742,519
Gross margin	351,624	273,650	303,631
Operating expenses:
Net research and development expenses	94,358	85,722	75,214
Selling, general and administrative expenses	155,579	132,693	109,554
Impairment of goodwill	19,509
Restructuring expenses	4,739	637	3,857
Impairment of intangible assets and property and equipment		6,291
Total operating expenses	274,185	225,343	188,625
Operating income	77,439	48,307	115,006
Interest expense, net	(14,641)	(4,294)	(2,758)
Foreign currency (loss) gain	(5,918)	(6,778)	1,487
Other (loss) income	(1,926)	1,147	117
Earnings before income tax	54,954	38,382	113,852
Income tax expense	14,611	13,941	20,418
Net income	$ 40,343	$ 24,441	$ 93,434
Basic earnings per share	$ 1.23	$ 0.74	$ 2.82
Diluted earnings per share	$ 1.22	$ 0.73	$ 2.79
Weighted average number of shares – basic	32,778,055	33,126,202	33,085,732
Weighted average number of shares – diluted	33,066,917	33,503,154	33,509,720

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Comprehensive Income [Abstract]
Net income	$ 40,343	$ 24,441	$ 93,434
Other comprehensive income (loss):
Pension benefit obligations	56	1,826	558
Foreign currency translation adjustments	13,439	(14,081)	(21,551)
Unrealized gain (loss) on foreign currency derivative securities, net of tax	2,834	2,693	(952)
Unrealized (loss) gain on commodity derivative securities, net of tax		(5)	5
Other comprehensive income (loss), net of tax	16,329	(9,567)	(21,940)
Comprehensive income	$ 56,672	$ 14,874	$ 71,494

Consolidated Statements of Chan

Consolidated Statements of Changes In Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Earnings
Beginning Balance at Dec. 31, 2020	$ 586,331	$ 121,073	$ 7,458	$ (14,982)	$ 472,782
Beginning Balance (in shares) at Dec. 31, 2020		32,921,000
Net income	93,434				93,434
Other comprehensive income (loss)	(21,940)			(21,940)
Stock compensation, net	15,981	$ 17,573	(1,592)
Stock compensation, net, shares		327,000
Stock repurchase	(20,000)	$ (20,000)
Stock repurchase (in shares)		(240,000)
Ending Balance at Dec. 31, 2021	653,806	$ 118,646	5,866	(36,922)	566,216
Ending Balance (in shares) at Dec. 31, 2021		33,008,000
Net income	24,441				24,441
Other comprehensive income (loss)	(9,567)			(9,567)
Stock compensation, net	3,593	$ 4,012	(419)
Stock compensation, net, shares		194,000
Ending Balance at Dec. 31, 2022	$ 672,273	$ 122,658	5,447	(46,489)	590,657
Ending Balance (in shares) at Dec. 31, 2022	33,202,082	33,202,000
Net income	$ 40,343				40,343
Other comprehensive income (loss)	16,329			16,329
Stock compensation, net	9,079	$ 9,147	(68)
Stock compensation, net, shares		129,000
Stock repurchase	(93,302)	$ (81,302)	$ (5,379)		(6,621)
Stock repurchase (in shares)		(1,789,000)
Ending Balance at Dec. 31, 2023	$ 644,722	$ 50,503		$ (30,160)	$ 624,379
Ending Balance (in shares) at Dec. 31, 2023	31,542,001	31,542,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating Activities:
Net income	$ 40,343	$ 24,441	$ 93,434
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	50,948	44,394	38,780
Deferred income taxes	(13,072)	(7,322)	(150)
Stock based compensation	11,627	6,599	14,530
Loss on disposition of property and equipment	721	771	973
Impairment of intangible assets and property and equipment		6,291
Impairment of goodwill	19,509
Provisions for inventory	6,867	15,923	2,499
Other	2,920	721	(271)
Changes in assets and liabilities:
Accounts receivable, net	(4,195)	(44,221)	25,099
Inventory	6,907	(40,322)	(42,372)
Other assets	(26,179)	(11,906)	10,307
Accounts payable	31,029	28,314	8,166
Other liabilities	(8,160)	(8,736)	(7,919)
Net cash provided by operating activities	119,265	14,947	143,076
Investing Activities:
Purchases of property and equipment	(37,602)	(39,703)	(38,468)
Proceeds from the sale of property and equipment	391	248	22
Acquisition of businesses, net of cash acquired		(205,487)	(2,827)
Proceeds from deferred purchase price of factored receivables	13,903	5,538
Cost of technology investments	(815)	(495)	(7,557)
Net cash used in investing activities	(24,123)	(239,899)	(48,830)
Financing Activities:
Borrowings on debt	60,000	207,000
Repayments of debt	(72,280)	(13,272)	(153,243)
Proceeds from the exercise of Common Stock options	263	1,670	8,279
Taxes withheld and paid on employees' share-based payment awards	(2,940)	(5,471)	(4,108)
Cash paid for the repurchase of Common Stock	(91,094)		(20,000)
Acquisition contingent consideration payment			(69)
Net cash (used in) provided by financing activities	(106,051)	189,927	(169,141)
Foreign currency effect	6,691	(1,690)	(2,844)
Net decrease in cash and cash equivalents	(4,218)	(36,715)	(77,739)
Cash and cash equivalents at beginning of period	153,891	190,606	268,345
Cash and cash equivalents at end of period	149,673	153,891	190,606
Supplemental disclosure of cash flow information:
Cash paid for taxes	23,273	21,645	14,857
Cash paid for interest	13,242	6,338	2,378
Non-Cash Investing Activities [Abstract]
Period-end balance of accounts payable for property and equipment	7,754	2,526	$ 2,147
Deferred purchase price of receivables factored in the period	$ 13,885	$ 3,769

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2023 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	Except as set forth below, during the three months ended December 31, 2023, none of the Company's directors or Section 16 officers adopted or terminated (i) any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or (ii) any non-Rule 10b5-1 trading arrangement. On December 6, 2023 , Phillip Eyler , our President and Chief Executive Officer and a director of our Board , entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act. The trading plan provides for the sale of up to 134,684 shares of our Common Stock upon the exercise of stock options; such stock options have an expiration date of December 4, 2024 . The trading plan expires on November 29, 2024 or such earlier date when all transactions under the trading plan are completed.
Name	Phillip Eyler
Title	President and Chief Executive Officer and a director of our Board
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Adoption Date	December 6, 2023
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Aggregate Available	134,684
Trd Arr Expiration Date	December 4, 2024

Overview

Overview	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Overview	Note 1 — Overview Gentherm Incorporated, a Michigan corporation, and its consolidated subsidiaries (“Gentherm”, “we”, “us”, “our” or the “Company”) is the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical patient temperature management. Automotive products include variable temperature Climate Control Seats, heated automotive interior systems (including heated seats, steering wheels, armrests and other components), battery performance solutions, cable systems, lumbar and massage comfort solutions, fuel management valves and other valves for brake and engine systems, and other electronic devices. Our automotive products can be found on vehicles manufactured by nearly all the major original equipment manufacturers (“OEMs”) operating in North America and Europe, and several major OEMs in Asia. We operate in locations aligned with our major customers’ product strategies to provide locally enhanced design, integration and production capabilities. Medical products include patient temperature management systems. Our medical products can be found in hospitals throughout the world, primarily in the U.S., China, Germany and Brazil. The Company is also developing a number of new technologies and products that will help enable improvements to existing products, improve health, wellness and patient outcomes and will lead to new product applications for existing and new and adjacent markets.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 — Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Principles of Consolidation The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and those entities in which it has a controlling financial interest. The Company evaluates its relationship with other entities for consolidation and to identify whether such entities are variable interest entities (“VIE”) and to assess whether the Company is the primary beneficiary of such entities. Investments in affiliates in which Gentherm does not have control but does have the ability to exercise significant influence over operating and financial policies are accounted for under the equity method. When Gentherm does not have the ability to exercise significant influence (generally when ownership interest is less than 20 %), investments in affiliates are measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Intercompany transactions and balances between consolidated businesses have been eliminated. Use of Estimates In preparing these consolidated financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements. Business combinations In accordance with ASC Topic 805, “Business Combinations,” acquisitions are recorded using the acquisition method of accounting. The Company includes the operating results of acquired entities from their respective dates of acquisition. The Company recognizes and measures the identifiable assets acquired, liabilities assumed, and any non-controlling interest as of the acquisition date fair value. The excess, if any, of total consideration transferred in a business combination over the fair value of identifiable assets acquired, liabilities assumed and any non-controlling interest is recognized as goodwill. Costs incurred as a result of a business combination other than costs related to the issuance of debt or equity securities are recorded in the period the costs are incurred. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to assets acquired and liabilities assumed with the corresponding offset to goodwill. Segment Reporting The Company has two reportable segments: Automotive and Medical . The Automotive reporting segment is comprised of the results from our global automotive businesses, including the design, development, manufacturing and sales of automotive climate comfort systems, automotive cable systems, battery performance solutions, lumbar and massage comfort solutions, valve systems, and automotive electronic and software systems. The Medical reporting segment is comprised of the results from our patient temperature management business in the medical industry. Patient temperature management includes temperature management systems across multiple product categories addressing the needs of hyper-hypothermia therapy in intensive care, normothermia in surgical procedures and additional warming/cooling therapies utilized in acute and chronic care departments and non-hospital facilities. Revenue Recognition Revenue is recognized from agreements containing enforceable rights and obligations, when promised goods are delivered or services are completed. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from Product revenues. Shipping and handling fees billed to customers are included in Product revenues, while costs of shipping and handling are included in Cost of sales. Automotive Revenues The Company provides production parts to its customers under long-term supply agreements (“LTAs”). The duration of an LTA is generally consistent with the life cycle of a vehicle; however, a LTA does not reach the level of a performance obligation until Gentherm receives either a purchase order and/or a materials release from its customer for a specific number of production parts at a specified price, at which point an enforceable contract exists. Revenue is recognized when control of the production parts has transferred to the customer according to the terms of the contract, which typically occurs when the parts are shipped or delivered to the customer’s premises. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring production parts. Certain LTAs provide for annual price reductions over the production life of the vehicle. Agreements that are determined to provide customers with purchase option discounts that would not be received without entering into the contract are considered to contain a material right (for example, a discount given to a customer that is incremental to the range of discounts typically given to that class of customer). The material right represents a purchase option that provides the customer with the ability to purchase additional production parts at a set price in the future and is accounted for as a separate performance obligation. Under these circumstances, each transfer of production parts under the LTA requires allocation of the purchase price to the production part and the purchase option. As a practical alternative to estimating the standalone selling price of an option, the Company allocates transaction price to the purchase option by reference to the production part volumes expected to be ordered and the consideration expected to be received over the life of the vehicle program. The production part’s relative standalone selling price observed under the LTA is subtracted from the total amount of consideration expected to be received in exchange for transferring of parts under the current contract and the difference is allocated to the purchase option. Revenue from options containing a material right is recognized when the amounts billed to the customer for production parts transferred, under the LTA, is less than the standalone selling price of those production parts. Medical Revenues Revenues from our patient temperature management business unit are generated from the sale of products and equipment. Our medical products and equipment focus on body and blood temperature management. The Company sells medical products and equipment primarily through distributor and group purchasing organization agreements. These agreements allow member participants to the distributor or group purchasing organization to make purchases at discounted prices negotiated by the distributor or group purchasing organization. A rebate is incurred at the point in time a member participant purchases product covered under these types of agreements. Rebates are accounted for as variable consideration, using an expected value, probability weighted approach, based on the level of sales to the distributor and the time lag between the initial sale and the rebate claim in determining the transaction price of a contract. Revenue is recognized at the point in time the medical products or equipment is transferred to the customer. Assets Recognized from the Costs to Obtain a Contract with a Customer The Company has no material contract assets or contract liabilities as of December 31, 2023. The Company recognizes an asset for the incremental costs of obtaining a contract with a customer if the benefits of those costs are expected to be realized for a period greater than one year . Total capitalized costs to obtain a contract were $ 7,305 and $ 2,239 as of December 31, 2023 and 2022, respectively. These amounts are recorded in Other non-current assets and are being amortized into Product revenues over the expected production life of the applicable program. During the year ended December 31, 2023 and 2022 , $ 179 and $ 78 , respectively, was amortized into Product revenues. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of less than 90 days to be cash equivalents. The Company had Cash and cash equivalents of $ 125,251 and $ 108,620 held in foreign jurisdictions as of December 31, 2023 and 2022 , respectively. Concentration of Credit Risk Financial assets, which subject the Company to concentration of credit risk, consist primarily of cash equivalents, short-term investments, accounts receivable and notes receivable. Cash equivalents consist primarily of money market funds managed by major financial services companies. The credit risk for these cash equivalents is considered low. As of December 31, 2023 , the Company’s Automotive customers, Adient and Lear both individually represented 19 % and 17 %, respectively, of the Company’s accounts receivable balance. As of December 31, 2022 , the Company’s Automotive customers, Adient and Lear both individually represented 18 % and 17 %, respectively, of the Company’s accounts receivable balance. Accounts Receivable Accounts receivable are stated at the invoiced amount, less allowance for doubtful accounts for estimated amounts not expected to be collected, and do not bear interest. The Company determines the allowances based on historical write-off experience by industry and regional economic data, current expectations of future credit losses and historical cash discounts. The Company’s accounts receivables are continually assessed for collectability and any allowance is recorded based upon the age of outstanding receivables, historical payment experience and customer creditworthiness. We write-off accounts receivable when they become uncollectible. The allowance for doubtful accounts was $ 1,171 and $ 1,220 as of December 31, 2023 and 2022, respectively. The allowance for doubtful accounts related to accounts receivable and related activity are summarized below: Year Ended December 31, 2023 2022 2021 Balance at beginning of year $ 1,220 $ 1,399 $ 1,161 Charged to costs and expenses 195 1,088 1,066 Currency translation and other 4 — ( 12 ) Deductions from reserves ( 248 ) ( 1,267 ) ( 816 ) Balance at end of year $ 1,171 $ 1,220 $ 1,399 I n the Asia-Pacific region, the Company receives bank notes from certain customers to settle trade receivables. The collection of such bank notes is included in operating cash flows based on the substance of the underlying transactions, which are operating in nature. Bank notes held by the Company are classified as notes receivable within other current assets. The Company may hold such bank notes until maturity, exchange them with suppliers to settle liabilities, or sell them to third-party financial institutions in exchange for cash. Inventory The Company’s inventory is measured at the lower of cost or net realizable value. Raw materials, components and consumables are measured using the weighted average cost method. Work-in-process and finished goods are measured using the first-in first-out method. If the net realizable value expected on the reporting date is below cost, a write-down is recorded to adjust inventory to its net realizable value. We recognize a reserve for obsolete and slow-moving inventories based on estimates of future sales and an inventory item’s capacity to be repurposed for a different use. We consider the number of months' supply on hand based on current planned requirements, uncommitted future projections and historical usage in estimating the inventory reserve. Property and Equipment Property and equipment, including additions and improvements, are recorded at cost less accumulated depreciation. Expenditures for general repairs and maintenance are charged to expense as incurred. When property or equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the accounts. Gains or losses from retirements and disposals are recorded as Operating income or expense. The Company evaluates the recoverability of long-lived assets when events and circumstances indicate that the assets may be impaired and the undiscounted net cash flows estimated to be generated by those assets are less than their carrying value. If the net carrying value exceeds the fair value, an impairment loss exists and is calculated based on either estimated salvage value or estimated orderly liquidation value. Depreciation is computed using the straight-line method. The estimated useful lives of the Company’s Property and equipment are as follows: Asset Category Useful Life Buildings and improvements 1 to 30 years Plant and equipment 10 years Production tooling 2 to 10 years Leasehold improvements Term of lease Information technology 1 to 5 years The Company recognized depreciation expense of $ 42,186 , $ 33,730 and $ 29,622 for the years ended December 31, 2023, 2022 and 2021 , respectively. Tooling The Company incurs costs related to tooling used in the manufacture of products sold to its customers. In some cases, the Company enters into contracts with its customers whereby the Company incurs the costs to design, develop and purchase tooling and is then reimbursed by the customer under a reimbursement contract. Tooling costs that will be reimbursed by customers are included in Other current assets in the accompanying consolidated balance sheets at the lower of accumulated cost or the customer reimbursable amount. As of December 31, 2023 and 2022 , the Company had $ 16,877 and $ 15,267 , respectively, of reimbursable tooling costs capitalized. Company-owned tooling is included in Property and equipment and depreciated over its expected useful life, generally two to ten years . Goodwill and Other Intangible Assets Goodwill and other intangible assets recorded in conjunction with business combinations are based on the Company’s estimate of fair value, as of the date of acquisition. Amortization of other intangible assets is computed using the straight-line method. The fair value and corresponding useful lives for acquired intangible assets are listed below as follows: Asset Category Useful Life Customer relationships 8 to 15 years Technology 5 to 12 years Product development costs 5 to 10 years Trade names Indefinite Software development costs 4 to 5 years Our business strategy largely centers on designing products based upon internally developed and purchased technology, and we protect certain technology with patents that have value to our business strategy. All costs associated with the development and issuance of new patents are expensed as incurred. Such costs are classified as Net research and development expenses in the accompanying consolidated statements of income. Impairments of Other Intangible Assets and Goodwill Goodwill is tested for impairment at least annually as of December 31 and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. In conducting our annual impairment assessment testing, we first perform a qualitative assessment of whether it is more likely than not that a reporting unit’s fair value is less than its carrying amount. If not, no further goodwill impairment testing is performed. If it is more likely than not that a reporting unit’s fair value is less than its carrying amount, or if we elect not to perform a qualitative assessment of a reporting unit, we then compare the fair value of the reporting unit to the related net book value. If the net book value of a reporting unit exceeds its fair value, an impairment loss is measured and recognized. The Company utilizes an income approach to estimate the fair value of a reporting unit and a market valuation approach to further support this analysis (level 3). The income approach is based on projected debt-free cash flow that is discounted to the present value using discount factors that consider the timing and risk of cash flows. We believe that this approach is appropriate because it provides a fair value estimate based on the reporting unit’s expected long-term operating cash flow performance. This approach also mitigates the impact of cyclical trends that occur in our industry. Fair value is estimated using internally developed forecasts, as well as commercial and discount rate assumptions. The discount rate used is the value-weighted average of our estimated cost of equity and of debt (“cost of capital”) derived using both known and estimated customary market metrics. Our weighted average cost of capital is adjusted to reflect risk, if necessary. Other significant assumptions include terminal value growth rates and terminal value margin rates. While there are inherent uncertainties related to the assumptions used and to management’s application of these assumptions to this analysis, we believe that the income approach provides a reasonable estimate of the fair value of a reporting unit. The Company performs its indefinite-lived intangible asset impairment assessment annually as of December 31, and between annual assessments if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. See Note 7, "Goodwill and Other Intangibles," for additional information about the goodwill impairment analysis. Investments in non-consolidated affiliates During 2021, the Company’s Automotive segment invested $ 5,200 for an ownership interest in Carrar Ltd. (“Carrar”), an Israel-based technology developer of advanced thermal management systems for the electric mobility market. In June 2023, the Company made an additional investment in Carrar of $ 500 , totaling $ 5,700 invested in Carrar as of December 31, 2023 . In December 2023, we recorded a non-cash impairment charge of $ 2,900 in Other (loss) income. The Company determined that Carrar is a VIE; however, the Company does not have a controlling financial interest or have the power to direct the activities that most significantly affect the economic performance of the investment. Therefore, the Company has concluded that it is not the primary beneficiary. Gentherm’s investment in Carrar is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer, and is recorded in Other non-current assets. During 2021, the Company’s Automotive segment invested $ 2,357 for an ownership interest in Forciot Oy (“Forciot”), a Finland-based technology developer of sensors for touch, motion and force measurement. Gentherm’s investment in Forciot is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer, and is recorded in Other non-current assets. In December 2021, the Company committed to make a $ 5,000 investment in Autotech Fund III, L.P., pursuant to a limited partnership agreement. As a limited partner, the Company will periodically make capital contributions toward this total commitment amount over the expected ten-year life of the fund. The Company has made contributions totaling approximately $ 810 to the Autotech Fund III, L.P. as of December 31, 2023 . This fund focuses broadly on the automotive industry and compliments the Company’s innovation strategy. Research and Development Expenses Research and development activities are expensed as incurred. Such costs and related reimbursements are classified as Net research and development expenses in the accompanying consolidated statements of income. Leases The Company has operating leases for office, manufacturing and research and development facilities, as well as land leases for certain manufacturing facilities that are accounted for as operating leases. We also have operating leases for office equipment and automobiles. Excluding land leases, our leases have remaining lease terms ranging from less than 1 year to 8 years and may include options to extend the lease. Land leases have remaining lease terms that range from 2 to 39 years and some which specify that the end of the lease term is at the discretion of the lessee. We do not have lease arrangements with related parties. The Company determines whether a contractual arrangement is or contains a lease at inception. Leases that are operating in nature are recognized in Operating lease right-of-use assets, Current lease liabilities and Non-current lease liabilities in the accompanying consolidated balance sheets. Finance leases are included in property and equipment, net, current maturities of long-term debt, and long-term debt on the Company’s consolidated balance sheets. Lease liabilities are measured initially at the present value of the sum of the future minimum rental payments at the commencement date of the lease. Lease payments that will vary in the future due to changes in facts and circumstances are excluded from the calculation of rental payments, unless those variable payments are based on an index or rate. Rental payments are discounted using an incremental borrowing rate, unless there is a rate implicit in the lease agreement. The incremental borrowing rate is based on the Company’s credit rating, determined on a fully collateralized loan basis from information available at commencement date, and the duration of the lease term (the “reference rate”). Judgment is used to assess the importance of risk factor inputs during the computation of the Company’s credit rating. For leases at foreign subsidiaries denominated in U.S. Dollars, a risk premium associated with the borrower subsidiary’s country is added to the reference rate. For significant leases at foreign subsidiaries denominated in a foreign currency, the U.S. Dollar risk free rate with a duration similar to that of the lease term is subtracted from the reference rate and a corresponding foreign currency risk free rate with a duration similar to that of the lease term is added to the reference rate. Operating lease right-of-use assets are measured at the amount of the lease liability, adjusted for prepaid or accrued lease payments, lease incentive received, and initial direct costs incurred, as applicable. Periods covered by an option to extend the lease are initially included in the measurement of an operating lease right-of-use asset and lease liability only when it is reasonably certain we will exercise the option. Gentherm’s lease agreements do not contain residual value guarantees or impose restrictions or covenants on the Company. For all classes of underlying assets, the Company accounts for leases that contain separate lease and non-lease components as containing a single lease component. The Company does not recognize lease right-of-use assets and lease liabilities from leases with an original lease term of 12 months or less and, instead, recognizes rent payments on a straight-line basis over the lease term in the consolidated statements of income. Income Taxes The Company records income tax expense using the liability method which specifies that deferred tax assets and liabilities be measured each year based on the difference between the financial statement and tax base of assets and liabilities at the applicable enacted tax rates. A valuation allowance is provided for deferred tax assets when management considers it more likely than not that the asset will not be realized. At December 31, 2023 and 2022, a valuation allowance has been provided for certain deferred tax assets which the Company has concluded are more likely than not to not be realized. If future annual taxable income were to be significantly less than current and projected levels, there is a risk that certain of our deferred tax assets not already provided for by the valuation allowance would expire prior to utilization. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties related to income tax matters in Income tax expense. Derivative Financial Instruments – Hedge Accounting All derivative instruments are required to be reported on the balance sheet at fair value unless the transactions qualify and are designated as normal purchases or sales. Changes in fair value are reported currently through earnings unless they meet hedge accounting criteria. The Company’s designated hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. The Company accounts for its designated derivative financial instruments as cash flow hedges. For derivative contracts which are designated as a cash flow hedge, the effective portion of the change in the fair value of the derivative contract is recorded to Accumulated other comprehensive loss (“AOCI”) in the accompanying consolidated balance sheets. When the underlying hedge transaction is realized, the gain or loss included in AOCI is recorded into earnings in the accompanying consolidated statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. Any ineffective portion of the gain or loss is recognized in the accompanying consolidated statements of income under Cost of goods sold for foreign currency derivatives and commodity derivatives. These hedging transactions and the respective correlations meet the requirements for hedge accounting. Exposure to fluctuations in interest rates and certain commodity prices are managed by entering into swaps with various counterparties. The Company does not enter into derivative transactions for speculative or trading purposes. As part of the hedging program approval process, Gentherm identifies the specific financial risk which the derivative transaction will minimize, the appropriate hedging instrument to be used to reduce the risk and the correlation between the financial risk and the hedging instrument. Hedge positions, as well as the correlation between the transaction risks and the hedging instruments, are reviewed on an ongoing basis. Earnings per Share Basic earnings per share is computed by dividing net income by the weighted average number of shares of the Company's common stock, no par value ("Common Stock") outstanding during the respective period. The Company’s diluted earnings per share give effect to all potential shares of Common Stock outstanding during a period that do not have an anti-dilutive impact to the calculation. In computing the number of diluted shares outstanding, the treasury stock method is used in order to arrive at a net number of shares created upon the conversion of Common Stock equivalents. Stock Based Compensation Share based payments that involve the issuance of Common Stock to employees, including grants of employee stock options, restricted stock, and time-based and performance-based restricted stock units, are recognized in the consolidated financial statements as compensation expense based upon the fair value on the date of grant. Share based payments that are satisfied only by the payment of cash, such as stock appreciation rights, are accounted for as liabilities. The liability is reported at market value of the vested portion of the underlying units. During each period, the change in the liability is recorded as compensation expense.

New Accounting Pronouncements

New Accounting Pronouncements	12 Months Ended
	Dec. 31, 2023
Accounting Standards Update and Change in Accounting Principle [Abstract]
New Accounting Pronouncements	Note 3 — New Accounting Pronouncements Recently Adopted Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs") issued by the Financial Accounting Standards Board. ASUs effective in 2023 were assessed and determined to be either not applicable or are not expected to have a significant impact on the Company's consolidated financial statements. Recently Issued Accounting Pronouncements Not Yet Adopted Segment Reporting In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures". ASU 2023-07 requires a public entity to disclose, on an annual and interim basis, significant segment expenses that are included within each reported measure of segment profit or loss and regularly reviewed by the chief operating decision maker ("CODM"), the title and position of the CODM, clarification regarding the CODM's use of multiple measures of a segment's profit or loss in assessing segment performance (this must include a measure that is consistent with the measurement principles under GAAP, but may also include additional measures of a segment's profit or loss), and a description of the composition of amounts within an "Other" segment line item. Further, ASU 2023-07 requires that all annual disclosures about a reportable segment's profit or loss and assets currently required by Topic 280 to be provided in interim periods. This update is effective for fiscals years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. ASU 2023-07 should be adopted retrospectively to all periods presented in the financial statements and early adoption is permitted. We are currently in the process of determining the impact the implementation of ASU 2023-07 will have on the Company’s financial statement disclosures. Income Taxes In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". ASU 2023-09 enhances income tax disclosures to further disaggregate the effective tax rate reconciliation and income taxes paid. This update is effective for fiscal years beginning after December 15, 2024. ASU 2023-09 should be adopted prospectively, but retrospective application is permitted. Further, early adoption is permitted. We are currently in the process of determining the impact the implementation of ASU 2023-09 will have on the Company’s financial statement disclosures.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2023
Business Combinations [Abstract]
Acquisitions	Note 4 – Acquisitions Alfmeier Präzision SE On August 1, 2022 , the Company acquired 100 % of the equity interests of Alfmeier Präzision SE (“Alfmeier”), a global leader in automotive lumbar and massage comfort solutions and a leading provider of advanced valve systems technology, integrated electronics and software. The acquisition further expanded the Company's current value proposition beyond thermal to comfort, health, wellness, and energy efficiency and aligned with global consumer demand for expanded offerings in vehicle passenger comfort. The total consideration transferred was $ 170,700 . The results of Alfmeier's operations are reported within the Automotive segment from the acquisition date. The following table provides product revenues and operating income from Alfmeier that are included in our consolidated financial statements for the year ended December 31, 2022, following the August 1, 2022 acquisition date: Year Ended December 31, 2022 Product revenues $ 98,960 Net loss ( 2,675 ) The acquisition was accounted for as a business combination. The following table summarizes the final purchase consideration and estimated fair values of assets acquired and liabilities assumed as of the acquisition date: Initial Allocation Measurement Period Adjustments Final Allocation Purchase price, consideration, net of cash acquired $ 164,887 $ 5,813 $ 170,700 Accounts receivable 24,988 ( 121 ) 24,867 Inventory 36,026 417 36,443 Prepaid expenses and other assets 20,920 ( 74 ) 20,846 Operating lease right-of-use assets 4,608 — 4,608 Property and equipment 89,942 1,242 91,184 Other intangible assets 22,668 8,791 31,459 Goodwill 43,678 ( 9,707 ) 33,971 Assumed liabilities ( 55,994 ) 975 ( 55,019 ) Deferred tax liabilities ( 21,949 ) 4,290 ( 17,659 ) Net assets acquired $ 164,887 $ 5,813 $ 170,700 The following table summarizes the allocation of the purchase consideration to the other intangible assets acquired: Preliminary Fair Value Weighted Average Life (in years) Definite-lived: Customer related $ 19,812 14 Technology 11,647 9 Total $ 31,459 Assets acquired and liabilities assumed were recorded at estimated fair values based on third-party valuations, management’s estimates, available information, and supportable assumptions that management considered reasonable. The fair value of the intangible assets was based on third-party valuations and management’s estimates, generally utilizing income and market approaches. Goodwill recognized in this transaction is primarily attributable to the Company’s expected future economic benefits from combining operations to offer more compelling and high-value solutions across complementary customer relationships as well as expected future synergies. The goodwill is not expected to be deductible for tax purposes. The following unaudited pro forma information represents our product revenues and net income as if the acquisition of Alfmeier had occurred as of January 1, 2021: Year Ended December 31, 2022 2021 Product revenues $ 1,348,295 $ 1,304,505 Net Income 17,645 92,079 Jiangmen Dacheng Medical Equipment Co. Ltd On July 13, 2022 , the Company acquired 100 % of the equity interests of Jiangmen Dacheng Medical Equipment Co. Ltd (“Dacheng”) and its wholly owned subsidiary, IOB Medical, Inc. Dacheng, is a manufacturer of medical materials and medical equipment, including patient temperature management solutions, for numerous local and international customers. The acquisition provided Gentherm Medical a local presence in China’s high-growth market for patient warming devices and other medical device products, and expanded overall manufacturing capacity to include a low-cost manufacturing site. The total consideration was $ 35,048 . The purchase agreement also included potential cash payments contingent upon the achievement of certain performance metrics and continued employment of the former majority shareholder through a series of defined dates. The achievement of these performance metrics resulted in cash payments of $ 500 . These cash payments were accounted for as compensation expense and recorded as a component of Selling, general and administrative expenses ratably over the service period. The results of Dacheng's operations are reported within the Medical segment from the acquisition date. The following table provides product revenues and operating income from Dacheng that are included in our consolidated financial statements for the year ended December 31, 2022, following the July13, 2022 acquisition date: Year Ended December 31, 2022 Product revenues $ 3,499 Net Loss ( 217 ) The acquisition was accounted for as a business combination. The following table summarizes the final purchase consideration and estimated fair values of assets acquired and liabilities assumed as of the acquisition date: Initial Allocation Measurement Period Adjustments Final Allocation Purchase price, cash consideration, net of cash acquired $ 35,048 $ — $ 35,048 Accounts receivable 746 ( 124 ) 622 Inventory 1,942 ( 177 ) 1,765 Prepaid expenses and other assets 152 22 174 Operating lease right-of-use assets 841 — 841 Property and equipment 684 — 684 Other intangible assets 19,094 965 20,059 Goodwill 22,995 ( 3,464 ) 19,531 Assumed liabilities ( 2,799 ) ( 515 ) ( 3,314 ) Deferred tax liabilities ( 8,607 ) 3,293 ( 5,314 ) Net assets acquired $ 35,048 $ — $ 35,048 The following table summarizes the allocation of the purchase consideration to the other intangible assets acquired: Preliminary Fair Value Weighted Average Life (in years) Definite-lived: Customer related $ 12,837 12 Technology 4,749 12 Indefinite-lived: Tradenames 2,473 — Total $ 20,059 Assets acquired and liabilities assumed were recorded at estimated fair values based on third-party valuations, management’s estimates, available information, and supportable assumptions that management considered reasonable. The fair value of the intangible assets was based on third-party valuations and management’s estimates, generally utilizing income and market approaches. Goodwill recognized in this transaction is primarily attributable to the Company’s expected future economic benefits from the enhanced access to high-growth markets including private label opportunities through Dacheng’s innovative patient temperature management devices. The goodwill is not expected to be deductible for tax purposes. The pro forma effects of this acquisition would not materially impact the Company’s reported results for any period presented, and as a result no pro forma financial statements are presented.

Restructuring and Impairments

Restructuring and Impairments	12 Months Ended
	Dec. 31, 2023
Restructuring and Related Activities [Abstract]
Restructuring and Impairments	Note 5 — Restructuring and Impairments The Company continuously monitors market developments, industry trends and changing customer needs and in response, may undertake restructuring actions, as necessary, to execute management’s strategy, streamline operations and optimize the Company’s cost structure. Restructuring actions may include the realignment of existing manufacturing footprint, facility closures, or similar actions, either in the normal course of business or pursuant to significant restructuring programs. These actions may result in employees receiving voluntary or involuntary employee termination benefits, which are mainly statutory requirements or other contractual agreements. Voluntary termination benefits are accrued when an employee accepts the related offer. Involuntary termination benefits are accrued upon the commitment to a termination plan and when the benefit arrangement is communicated to affected employees, or when liabilities are determined to be probable and estimable, depending on the existence of a substantive plan for severance or termination. 2023 Manufacturing Footprint Rationalization On September 19, 2023, the Company committed to a restructuring plan (“2023 Plan”) to improve the Company’s manufacturing productivity and rationalize its footprint. Under this 2023 Plan, the Company will relocate certain existing manufacturing and related activities in its Greenville, South Carolina facility to a new facility in Monterrey, Mexico. The Company expects to incur total costs of between $ 12,000 and $ 16,000 , of which between $ 11,000 and $ 15,000 are expected to be cash expenditures. The total expected costs include employee severance, retention and termination costs of between $ 2,000 and $ 4,000 , capital expenditures of between $ 7,000 and $ 8,000 and non-cash expenses for accelerated depreciation and impairment of fixed assets of approximately $ 1,000 . The Company also expects to incur other transition costs including recruiting, relocation, and machinery and equipment move and set up costs of between $ 2,000 and $ 3,000 . The actions under this 2023 Plan are expected to be substantially completed by the end of 2025. The actual timing, costs and savings of the 2023 Plan may differ materially from the Company’s current expectations and estimates. During the year ended December 31, 2023 , the Company recognized restructuring expense of $ 538 for employee separation costs and $ 159 for other costs. Other Restructuring Activities The Company has undertaken several discrete restructuring actions. During the years ended December 31, 2023, 2022 and 2021 , the Company recognized $ 3,208 , $ 56 and $ 2,192 of employee separation costs, respectively, and $ 834 , $ 581 and $ 1,665 of other related costs, respectively. These restructuring expenses were primarily associated with restructuring actions focused on the rotation of our manufacturing footprint to best cost locations and the reduction of global overhead costs. Restructuring Expenses By Reporting Segment Restructuring expense by reporting segment for the years ended December 31, 2023, 2022 and 2021 was as follows: Year Ended December 31, 2023 2022 2021 Automotive $ 3,187 $ 637 $ 2,793 Medical 363 — — Corporate 1,189 — 1,064 Total $ 4,739 $ 637 $ 3,857 Restructuring Liability The following table summarizes restructuring activity for all restructuring initiatives for the years ended December 31, 2023 and 2022: Employee Separation Costs Other Related Costs Total Balance at December 31, 2021 $ 1,494 $ — $ 1,494 Additions, charged to restructuring expenses 6 581 587 Change in estimate 50 — 50 Cash payments ( 881 ) ( 581 ) ( 1,462 ) Currency translation and other ( 81 ) — ( 81 ) Balance at December 31, 2022 $ 588 $ — $ 588 Additions, charged to restructuring expenses 3,892 993 4,885 Change in estimate ( 146 ) — ( 146 ) Cash payments ( 2,224 ) ( 878 ) ( 3,102 ) Non-cash utilization — ( 115 ) ( 115 ) Currency translation and other 40 — 40 Balance at December 31, 2023 $ 2,150 $ — $ 2,150 Impairments Non-Automotive Electronics Business On December 31, 2022, the Company approved a plan to exit its non-automotive electronics business to strengthen the Company’s core business and focus its resources and equipment with businesses and investments that are more strategic and profitable. As of December 31, 2023, the Company has substantially completed the exit of this business. During the year ended December 31, 2023, the Company recorded non-cash impairment charges of $ 6,064 for the write down of inventory within the Automotive segm ent. This charge is recorded in Cost of sales in the accompanying consolidated statements of income. During the year ended December 31, 2022, the Company recorded non-cash impairment charges of $ 9,378 , $ 5,601 and $ 690 for write downs of inventory, intangible assets and property and equipment, respectively, within the Automotive segment. Write downs of inventory are recorded in Cost of sales and write downs of intangible assets and property and equipment are recorded in Impairment of intangible assets and property and equipment in the accompanying consolidated statements of income. Medical Segment During the three months ended June 30, 2023, the Company determined that there were impairment indicators for its Medical reporting unit and conducted an impairment analysis, following which the Company concluded that $ 19,509 of goodwill was impaired. Such non-cash impairment charge was recorded in Impairment of goodwill in the accompanying consolidated statements of income. See Note 7, "Goodwill and Other Intangibles," for additional information about the goodwill impairment.

Details of Certain Financial St

Details of Certain Financial Statement Components	12 Months Ended
	Dec. 31, 2023
Financial Statement Components [Abstract]
Details of Certain Financial Statement Components	Note 6 — Details of Certain Financial Statement Components December 31, 2023 2022 Inventory: Raw materials, net $ 126,013 $ 136,217 Work in process, net 15,704 17,695 Finished goods, net 64,175 64,336 Total inventory, net $ 205,892 $ 218,248 Other current assets: Notes receivable $ 18,226 $ 12,127 Billable tooling 16,877 15,267 Income tax and other tax receivable 16,017 15,041 Short-term derivative financial instruments 10,717 6,564 Prepaid expenses 7,889 6,239 Receivables due from factor 4,422 5,490 Other 4,272 3,869 Total other current assets $ 78,420 $ 64,597 Property and equipment: Machinery and equipment $ 236,277 $ 214,342 Buildings and improvements 130,374 123,714 Information technology 41,543 39,726 Production tooling 28,033 24,839 Leasehold improvements 12,269 12,271 Construction in progress 27,461 29,023 Total property and equipment 475,957 443,915 Less: accumulated depreciation ( 230,723 ) ( 199,435 ) Total property and equipment, net $ 245,234 $ 244,480 Other current liabilities: Accrued employee liabilities $ 43,176 $ 32,031 Liabilities from discounts and rebates 22,916 26,640 Income tax and other taxes payable 19,327 14,459 Restructuring 2,150 588 Accrued warranty 3,945 2,380 Other 9,291 17,716 Total other current liabilities $ 100,805 $ 93,814

Goodwill and Other Intangibles

Goodwill and Other Intangibles	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangibles	Note 7 — Goodwill and Other Intangibles Goodwill Changes in the carrying amount of goodwill, by reportable segment, for the years ended December 31, 2023 and 2022 were as follows: Automotive Medical Total Balance as of December 31, 2021 $ 37,329 $ 28,704 $ 66,033 Acquisition of Dacheng — 19,016 19,016 Acquisition of Alfmeier 34,494 — 34,494 Currency translation and other 1,246 ( 1,015 ) 231 Balance as of December 31, 2022 $ 73,069 $ 46,705 $ 119,774 Impairment of goodwill — ( 19,509 ) ( 19,509 ) Currency translation and other 3,627 181 3,808 Balance as of December 31, 2023 $ 76,696 $ 27,376 $ 104,073 Other Intangible Assets Other intangible assets and accumulated amortization balances as of December 31, 2023 and 2022 were as follows: Gross Accumulated Net Carrying Definite-lived: Customer relationships $ 115,465 $ ( 73,737 ) $ 41,728 Technology 45,861 ( 29,317 ) 16,544 Product development costs 19,434 ( 19,270 ) 164 Software development 1,007 — 1,007 Indefinite-lived: Tradenames 7,039 — 7,039 Balance as of December 31, 2023 $ 188,806 $ ( 122,324 ) $ 66,482 Gross Accumulated Net Carrying Definite-lived: Customer relationships $ 112,286 $ ( 65,748 ) $ 46,538 Technology 44,745 ( 25,709 ) 19,036 Product development costs 18,774 ( 18,456 ) 318 Software development 1,007 — 1,007 Indefinite-lived: Tradenames 7,034 — 7,034 Balance as of December 31, 2022 $ 183,846 $ ( 109,913 ) $ 73,933 As of December 31, 2022, the estimated fair value of the Medical reporting unit exceeded its carrying value by less than 10 %. During the second quarter of 2023, the Company’s Medical reporting unit did not perform in-line with forecasted results primarily driven by slower than anticipated revenue growth. As a result, an indicator of impairment was identified and the Company performed an interim quantitative assessment as of June 30, 2023. The results of this quantitative analysis indicated the carrying value of the reporting unit exceeded the fair value of the reporting unit, and accordingly an impairment expense was recorded for $ 19,509 . No further impairment was recorded as of December 31, 2023. The Company utilized an income approach to estimate the fair value of the reporting unit and a market valuation approach to further support this analysis (level 3). The income approach was based on projected debt-free cash flow that was discounted to the present value using discount factors that considered the timing and risk of cash flows. Fair value was estimated using internally developed forecasts, as well as commercial and discount rate assumptions. The discount rate used was the value-weighted average of our estimated cost of equity and of debt (“cost of capital”) derived using both known and estimated customary market metrics. Our weighted average cost of capital includes a company specific risk premium to address the risks associated with achieving the projected revenue and profitability growth rates. Other significant assumptions included terminal value growth rates and terminal value margin rates. Our ability to realize the future cash flows used in our calculations is affected by factors such as the success of strategic initiatives, changes in economic conditions, changes in our operating performance and changes in our business strategies. To further support the fair value estimate determined by the income approach, the Company utilized a market valuation approach to estimate the fair value of the Medical reporting unit. The market approach considered historical and anticipated financial metrics of the Medical reporting unit and applied valuation multiples based on recent observed transactions involving companies similar enough to the Medical reporting unit from which to draw meaningful conclusions. On December 31, 2022, the Company approved a plan to exit its non-automotive electronics business, resulting in an impairment of our customer relationships intangible assets of $ 5,601 . See Note 5, " Restructuring and Impairments ," for additional information. In connection with the acquisition of Alfmeier, the Company recorded technology of $ 11,647 and customer relationships of $ 19,812 . These definite-lived assets are being amortized using the straight-line method over their estimated useful lives of approximately 9 years and 14 years , respectively. In connection with the acquisition of Dacheng, the Company recorded technology of $ 4,749 , customer relationships of $ 12,837 , and indefinite-lived tradenames of $ 2,473 . Technology and customer relationships are definite-lived assets that are being amortized using the straight-line method over their estimated useful lives of approximately 12 years for each. A total of $ 8,290 , $ 9,018 , and $ 8,821 in other intangible assets were amortized in 2023, 2022 and 2021, respectively. An estimate of future amortization of other intangible assets, is as follows: 2024 $ 6,991 2025 6,977 2026 6,541 2027 6,454 2028 6,389

Leases

Leases	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Leases	Note 8 — Leases Components of lease expense for the years ended December 31, 2023, 2022 and 2021 were as follows: Year Ended December 31, 2023 2022 2021 Lease cost: Operating lease cost $ 9,606 $ 8,040 $ 8,227 Amortization of ROU assets - finance leases 390 168 — Interest on lease liabilities - finance leases 28 16 — Short-term lease cost 2,651 1,773 1,941 Sublease income — ( 101 ) ( 163 ) Total lease cost $ 12,675 $ 9,896 $ 10,005 Other information related to leases is as follows: Year Ended December 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 9,249 $ 10,381 Operating cash flows for finance leases 81 16 Financing cash flows for finance leases 390 164 Right-of-use lease assets obtained in exchange for lease obligations: Operating leases $ 4,704 $ 15,902 Finance leases — 1,180 December 31, 2023 December 31, 2022 Weighted average remaining lease term: Operating leases 5.6 years 5.7 years Finance leases 1.9 years 2.7 years Weighted average discount rate: Operating leases 4.96 % 4.35 % Finance leases 3.53 % 3.57 % A summary of operating leases as of December 31, 2023, under all non-cancellable operating leases with terms exceeding one year is as follows: 2024 $ 8,533 2025 5,588 2026 3,656 2027 2,027 2028 1,798 2029 or later 5,827 Total future minimum lease payments 27,429 Less imputed interest ( 3,554 ) Total $ 23,875 A summary of finance leases as of December 31, 2023, under all non-cancellable finance leases with terms exceeding one year is as follows: 2024 $ 388 2025 152 2026 70 2027 — Total future minimum lease payments 610 Less imputed interest ( 5 ) Total $ 605

Debt

Debt	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Debt	Note 9 — Debt The following table summarizes the Company’s debt as of December 31, 2023 and 2022: December 31, 2023 2022 Interest Principal Interest Principal Credit Agreement: U.S. Revolving Note (U.S. Dollar denominations) 6.58 % $ 222,000 5.80 % $ 232,000 Other loans 3.90 % 233 3.89 % - 5.21 % 2,011 Finance leases 3.53 % 605 3.57 % 1,085 Total debt 222,838 235,096 Current maturities ( 621 ) ( 2,443 ) Long-term debt, less current maturities $ 222,217 $ 232,653 Credit Agreement On June 10, 2022, the Company entered into a Second Amended and Restated Credit Agreement (the “Second Amended and Restated Credit Agreement”) with a consortium of lenders and Bank of America, N.A. as administrative agent (the “Agent”). The Second Amended and Restated Credit Agreement amended and restated in its entirety the Amended and Restated Credit Agreement dated June 27, 2019, by and among Gentherm, certain of its direct and indirect subsidiaries, the lenders party thereto and the Agent. The Second Amended and Restated Credit Agreement provides for a $ 500,000 secured revolving credit facility (the “Revolving Credit Facility”) (a $ 25,000 increase from the revolving credit facility under the Amended and Restated Credit Agreement), with a $ 50,000 sublimit for swing line loans and a $ 15,000 sublimit for the issuance of standby letters of credit. Any amount of the facility utilized for swing line loans or letters of credit outstanding will reduce the amount available under the Second Amended and Restated Credit Agreement. The Company h ad no out standing letters of credit issued as of December 31, 2023 and 2022. Subject to specified conditions, Gentherm can increase the Revolving Credit Facility or incur secured term loans in an aggregate amount of up to $ 200,000 . The Second Amended and Restated Credit Agreement extended the maturity of the Revolving Credit Facility from June 27, 2024 to June 10, 2027 . The U.S. borrowers and guarantors participating in the Second Amended and Restated Credit Agreement also entered into a Second Amended and Restated Pledge and Security Agreement (the “Second Amended and Restated Security Agreement”). The Second Amended and Restated Security Agreement grants a security interest to the Agent in substantially all of the personal property of the Company and its U.S. subsidiaries designated as borrowers to secure their respective obligations under the Second Amended and Restated Security Agreement, including the stock and membership interests of specified subsidiaries (limited to 66 % of the stock in the case of certain non-U.S. subsidiaries). In addition to the security obligations, all obligations under the Second Amended and Restated Credit Agreement (including all obligations of any U.S. or non-U.S. loan party) are unconditionally guaranteed by certain of Gentherm’s domestic subsidiaries, and the German subsidiary borrowers and certain other foreign subsidiaries guarantee all obligations of the non-U.S. loan parties under the Second Amended and Restated Credit Agreement. The Second Amended and Restated Credit Agreement restricts, among other things, the amount of dividend payments the Company can make to shareholders. The Second Amended and Restated Credit Agreement contains covenants, that, among other things, (i) prohibit or limit the ability of the borrowers and any material subsidiary to incur additional indebtedness, create liens, pay dividends, make certain types of investments (including acquisitions), enter into certain types of transactions with affiliates, prepay other indebtedness, sell assets or enter into certain other transactions outside the ordinary course of business, and (ii) require that Gentherm maintain a minimum Consolidated Interest Coverage Ratio and a maximum Consolidated Net Leverage Ratio (based on consolidated EBITDA for the applicable trailing four fiscal quarters) as of the end of any fiscal quarter. The Second Amended and Restated Credit Agreement also contains customary events of default. As of December 31, 2023, the Company was in compliance with the terms of the Second Amended and Restated Credit Agreement. The Second Amended and Restated Credit Agreement additionally contains customary events of default. Upon the occurrence of an event of default, the amounts outstanding under the Revolving Credit Facility may be accelerated and may become immediately due and payable. Under the Second Amended and Restated Credit Agreement, U.S. Dollar denominated loans bear interest at either a base rate (“Base Rate Loans”) or Term SOFR rate (“Term SOFR Rate Loans”), plus a margin (“Applicable Rate”). The rate for Base Rate Loans is equal to the highest of the Federal Funds Rate plus 0.50 %, Bank of America’s prime rate, or the Term SOFR rate plus 1.00 %. The rate for Term SOFR Rate Loans denominated in U.S. Dollars is equal to the forward-looking Secured Overnight Financing Rate (“SOFR”) term rate administered by the CME with a term of one month. All loans denominated in a currency other than the U.S. Dollar must be Term SOFR Rate Loans. Interest is payable at least quarterly. Additionally, a commitment fee of between 0.175 % to 0.300 %, which will vary based on the Consolidated Net Leverage Ratio, as defined in the Second Amended and Restated Credit Agreement, is payable on the average daily unused amounts under the Revolving Credit Facility. The Applicable Rate varies based on the Consolidated Net Leverage Ratio reported by the Company. As long as the Company is not in default of the terms and conditions of the Second Amended and Restated Credit Agreement, the lowest and highest possible Applicable Rate is 1.125 % and 2.125 %, respectively, for Term SOFR Rate Loans and 0.125 % and 1.125 %, respectively, for Base Rate Loans. Borrowing availability is subject to, among other things, the Company’s compliance with the minimum Consolidated Interest Coverage Ratio and the maximum Consolidated Net Leverage Ratio as of the end of any fiscal quarter. Based upon consolidated EBITDA for the trailing four fiscal quarters calculated for purposes of the Consolidated Net Leverage Ratio, $ 278,000 remained available as of December 31, 2023 for additional borrowings under the Second Amended and Restated Credit Agreement subject to specified conditions that Gentherm currently satisfies. In connection with the Second Amended and Restated Credit Agreement, the Company incurred debt issuance costs of $ 1,520 , which have been capitalized and are amortized into interest expense over the term of the Revolving Credit Facility. In addition, unamortized deferred debt issuance costs of $ 144 were written-off and recognized in Interest expense, net during the twelve months ended December 31, 2022. The scheduled principal maturities of our debt as of December 31, 2023 were as follows: U.S. Other Debt Total 2024 $ — $ 621 $ 621 2025 — 152 152 2026 — 70 70 2027 222,000 — 222,000 2028 — — — Total $ 222,000 $ 843 $ 222,843

Pension and Other Post Retireme

Pension and Other Post Retirement Benefit Plans	12 Months Ended
	Dec. 31, 2023
Retirement Benefits [Abstract]
Pension and Other Post Retirement Benefit Plans	Note 10 — Pension and Other Post Retirement Benefit Plans The Company maintains a U.S. defined benefit pension plan covering its former Chief Executive Officer (“U.S. Plan”) and a German defined benefit pension plan covering certain retired executive employees of the Company’s wholly owned subsidiary, Gentherm GmbH (“German Plan”). The components of net periodic benefit cost for the Company’s defined benefit plans for the years ended December 31, 2023, 2022 and 2021 were as follows: U.S. Plan German Plan Year Ended December 31, Year Ended December 31, 2023 2022 2021 2023 2022 2021 Net periodic benefit cost: Service cost $ — $ — $ — $ — $ — $ — Interest cost 115 56 42 217 92 91 Expected return on plan assets — — — ( 115 ) ( 109 ) ( 120 ) Amortization of prior service cost and actuarial loss — 22 26 23 114 133 Net periodic benefit cost $ 115 $ 78 $ 68 $ 125 $ 97 $ 104 Assumptions: Discount rate 4.65 % 1.80 % 1.20 % 4.10 % 1.08 % 1.06 % Long-term return on assets N/A N/A N/A 3.20 % 2.90 % 2.90 % A reconciliation of the change in benefit obligation and the change in plan assets for the years ended December 31, 2023 and 2022 is as follows: U.S. Plan German Plan As of December 31, As of December 31, 2023 2022 2023 2022 Change in projected benefit obligation: Balance at beginning of year $ 2,811 $ 3,446 $ 5,398 $ 8,102 Interest cost 115 56 217 92 Paid pension distributions ( 342 ) ( 342 ) ( 290 ) ( 281 ) Actuarial loss (gain) 18 ( 349 ) ( 89 ) ( 2,001 ) Exchange rate impact — — 170 ( 514 ) Balance at end of year $ 2,602 $ 2,811 $ 5,406 $ 5,398 Change in plan assets: Balance at beginning of year — — 3,918 4,069 Actual return on plan assets — — 98 89 Contributions — — — — Paid pension distributions — — — — Exchange rate impact — — 129 ( 240 ) Balance at end of year $ — $ — $ 4,145 $ 3,918 Underfunded Status $ ( 2,602 ) $ ( 2,811 ) $ ( 1,261 ) $ ( 1,480 ) Balance sheet classification: Other current liabilities $ ( 357 ) $ ( 342 ) $ ( 297 ) $ ( 314 ) Pension benefit obligation ( 2,245 ) ( 2,469 ) ( 964 ) ( 1,166 ) Accumulated other comprehensive loss (pre-tax): Actuarial losses 223 205 899 965 Assumptions: Discount rate 4.45 % 4.65 % 4.56 % 4.10 % Pre-tax amounts included in AOCI that are expected to be recognized in net periodic benefit cost during the year ended December 31, 2024 are as follows: U.S Plan German Plan Actuarial losses $ — $ 20 The accumulated benefit obligations were as follows: U.S. Plan German Plan As of December 31, As of December 31, 2023 2022 2023 2022 Accumulated benefit obligation $ 2,602 $ 2,811 $ 5,406 $ 5,398 Interest costs are recognized in Selling, general and administrative expenses in the consolidated statements of income and actuarial gains and losses are included the consolidated balance sheets as part of Accumulated other comprehensive loss within shareholders’ equity. Actuarial gains or losses are amortized to Selling, general and administrative expense in the consolidated statements of income based on the average future life of the U.S Plan or German Plan using the corridor method. Prior service cost is included in Selling, general and administrative expenses in the consolidated statements of income. Plan assets – German Plan Plan assets are comprised of Gentherm GmbH’s pension insurance policies and are pledged to the beneficiaries of the German Plan. A market valuation technique, based on observable underlying insurance charges, is used to determine the fair value of the pension plan assets (Level 2). The expected return on plan assets assumption used to calculate Gentherm GmbH’s pension benefit obligation was determined using actual returns realized on plan assets in the prior year. Contributions We do no t expect contribu tions to be paid to the U.S. Plan or the German Plan during the next fiscal year. The schedule of future expected pension payments is as follows: Projected Pension Year U.S Plan German Plan 2024 $ 342 $ 324 2025 342 314 2026 342 303 2027 342 292 2028 342 279 2029-2032 1,368 2,893 Total $ 3,078 $ 4,405 Defined contribution plans The Company also sponsors defined contribution plans for eligible employees. On a discretionary basis, the Company matches a portion of the employee contributions and or makes additional discretionary contributions. Gentherm recognized costs of $ 2,344 , $ 1,984 and $ 1,724 related to contributions to its defined contribution plans during the years ended December 31, 2023, 2022 and 2021 , respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 11 — Commitments and Contingencies Legal and other contingencies The Company may be subject to various legal actions and claims in the ordinary course of its business, including those arising out of breach of contracts, intellectual property rights, environmental matters, regulatory matters and employment-related matters. The Company establishes accruals for matters which it believes that losses are probable and can be reasonably estimated. Although it is not possible to predict with certainty the outcome of these matters, the Company is of the opinion that the ultimate resolution of these matters will not have a material adverse effect on its consolidated results of operations or financial position. Product liability and warranty reserves are recorded separately from legal reserves. Product Liability and Warranty Matters In the event that the Company’s products fail to perform as expected or result in alleged bodily injury or property damage, our products may subject us to warranty claims and product liability. If any of our products are or are alleged to be defective, we may be required to participate in a recall or other corrective action involving such products. The Company maintains liability insurance coverage at levels based on commercial norms and historical claims experience. The Company can provide no assurances that it will not experience material claims in the future or that it will not incur significant costs to defend such claims. The Company accrues warranty obligations for products sold based on management estimates of future failure rates and current claim cost experience, with support from the sales, engineering, quality and legal functions. Using historical information available to the Company, including claims already filed by customers, the warranty accrual is adjusted quarterly to reflect management’s best estimate of future claims. The following is a reconciliation of the changes in accrued warranty costs: Year Ended December 31, 2023 2022 Balance at beginning of year $ 2,380 $ 1,916 Warranty opening balance from acquired entities — 907 Warranty claims paid ( 2,252 ) ( 1,841 ) Warranty expense for products shipped during the current period 3,955 1,584 Adjustments to warranty estimates from prior periods ( 174 ) ( 274 ) Adjustments due to currency translation 36 88 Balance at end of year $ 3,945 $ 2,380 Employees Approximately 33 % of the Company’s workforce are members of industrial trade unions and are employed under the terms of various labor agreements. In 2024, certain agreements will require a vote on the terms of their respective labor contracts.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Earnings per Share	Note 12 — Earnings Per Share Basic earnings per share are computed by dividing net income by the weighted average number of shares of Common Stock outstanding during the period. The Company’s diluted earnings per share give effect to all potential shares of Common Stock outstanding during a period that do not have an anti-dilutive impact to the calculation. In computing the diluted earnings per share, the treasury stock method is used in determining the number of shares assumed to be issued from the exercise of Common Stock equivalents. The following table illustrates earnings per share and the weighted average shares outstanding used in calculating basic and diluted earnings per share: Year Ended December 31, 2023 2022 2021 Net income $ 40,343 $ 24,441 $ 93,434 Basic weighted average shares of Common Stock outstanding 32,778,055 33,126,202 33,085,732 Dilutive effect of stock options, restricted stock awards and restricted stock units 288,862 376,952 423,988 Diluted weighted average shares of Common Stock outstanding 33,066,917 33,503,154 33,509,720 Basic earnings per share $ 1.23 $ 0.74 $ 2.82 Diluted earnings per share $ 1.22 $ 0.73 $ 2.79 See Note 17, "Accounting for Stock Based Compensation," for information about the Company’s different equity incentive plans.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	Note 13 —Financial Instruments Derivative Financial Instruments The Company is exposed to various market risks including, but not limited to, changes in foreign currency exchange rates, changes in interest rates and price fluctuations of certain material commodities such as copper. Market risks for changes in interest rates relate primarily to its debt obligations under the Second Amended and Restated Credit Agreement. Foreign currency exchange risks are attributable to sales to foreign customers and purchases from foreign suppliers not denominated in a location’s functional currency, foreign plant operations, intercompany indebtedness, intercompany investments and include exposures to the Euro, Mexican Peso, Canadian Dollar, Hungarian Forint, North Macedonian Denar, Ukrainian Hryvnia, Japanese Yen, Chinese Renminbi, Korean Won, Czech Koruna and Vietnamese Dong. The Company regularly enters into derivative contracts with the objective of managing its financial and operational exposure arising from these risks by offsetting gains and losses on the underlying exposures with gains and losses on the financial instruments used to hedge them. The decision of whether and when to execute derivative financial instruments, along with the duration of the instrument, may vary from period to period depending on market conditions, the relative costs of the instruments and capacity to hedge. The duration is linked to the timing of the underlying exposure, with the connection between the two being regularly monitored. The Company does not enter into derivative financial instruments for speculative or trading purposes. Some derivative contracts do not qualify for hedge accounting; for other derivative contracts, we elect to not apply hedge accounting. The Company’s designated hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to Accumulated other comprehensive loss in the consolidated balance sheets. When the underlying hedge transaction is realized, the gain or loss included in Accumulated other comprehensive loss is recorded in earnings in the consolidated statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. The Company records the ineffective portion of foreign currency and copper commodity hedging instruments, if any, to Cost of sales, in the consolidated statements of income. Cash flows associated with derivatives are reported in Net cash provided by operating activities in the Company’s consolidated statements of cash flows. The Company uses an income approach to value derivative instruments, analyzing quoted market prices to calculate the forward values and then discounting such forward values to the present value using benchmark rates at commonly quoted intervals for the instrument’s full term. In the second quarter of 2022, the Company entered into a floating-to-fixed interest rate swap agreement with a notional amount of $ 100,000 and a maturity date of July 2025 . This interest rate swap is an undesignated hedge of the Company’s exposure to interest payment fluctuations on a portion of the Revolving Credit Facility borrowings that were drawn for the acquisitions of Alfmeier and Dacheng. The periodic changes in fair value are recognized in Interest expense, net. In the second and third quarter of 2022, the Company entered into forward contracts with a notional amount of $ 128,319 to hedge the foreign currency risk associated with the forecasted purchase of Alfmeier. These contracts matured and were settled in the third quart er of 2022. During the year ended December 31, 2022 the Company recognized expense of $ 3,806 in Foreign currency (loss) gain within the consolidated income statement. Information related to the recurring fair value measurement of derivative financial instruments in the consolidated balance sheet as of December 31, 2023 is as follows: Asset Derivatives Liability Derivatives Fair Value Notional Amount Balance Sheet Fair Balance Sheet Fair Net Asset/ Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Level 2 $ 101,109 Other current assets $ 8,655 Other current liabilities $ — $ 8,655 Derivatives Not Designated as Hedging Instruments Interest rate contracts Level 2 $ 100,000 Other current assets $ 2,062 Other current liabilities $ — $ 2,062 Information related to the recurring fair value measurement of derivative financial instruments in the consolidated balance sheet as of December 31, 2022 is as follows: Asset Derivatives Liability Derivatives Fair Value Notional Amount Balance Sheet Fair Balance Sheet Fair Net Asset/ Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Level 2 $ 40,063 Other current assets $ 3,791 Other current liabilities $ — $ 3,791 Derivatives Not Designated as Hedging Instruments Interest rate contracts Level 2 $ 100,000 Other current assets $ 2,772 Other current liabilities $ — $ 2,772 Information related to the effect of derivative instruments in the consolidated statements of income is as follows: Year Ended December 31, Location 2023 2022 2021 Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Cost of sales – income $ 8,630 $ 1,458 $ 1,609 Other comprehensive (loss) income 3,483 3,496 ( 1,217 ) Total foreign currency derivatives $ 12,113 $ 4,954 $ 392 Commodity derivatives Cost of sales – income $ — $ 19 $ 14 Other comprehensive (loss) income — ( 6 ) 6 Total commodity derivatives $ — $ 13 $ 20 Derivatives Not Designated as Hedging Instruments Foreign currency derivatives Foreign currency (loss) gain $ — $ ( 3,806 ) $ — Total foreign currency derivatives $ — $ ( 3,806 ) $ — Interest rate contracts Interest income (expense), net $ ( 710 ) $ 2,772 $ — Total interest rate derivatives $ ( 710 ) $ 2,772 $ — The Com pany did no t incur any hedge ineffectiveness duri ng the years ended December 31, 2023 and 2022. Accounts Receivable Factoring The Company sells certain customer trade receivables on a non-recourse basis under factoring arrangements with designated financial institutions. The sale of receivables under these agreements is considered an off-balance sheet arrangement to the Company and is accounted for as a true sale and excluded from accounts receivable in the consolidated balance sheets. These factoring arrangements include a deferred purchase price component in which a portion of the purchase price for the receivable is paid by the financial institution in cash upon sale and the remaining portion is recorded as a deferred purchase price receivable and paid at a later date. Deferred purchase price receivables are recorded in Other current assets within the consolidated balance sheets. Cash proceeds received upon the sale of the receivables are included in Net cash provided by operating activities and the cash proceeds received on the deferred purchase price receivables are included in Net cash used in investing activities. All factoring arrangements incorporate customary representations, including representations as to validity of amounts due, completeness of performance obligations and absence of commercial disputes. Receivables factored and availability under receivables factoring agreements balances as of December 31, 2023 and 2022 were as follows: December 31, 2023 2022 Receivables factored and outstanding $ 18,532 $ 19,108 Amount available under the credit limit 5,891 5,034 Collective factoring limit $ 24,423 $ 24,142 Trade receivables sold and factoring fees incurred during the years ended December 31, 2023 and 2022 were as follows: Year Ended December 31, 2023 2022 (a) Trade receivables sold $ 135,116 $ 61,482 Factoring fees incurred 800 180 (a) Represents trade receivables sold and factoring fees incurred since the acquisition of Alfmeier (acquired on August 1, 2022).

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurement	Note 14 — Fair Value Measurement Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on one or more of the following three valuation techniques: Market : This approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. Income : This approach uses valuation techniques to convert future amounts to a single present value amount based on current market expectations. Cost : This approach is based on the amount that would be required to replace the service capacity of an asset (replacement cost). The Company uses the following fair value hierarchy to measure fair value into three broad levels, which are described below: Level 1 : Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2 : Inputs, other than quoted market prices included in Level 1, that are observable either directly or indirectly for the asset or liability. Level 3 : Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. Items Measured at Fair Value on a Recurring Basis Except for derivative financial instruments (see Note 13) and pension plan assets (see Note 10), the Company has no material financial assets and liabilities that are carried at fair value at December 31, 2023 and 2022. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and also considers counterparty credit risk in its assessment of fair value. Items Measured at Fair Value on a Nonrecurring Basis The Company measures certain assets and liabilities at fair value on a non-recurring basis. As these nonrecurring fair value measurements are generally determined using unobservable inputs, these fair value measurements are classified within Level 3 of the fair value hierarchy. The Company utilized a third-party to assist in the Level 3 fair value estimates of other intangible assets, property and equipment, and inventory for recent acquisitions (see Note 4) and goodwill of the Medical reporting unit (see Note 7). The estimated fair values of these assets were based on third-party valuations and management’s estimates, generally utilizing income and market approaches. As of December 31, 2023, and December 31, 2022 , there were no other significant assets or liabilities measured at fair value on a non-recurring basis. Items Not Carried at Fair Value The Company uses an income valuation technique to measure the fair values of its debt instruments by converting amounts of future cash flows to a single present value amount using rates based on current market expectations (Level 2 inputs). As of December 31, 2023, and 2022, the carrying values of the indebtedness under the Company’s Credit Agreement were not materially different than their estimated fair values because the interest rates on variable rate debt approximated rates currently available to the Company (see Note 9). The carrying amounts of financial instruments comprising cash and cash equivalents, short-term investments, accounts receivable, notes receivable and accounts payable approximate fair value because of the short maturities of these instruments.

Equity

Equity	12 Months Ended
	Dec. 31, 2023
Stockholders' Equity Note [Abstract]
Equity	Note 15 — Equity Common Stock The Company is authorized to issue up to 59,991,000 shares, of which 55,000,000 shares shall be Common Stock, without par value, and 4,991,000 shall be Preferred Stock, without par value. As of December 31, 2023 , an aggregate of 31,542,001 shares of its Common Stock were issued and outstanding. As of December 31, 2023, the re are no pref erred stock shares issued or outstanding. The Common Stock is listed on the Nasdaq Global Select Market under the symbol, “THRM”, and has the following rights and privileges: ▪ Voting rights. All shares of the Common Stock have identical rights and privileges. With limited exceptions, holders of common stock are entitled to one vote for each outstanding share of Common Stock held of record by each shareholder on all matters properly submitted for the vote of the Company’s shareholders. ▪ Dividend rights . Subject to applicable law, any contractual restrictions and the rights of the holders of outstanding preferred stock, if any, holders of Common Stock are entitled to receive ratably such dividends and other distributions that the Company’s Board of Directors, in its discretion, declares from time to time. ▪ Liquidation rights . Upon the dissolution, liquidation or winding up of the Company, subject to the rights of the holders of outstanding preferred stock, if any, holders of Common Stock are entitled to receive ratably the assets of the Company available for distribution to the Company’s shareholders in proportion to the number of shares of Common Stock held by each shareholder. ▪ Conversion, Redemption and Preemptive Rights . Holders of Common Stock have no conversion, redemption, sinking fund, preemptive, subscription or similar rights. Stock Repurchase Program In December 2020, the Board of Directors of Gentherm Incorporated (“Board of Directors”) authorized a stock repurchase program (the “2020 Stock Repurchase Program”) to commence upon expiration of the prior stock repurchase program on December 15, 2020. Under the 2020 Stock Repurchase Program, the Company is authorized to repurchase up to $ 150,000 of its issued and outstanding Common Stock over a three-year period, expiring December 15, 2023 . On November 1, 2023, the Board of Directors extended the maturity date of the program from December 15, 2023 to June 30, 2024 . Repurchases may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations. Any such repurchases may be executed using open market purchases, privately negotiated agreements or other transactions. Repurchases may be funded from cash on hand, available borrowings or proceeds from potential debt or other capital markets sources. During the year ended December 31, 2023 , the Company repurchased shares under the 2020 Stock Repurchase Program for $ 92,510 and have a remaining repurchase authorization of $ 37,491 as of December 31, 2023. On November 1, 2023, following the above-noted extension, the Company entered into a Confirmation of Issuer Forward Repurchase Transaction agreement (the “ASR Agreement”) with Bank of America, N.A. (“Bank of America”) that provides for the Company to purchase shares of Common Stock in an aggregate amount of $ 60,000 (the “ASR Repurchase Amount”) under the 2020 Stock Repurchase Program. Under the terms of the ASR Agreement, on November 2, 2023, the Company paid $ 60,000 to Bank of America for an initial purchase of approximately 1.22 million shares of Common Stock, representing 80 % of ASR Repurchase Amount. The final settlement date is scheduled to occur no later than the second quarter of 2024 and may end earlier at the option of Bank of America. As of the final settlement date, Bank of America may be required to deliver additional shares of Common Stock to the Company or the Company may be required to deliver shares of Common Stock to Bank America, such that the Company’s repurchase of Common Stock under the ASR Agreement in aggregate will equal the ASR Repurchase Amount (based on the average of the daily volume-weighted average prices of the Common Stock during the term of the ASR Agreement, less a specified discount). There is no cash requirement as of the final settlement date. The ASR Agreement contains provisions customary for agreements of this type, including the mechanisms to determine the number of shares of Common Stock that will be delivered at settlement, the required timing of delivery of the shares of Common Stock, the circumstances under which Bank of America is permitted to make adjustments to the transaction terms, the circumstances under which the ASR Agreement may be accelerated, extended or terminated early by Bank of America and specified representations and warranties of each party to the other party.

Reclassifications Out of Accumu

Reclassifications Out of Accumulated Other Comprehensive Loss	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Reclassifications Out of Accumulated Other Comprehensive Loss	N ote 16 – Reclassifications Out of Accumulated Other Comprehensive Loss Reclassification adjustments and other activities impacting accumulated other comprehensive income (loss) during the years ended December 31, 2023, 2022 and 2021 are as follows: Defined Foreign Commodity Hedge Derivatives Foreign Total Balance at December 31, 2022 $ ( 1,067 ) $ ( 48,269 ) $ — $ 2,847 $ ( 46,489 ) Other comprehensive income before reclassifications 54 13,125 — 13,086 26,265 Income tax effect of other comprehensive income before reclassifications ( 15 ) 314 — ( 2,770 ) ( 2,471 ) Amounts reclassified from accumulated other comprehensive loss into net income 23 — — ( 9,603 ) a ( 9,580 ) Income taxes reclassified into net income ( 6 ) — — 2,121 2,115 Net current period other comprehensive income 56 13,439 — 2,834 16,329 Balance at December 31, 2023 $ ( 1,011 ) $ ( 34,830 ) $ — $ 5,681 $ ( 30,160 ) (a) The amounts reclassified from Accumulated other comprehensive loss are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instruments on our consolidated statements of income. Defined Foreign Commodity Hedge Derivatives Foreign Total Balance at December 31, 2021 $ ( 2,893 ) $ ( 34,188 ) $ 5 $ 154 $ ( 36,922 ) Other comprehensive income (loss) before reclassifications 2,341 ( 13,786 ) 13 4,954 ( 6,478 ) Income tax effect of other comprehensive income (loss) before reclassifications ( 621 ) ( 295 ) ( 3 ) ( 1,092 ) ( 2,011 ) Amounts reclassified from accumulated other comprehensive loss into net income 137 — ( 19 ) a ( 1,458 ) a ( 1,340 ) Income taxes reclassified into net income ( 31 ) — 4 289 262 Net current period other comprehensive income (loss) 1,826 ( 14,081 ) ( 5 ) 2,693 ( 9,567 ) Balance at December 31, 2022 $ ( 1,067 ) $ ( 48,269 ) $ — $ 2,847 $ ( 46,489 ) (a) The amounts reclassified from Accumulated other comprehensive loss are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instruments on our consolidated statements of income. Defined Benefit Foreign Currency Commodity Hedge Derivatives Foreign Currency Total Balance at December 31, 2020 $ ( 3,451 ) $ ( 12,637 ) $ — $ 1,106 $ ( 14,982 ) Other comprehensive income (loss) before reclassifications 512 ( 21,274 ) 20 392 ( 20,350 ) Income tax effect of other comprehensive income (loss) before reclassifications ( 71 ) ( 277 ) ( 4 ) ( 85 ) ( 437 ) Amounts reclassified from accumulated other comprehensive loss into net income $ 159 — ( 14 ) a ( 1,609 ) a ( 1,464 ) Income taxes reclassified into net income $ ( 42 ) — 3 350 311 Net current period other comprehensive income (loss) 558 ( 21,551 ) 5 ( 952 ) ( 21,940 ) Balance at December 31, 2021 $ ( 2,893 ) $ ( 34,188 ) $ 5 $ 154 $ ( 36,922 ) (a) The amounts reclassified from Accumulated other comprehensive loss are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instruments on our consolidated statements of income. The Company expects all of the existing gains and losses related to foreign currency derivatives reported in Accumulated other comprehensive loss as of December 31, 2023 to be reclassified into earnings during the next twelve months. See Note 13, "Financial Instruments," for additional information about derivative financial instruments and the effects from reclassification to net income.

Accounting for Stock Based Comp

Accounting for Stock Based Compensation	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Accounting for Stock Based Compensation	Note 17 — Accounting for Stock Based Compensation On May 18, 2023 the Company’s shareholders approved the Gentherm Incorporated 2023 Equity Incentive Plan (the “2023 Equity Plan”), covering 3,730,000 shares of the Common Stock, plus the number of shares of Common Stock that, as of the effective date of the 2023 Equity Plan, that were subject to awards granted under the Gentherm Incorporated 2013 Equity Incentive Plan (the “2013 Equity Plan”) and that, on or after the effective date of the 2023 Equity Plan, were forfeited, surrendered, terminated (other than by exercise), cancelled, lapsed or reacquired by the Company prior to vesting, without the delivery of any shares of Common Stock, and otherwise comply with the recycling provisions of the 2013 Equity Plan and 2023 Equity Plan. The 2023 Equity Plan permits the granting of various awards including stock options (including both nonqualified stock options and incentive stock options), stock appreciation rights ("SARs"), restricted stock, restricted stock units ("RSUs"), performance stock units (including performance-based RSUs under the 2013 Equity Plan, "PSUs") and performance units, and other awards to employees, outside directors and consultants and advisors of the Company. As of December 31, 2023 , the Company had an aggregate of 3,683,330 shares of Common Stock available to issue under the 2023 Equity Plan. On May 16, 2013, the Compensation Committee of the Company’s Board of Directors (the “Board”) approved the 2013 Equity Plan. The 2013 Equity Plan permitted the granting of various awards including stock options (including both nonqualified options and incentive options), SARs, restricted stock, RSUs, PSUs and certain other awards to employees, outside directors and consultants and advisors of the Company. During the three-year period ended December 31, 2023 , the Company has outstanding stock options, SARs, restricted stock awards and RSUs to employees, directors and consultants. These awards become available to the recipient upon the satisfaction of a vesting condition, either based on a period of service or based on the performance of a specific achievement. For equity-based awards with a service condition, the requisite service period typically ranges between two to four years for employees and consultants and one year for directors. As of December 31, 2023 , there were 324,977 PSUs outstanding. These awards cliff vest after three-years based on the Company’s achievement of one of four separate performance metrics: a target return on invested capital ratio (“ROIC”), as defined in the award agreement, for a specified fiscal year; a target three-year cumulative Adjusted EBITDA (“Adjusted EBITDA”), as defined in the award agreement; the Company’s relative total shareholder return (“TSR”), as defined in the award agreement, during a specific three-year measurement period; and a target relative revenue growth relative to light vehicle production in the Company's relevant markets ("RRG"), as defined in the award agreement, during a specific three-year measurement period. In each case, awards will be earned at 50 % of the target number of shares for achieving a minimum threshold or up to 200 % of the target number of shares for exceeding the target, with a linear adjustment between threshold and target or between target and stretch performance goals. All other outstanding, unvested equity-based awards were service based. Equity-based award vesting may be accelerated at the discretion of the Board under conditions specified in the 2023 Equity Plan and the 2013 Equity Plan. Under FASB ASC Topic 718, the provisions of the PSUs that vest upon the achievement of relative TSR are considered a market condition, and therefore the effect of that market condition is reflected in the grant date fair value for this portion award. A third party was engaged to complete a Monte Carlo simulation to account for the market condition. That simulation takes into account the beginning stock price of our Common Stock, the expected volatilities for the relative TSR comparator group, the expected volatilities for the Company’s stock price, correlation coefficients, the expected risk-free rate of return and the expected dividend yield of the Company and the comparator group. The single grant-date fair value computed by this valuation method is recognized by the Company in accounting for the awards regardless of the actual future outcome of the relative TSR feature. The grant date fair value of the other PSUs and RSUs are calculated as the closing price of our Common Stock as quoted on Nasdaq on the grant date multiplied by the number of shares subject to the award. Each of ROIC, Adjusted EBITDA and RRG are considered a performance condition and the grant-date fair value for ROIC PSUs, Adjusted EBITDA PSUs and RRG PSUs correspond with management's expectation of the probable outcome of the performance condition as of the grant date. The total recognized and unrecognized stock-based compensation expense is as follows: Stock-Based Compensation Expense 2023 2022 2021 Unrecognized Stock-Based Compensation Expense at December 31, 2023 Remaining Weighted Average Vesting Period RSUs $ 6,216 $ 5,551 $ 4,594 $ 9,124 1.84 PSUs 4,661 954 5,535 9,724 1.97 Restricted Stock 878 888 1,198 437 0.38 SARs ( 128 ) ( 794 ) 2,721 — — Stock options — — 482 — — Total Stock-Based Compensation $ 11,627 $ 6,599 $ 14,530 $ 19,285 1.87 The related deferred tax benefit (expense) for the years ended December 31, 2023, 2022 and 2021 was $ 1,794 , $( 444 ), and $ 2,725 , respectively. If Gentherm were to realize expired share-based payment arrangements, they would be reported as a forfeit in the activity roll forward tables below. RSUs The following table summarizes RSU activity during the years ended December 31, 2023, 2022 and 2021: Unvested Restricted Stock Units Time Vesting Weighted-Average Outstanding at December 31, 2020 208,905 $ 37.26 Granted 93,539 79.79 Vested ( 88,296 ) 38.49 Forfeited ( 20,522 ) 48.76 Outstanding at December 31, 2021 193,626 $ 56.02 Granted 117,507 66.86 Vested ( 95,692 ) 49.85 Forfeited ( 13,863 ) 70.52 Outstanding at December 31, 2022 201,578 $ 64.27 Granted 136,964 58.68 Vested ( 82,695 ) 59.43 Forfeited ( 23,986 ) 59.47 Outstanding at December 31, 2023 231,861 $ 63.19 The total intrinsic value of RSUs vested during the years ended December 31, 2023, 2022 and 2021 was $ 4,915 , $ 4,774 and $ 3,398 , respectively. PSUs The following table summarizes PSU activity during the years ended December 31, 2023, 2022 and 2021: Unvested Performance Stock Units Relative TSR Target Weighted-Average ROIC Target Weighted-Average Adjusted EBITDA Target Shares Weighted-Average RRG Target Shares Weighted-Average Total Outstanding at December 31, 2020 157,918 $ 56.06 157,916 $ 38.58 — $ — — $ — 315,834 Granted 20,626 118.08 40,580 78.98 39,930 79.49 — — 101,136 Performance Adjustment 30,828 69.18 ( 30,830 ) 44.92 — — — — ( 2 ) Vested ( 61,656 ) 69.18 — — — — — — ( 61,656 ) Forfeited ( 16,148 ) 61.10 ( 17,374 ) 44.32 ( 2,454 ) 79.49 — ( 35,976 ) Outstanding at December 31, 2021 131,568 $ 62.09 150,292 $ 47.52 37,476 $ 79.49 — $ — 319,336 Granted 21,324 103.31 42,640 68.63 42,640 68.63 — — 106,604 Performance Adjustment 45,004 57.46 ( 2,258 ) 41.61 — — — — 42,746 Vested ( 90,371 ) 57.46 ( 43,106 ) 41.61 — — — — ( 133,477 ) Forfeited ( 4,724 ) 68.67 ( 6,493 ) 56.87 ( 3,543 ) 75.10 — — ( 14,760 ) Outstanding at December 31, 2022 102,801 $ 65.20 141,075 $ 55.18 76,573 $ 73.66 — $ — 320,449 Granted 30,622 89.87 30,622 59.91 61,255 59.91 30,622 59.91 153,121 Performance Adjustment — — ( 59,928 ) 33.90 — — — — ( 59,928 ) Vested ( 59,928 ) 49.25 — — — — — — ( 59,928 ) Forfeited ( 8,494 ) 75.67 ( 11,618 ) 55.94 ( 7,836 ) 70.95 ( 789 ) 59.91 ( 28,737 ) Outstanding at December 31, 2023 65,001 $ 101.15 100,151 $ 69.55 129,992 $ 67.34 29,833 $ 59.91 324,977 The total intrinsic value of PSUs vested during the years ended December 31, 2023, 2022 and 2021 was $ 2,951 , $ 6,986 and $ 4,265 , respectively. Restricted Stock The following table summarizes restricted stock activity during the years ended December 31, 2023, 2022 and 2021: Unvested Restricted Stock Shares Weighted-Average Outstanding at December 31, 2020 34,906 $ 39.82 Granted 13,742 70.18 Vested ( 37,272 ) 41.70 Forfeited — — Outstanding at December 31, 2021 11,376 $ 70.33 Granted 13,600 73.54 Vested ( 11,376 ) 70.33 Forfeited — — Outstanding at December 31, 2022 13,600 $ 73.54 Granted 17,923 56.96 Vested ( 11,900 ) 73.54 Forfeited ( 1,700 ) 73.54 Outstanding at December 31, 2023 17,923 $ 56.96 The compensation cost associated with restricted stock is estimated on the date of grant using quoted market prices (Level 1 input). The total fair value of restricted stock vested in 2023, 2022 and 2021 was $ 875 , $ 800 and $ 1,554 , respectively. SARs The following table summarizes SARs activity during the years ended December 31, 2023, 2022 and 2021: Stock Appreciation Rights Shares Weighted-Average Weighted-Average Aggregate Outstanding at December 31, 2020 171,600 $ 40.60 2.44 $ 4,224 Granted — — Exercised ( 116,000 ) 40.34 Forfeited — — Outstanding at December 31, 2021 55,600 $ 41.15 1.28 $ 2,544 Granted — — Exercised ( 40,850 ) 42.27 Forfeited — — Outstanding at December 31, 2022 14,750 $ 38.05 1.15 $ 402 Granted — — Exercised ( 12,500 ) 38.05 Forfeited — — Outstanding at December 31, 2023 2,250 $ 38.05 0.15 $ 32 Exercisable at December 31, 2023 2,250 $ 38.05 0.15 $ 32 There have been no SARs granted since the year ended December 31, 2017 and all SARs are currently vested. The total intrinsic value of SARs exercised during the years ended December 31, 2023, 2022 and 2021 was $ 242 , $ 1,348 and $ 4,301 , respectively. Stock Options The following table summarizes stock option activity during the years ended December 31, 2023, 2022 and 2021: Options Shares Weighted-Average Weighted-Average Aggregate Outstanding at December 31, 2020 428,000 $ 37.61 3.20 $ 11,815 Granted — — Exercised ( 215,250 ) 38.46 Forfeited ( 6,000 ) 38.05 Outstanding at December 31, 2021 206,750 $ 36.72 2.60 $ 10,375 Granted — — Exercised ( 44,116 ) 37.87 Forfeited — — Outstanding at December 31, 2022 162,634 $ 36.41 2.68 $ 8,212 Granted — — Exercised ( 6,450 ) 40.79 Forfeited ( 16,500 ) 41.59 Outstanding at December 31, 2023 139,684 $ 35.59 0.90 $ 2,342 Exercisable at December 31, 2023 139,684 $ 35.59 0.90 $ 2,342 There have been no stock options granted since the year ended December 31, 2017 and all stock options are currently vested. The total intrinsic value of stock options exercised during the years ended December 31, 2023, 2022 and 2021 was $ 201 , $ 1,582 and $ 8,269 , respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 18 — Income Taxes The income tax provisions were calculated based upon the following components of earnings before income tax for the years ended December 31, 2023, 2022 and 2021: Year Ended December 31, 2023 2022 2021 Earnings (loss) before income tax: Domestic $ ( 37,222 ) $ ( 34,211 ) $ ( 4,547 ) Foreign 92,176 72,593 118,399 Earnings before income tax $ 54,954 $ 38,382 $ 113,852 The components of the provision for income taxes for the years ended December 31, 2023, 2022 and 2021 are summarized as follows: Year Ended December 31, 2023 2022 2021 Current income tax expense: Federal $ 3,510 $ 3,006 $ 1,944 State and local 414 650 234 Foreign 23,759 17,607 18,390 Total current income tax expense 27,683 21,263 20,568 Deferred income tax (benefit) expense: Federal ( 7,495 ) ( 5,971 ) ( 4,400 ) State and local 444 ( 213 ) ( 91 ) Foreign ( 6,021 ) ( 1,138 ) 4,341 Total deferred (benefit) income tax expense ( 13,072 ) ( 7,322 ) ( 150 ) Total income tax expense $ 14,611 $ 13,941 $ 20,418 As of December 31, 2023 , deferred U.S. income taxes have not been provided on the undistributed earnings of the Company’s foreign subsidiaries since these earnings will not be taxable upon repatriation to the United States. These earnings will be primarily treated as previously taxed income from either the one-time transition tax or global intangible low-taxed income provision, or they will be offset with a 100 % dividend received deduction. However, the Company continues to provide a deferred tax liability for foreign income and withholding tax that will be incurred with respect to the undistributed foreign earnings that are not indefinitely reinvested. The deferred tax assets and deferred tax liabilities and related valuation allowance were comprised of the following as of December 31, 2023 and 2022: December 31, 2023 2022 Deferred tax assets: Net operating losses $ 44,053 $ 43,296 Intangible assets 4,314 4,417 Research and development credits 7,127 7,835 Property and equipment 4,800 6,983 Valuation reserves and accrued liabilities 11,221 8,388 Capitalized Research and Development Costs 23,658 19,087 Stock compensation 3,227 3,051 Defined benefit obligation 1,691 1,265 Inventory 181 6,762 Other credits 8,946 10,296 Other 9,154 790 Total deferred tax asset 118,372 112,170 Valuation allowance ( 35,888 ) ( 36,671 ) Deferred tax liabilities: Unrealized foreign currency exchange gains — ( 2,413 ) Undistributed profits of subsidiary ( 4,609 ) ( 5,981 ) Property and equipment ( 12,627 ) ( 15,423 ) Other ( 1,550 ) ( 3,056 ) Total deferred tax liability ( 18,786 ) ( 26,873 ) Net deferred tax asset $ 63,698 $ 48,626 Reconciliations between the statutory Federal income tax rate and the effective rate of income tax expense for the years ended December 31, 2023, 2022 and 2021 are as follows: Year Ended December 31, 2023 2022 2021 Statutory Federal income tax rate 21.0 % 21.0 % 21.0 % Increase (decrease) resulting from: Change in valuation allowance ( 3.1 )% 6.4 % ( 1.2 )% Effect of different tax rates of foreign jurisdictions 0.9 % ( 4.9 )% ( 5.2 )% Tax credits & deductions related to R&D ( 8.5 )% ( 10.1 )% ( 2.3 )% Goodwill impairment 4.1 % — — Non-deductible expenses 6.8 % 14.9 % 1.7 % Non-deductible expenses related to acquisitions — 7.0 % — Other foreign, state and local taxes 3.5 % 0.7 % 1.6 % Tax impact of foreign income 3.6 % 4.2 % 3.6 % Stock option compensation — ( 3.8 )% ( 2.0 )% Prior year adjustments 0.7 % 1.7 % ( 0.7 )% Other ( 2.4 )% ( 0.8 )% 1.4 % Effective rate 26.6 % 36.3 % 17.9 % The Company has Net Operating Loss (“NOL”) carryforwards as follows: Jurisdiction Amount as of December 31, 2023 Years of Expiration U.S. state income tax $ 51,235 2024 - 2042 Foreign $ 296,334 Never We have NOL carryforwards in various states associated with the benefits of the state dividends received reduction and foreign royalty exclusion. The state NOL carryforwards generally expire at various dates from 2024 to 2042 . We have concluded that there is not sufficient evidence these NOL carryforwards will be utilized, and thus have not recognized the benefit of these NOL carryforwards. At December 31, 2023, certain non-U.S. subsidiaries had NOL carryforwards totaling $ 296,334 which have no expiration date . The Company has a valuation allowance recorded against $ 16,413 of the total non-U.S. subsidiaries’ net operating loss carryforwards as of December 31, 2023. The Company is subject to taxation in the United States and various state and foreign jurisdictions. As of December 31, 2023, the Company was no longer subject to U.S. Federal examinations by tax authorities for tax years before 2020 and was no longer subject to foreign examinations by tax authorities for tax years before 2015. The Company currently benefits from tax holidays in various non-U.S. jurisdictions with expiration dates from 2024 – 2025 . For the years ended December 31, 2023, 2022 and 2021 , income in foreign jurisdictions with such holidays was $ 8,185 , $ 2,414 , and $ 4,721 , respectively. At December 31, 2023, 2022 and 2021, the Company had total unrecognized tax benefits of $ 5,486 , $ 6,185 and $ 5,665 , respectively, all of which, if recognized, would affect the effective income tax rates. The reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Year Ended December 31, 2023 2022 2021 Balance at beginning of year $ 6,185 $ 5,665 $ 4,967 Additions based on tax position related to current year 87 972 1,105 Additions based on tax position related to prior year 347 433 160 Reductions from settlements and statute of limitation expiration ( 1,266 ) ( 610 ) $ ( 312 ) Effect of foreign currency translation 133 ( 275 ) ( 255 ) Balance at end of year $ 5,486 $ 6,185 $ 5,665 The Company classifies income tax-related penalties and net interest as income tax expense. In the years ended December 31, 2023, 2022 and 2021 , income tax related interest and penalties were not material. It is reasonably possible that audit settlements, the conclusions of current examinations or the expiration of the statute of limitations in several jurisdictions could impact the Company’s unrecognized tax benefits.

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2023
Segment Reporting [Abstract]
Segment Reporting	Note 19 — Segment Reporting Segment information is used by management for making operating decisions for the Company. Management evaluates the performance of the Company’s segments based primarily on operating income or loss. The Company’s reportable segments are as follows: ▪ Automotive — the design, development, manufacturing and sales of automotive climate comfort systems, automotive cable systems, battery performance solutions, lumbar and massage comfort solutions, valve systems, and automotive electronic and software systems. ▪ Medical — this segment represents the results from our patient temperature management business within the medical industry. The Corporate category includes unallocated costs related to our corporate headquarter activities, including selling, general and administrative costs and acquisition transaction costs, which do not meet the requirements for being classified as an operating segment. The tables below present segment information about the reported product revenues and operating income of the Company for years ended December 31, 2023, 2022 and 2021. Automotive Medical Corporate Total 2023: Product revenues $ 1,422,952 $ 46,124 $ — $ 1,469,076 Depreciation and amortization 45,845 3,654 1,449 50,948 Operating income (loss) 185,956 ( 22,234 ) ( 86,283 ) 77,439 2022: Product revenues $ 1,161,616 $ 43,040 $ — $ 1,204,656 Depreciation and amortization 39,815 3,344 1,235 44,394 Operating income (loss) 118,433 ( 4,029 ) ( 66,097 ) 48,307 2021: Product revenues $ 1,004,633 $ 41,517 $ — $ 1,046,150 Depreciation and amortization 35,389 2,460 931 38,780 Operating income (loss) 162,994 ( 1,829 ) ( 46,159 ) 115,006 Automotive and Medical segment product revenues by product category for each of the years ended December 31, 2023, 2022 and 2021 are as follows: Year Ended December 31, 2023 2022 2021 Climate Control Seat $ 482,665 $ 426,046 $ 393,816 Seat Heaters 308,588 283,970 270,054 Steering Wheel Heaters 153,943 120,949 102,496 Lumbar and Massage Comfort Solutions (a) 144,923 56,980 — Valve Systems (a) 106,262 41,980 — Automotive Cables 79,993 76,962 84,114 Battery Performance Solutions 75,484 71,907 69,594 Electronics 40,387 44,106 51,648 Other Automotive 30,707 38,716 32,911 Subtotal Automotive segment 1,422,952 1,161,616 1,004,633 Medical segment (a) 46,124 43,040 41,517 Total Company $ 1,469,076 $ 1,204,656 $ 1,046,150 (a) Includes product revenues from acquisitions since their respective acquisition dates (see Note 4). Revenue (based on shipment destination) by geographic area for each of the years ended December 31, 2023, 2022 and 2021 is as follows: Year Ended December 31, 2023 2022 2021 United States $ 537,096 $ 472,468 $ 404,466 China 221,512 183,419 142,816 South Korea 115,854 94,937 93,516 Germany 102,383 75,367 66,929 Czech Republic 69,714 49,293 43,931 Japan 60,879 57,718 63,527 Romania 53,982 47,532 51,367 Mexico 45,733 23,233 18,194 Slovakia 44,946 34,686 30,004 Finland 39,632 33,627 29,325 Other 177,345 132,376 102,075 Total Non-U.S. 931,980 732,188 641,684 Total Company $ 1,469,076 $ 1,204,656 $ 1,046,150 The table below lists the percentage of total product revenues generated from sales to customers which contributed 10% or more to the Company’s total consolidated product revenue for the years ended December 31, 2023, 2022 and 2021: Year Ended December 31, 2023 2022 2021 Lear 15 % 16 % 15 % Adient 13 % 15 % 15 % Property and equipment, net, for each of the geographic areas in which the Company operates as of December 31, 2023 and 2022 is as follows: December 31, Property and equipment, net 2023 2022 Germany $ 46,586 $ 47,342 China 45,429 43,162 Mexico 39,943 31,597 United States 37,413 41,034 North Macedonia 27,675 27,808 Vietnam 21,664 19,808 Czech Republic 11,126 11,381 Hungary 9,097 11,736 Ukraine 5,986 5,077 Other 315 5,535 Total $ 245,234 $ 244,480

Valuation and Qualifying Accoun

Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2023
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Valuation and Qualifying Accounts	SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS For the Years Ended December 31, 2023, 2022 and 2021 (In thousands) Description Balance at Charged to Other Activity Deductions Balance at Allowance for Deferred Income Tax Assets Year Ended December 31, 2021 $ 17,197 $ 357 $ ( 102 ) $ ( 1,362 ) $ 16,090 Year Ended December 31, 2022 16,090 2,482 18,099 a — 36,671 Year Ended December 31, 2023 36,671 ( 1,746 ) 963 — 35,888 Reserve for Inventory Year Ended December 31, 2021 $ 7,141 $ 2,499 $ ( 134 ) $ ( 3,492 ) $ 6,014 Year Ended December 31, 2022 6,014 15,923 ( 133 ) ( 2,558 ) 19,246 Year Ended December 31, 2023 19,246 6,867 3,876 ( 1,972 ) 28,017 (a) Includes amount relates to valuation allowance from acquisitions .

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and those entities in which it has a controlling financial interest. The Company evaluates its relationship with other entities for consolidation and to identify whether such entities are variable interest entities (“VIE”) and to assess whether the Company is the primary beneficiary of such entities. Investments in affiliates in which Gentherm does not have control but does have the ability to exercise significant influence over operating and financial policies are accounted for under the equity method. When Gentherm does not have the ability to exercise significant influence (generally when ownership interest is less than 20 %), investments in affiliates are measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Intercompany transactions and balances between consolidated businesses have been eliminated.
Use of Estimates	Use of Estimates In preparing these consolidated financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements.
Business combinations	Business combinations In accordance with ASC Topic 805, “Business Combinations,” acquisitions are recorded using the acquisition method of accounting. The Company includes the operating results of acquired entities from their respective dates of acquisition. The Company recognizes and measures the identifiable assets acquired, liabilities assumed, and any non-controlling interest as of the acquisition date fair value. The excess, if any, of total consideration transferred in a business combination over the fair value of identifiable assets acquired, liabilities assumed and any non-controlling interest is recognized as goodwill. Costs incurred as a result of a business combination other than costs related to the issuance of debt or equity securities are recorded in the period the costs are incurred. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to assets acquired and liabilities assumed with the corresponding offset to goodwill.
Segment Reporting	Segment Reporting The Company has two reportable segments: Automotive and Medical . The Automotive reporting segment is comprised of the results from our global automotive businesses, including the design, development, manufacturing and sales of automotive climate comfort systems, automotive cable systems, battery performance solutions, lumbar and massage comfort solutions, valve systems, and automotive electronic and software systems. The Medical reporting segment is comprised of the results from our patient temperature management business in the medical industry. Patient temperature management includes temperature management systems across multiple product categories addressing the needs of hyper-hypothermia therapy in intensive care, normothermia in surgical procedures and additional warming/cooling therapies utilized in acute and chronic care departments and non-hospital facilities.
Revenue Recognition	Revenue Recognition Revenue is recognized from agreements containing enforceable rights and obligations, when promised goods are delivered or services are completed. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from Product revenues. Shipping and handling fees billed to customers are included in Product revenues, while costs of shipping and handling are included in Cost of sales. Automotive Revenues The Company provides production parts to its customers under long-term supply agreements (“LTAs”). The duration of an LTA is generally consistent with the life cycle of a vehicle; however, a LTA does not reach the level of a performance obligation until Gentherm receives either a purchase order and/or a materials release from its customer for a specific number of production parts at a specified price, at which point an enforceable contract exists. Revenue is recognized when control of the production parts has transferred to the customer according to the terms of the contract, which typically occurs when the parts are shipped or delivered to the customer’s premises. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring production parts. Certain LTAs provide for annual price reductions over the production life of the vehicle. Agreements that are determined to provide customers with purchase option discounts that would not be received without entering into the contract are considered to contain a material right (for example, a discount given to a customer that is incremental to the range of discounts typically given to that class of customer). The material right represents a purchase option that provides the customer with the ability to purchase additional production parts at a set price in the future and is accounted for as a separate performance obligation. Under these circumstances, each transfer of production parts under the LTA requires allocation of the purchase price to the production part and the purchase option. As a practical alternative to estimating the standalone selling price of an option, the Company allocates transaction price to the purchase option by reference to the production part volumes expected to be ordered and the consideration expected to be received over the life of the vehicle program. The production part’s relative standalone selling price observed under the LTA is subtracted from the total amount of consideration expected to be received in exchange for transferring of parts under the current contract and the difference is allocated to the purchase option. Revenue from options containing a material right is recognized when the amounts billed to the customer for production parts transferred, under the LTA, is less than the standalone selling price of those production parts. Medical Revenues Revenues from our patient temperature management business unit are generated from the sale of products and equipment. Our medical products and equipment focus on body and blood temperature management. The Company sells medical products and equipment primarily through distributor and group purchasing organization agreements. These agreements allow member participants to the distributor or group purchasing organization to make purchases at discounted prices negotiated by the distributor or group purchasing organization. A rebate is incurred at the point in time a member participant purchases product covered under these types of agreements. Rebates are accounted for as variable consideration, using an expected value, probability weighted approach, based on the level of sales to the distributor and the time lag between the initial sale and the rebate claim in determining the transaction price of a contract. Revenue is recognized at the point in time the medical products or equipment is transferred to the customer. Assets Recognized from the Costs to Obtain a Contract with a Customer The Company has no material contract assets or contract liabilities as of December 31, 2023. The Company recognizes an asset for the incremental costs of obtaining a contract with a customer if the benefits of those costs are expected to be realized for a period greater than one year . Total capitalized costs to obtain a contract were $ 7,305 and $ 2,239 as of December 31, 2023 and 2022, respectively. These amounts are recorded in Other non-current assets and are being amortized into Product revenues over the expected production life of the applicable program. During the year ended December 31, 2023 and 2022 , $ 179 and $ 78 , respectively, was amortized into Product revenues.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of less than 90 days to be cash equivalents. The Company had Cash and cash equivalents of $ 125,251 and $ 108,620 held in foreign jurisdictions as of December 31, 2023 and 2022 , respectively.
Concentration of Credit Risk	Concentration of Credit Risk Financial assets, which subject the Company to concentration of credit risk, consist primarily of cash equivalents, short-term investments, accounts receivable and notes receivable. Cash equivalents consist primarily of money market funds managed by major financial services companies. The credit risk for these cash equivalents is considered low. As of December 31, 2023 , the Company’s Automotive customers, Adient and Lear both individually represented 19 % and 17 %, respectively, of the Company’s accounts receivable balance. As of December 31, 2022 , the Company’s Automotive customers, Adient and Lear both individually represented 18 % and 17 %, respectively, of the Company’s accounts receivable balance.
Accounts Receivable	Accounts Receivable Accounts receivable are stated at the invoiced amount, less allowance for doubtful accounts for estimated amounts not expected to be collected, and do not bear interest. The Company determines the allowances based on historical write-off experience by industry and regional economic data, current expectations of future credit losses and historical cash discounts. The Company’s accounts receivables are continually assessed for collectability and any allowance is recorded based upon the age of outstanding receivables, historical payment experience and customer creditworthiness. We write-off accounts receivable when they become uncollectible. The allowance for doubtful accounts was $ 1,171 and $ 1,220 as of December 31, 2023 and 2022, respectively. The allowance for doubtful accounts related to accounts receivable and related activity are summarized below: Year Ended December 31, 2023 2022 2021 Balance at beginning of year $ 1,220 $ 1,399 $ 1,161 Charged to costs and expenses 195 1,088 1,066 Currency translation and other 4 — ( 12 ) Deductions from reserves ( 248 ) ( 1,267 ) ( 816 ) Balance at end of year $ 1,171 $ 1,220 $ 1,399 I n the Asia-Pacific region, the Company receives bank notes from certain customers to settle trade receivables. The collection of such bank notes is included in operating cash flows based on the substance of the underlying transactions, which are operating in nature. Bank notes held by the Company are classified as notes receivable within other current assets. The Company may hold such bank notes until maturity, exchange them with suppliers to settle liabilities, or sell them to third-party financial institutions in exchange for cash.
Inventory	Inventory The Company’s inventory is measured at the lower of cost or net realizable value. Raw materials, components and consumables are measured using the weighted average cost method. Work-in-process and finished goods are measured using the first-in first-out method. If the net realizable value expected on the reporting date is below cost, a write-down is recorded to adjust inventory to its net realizable value. We recognize a reserve for obsolete and slow-moving inventories based on estimates of future sales and an inventory item’s capacity to be repurposed for a different use. We consider the number of months' supply on hand based on current planned requirements, uncommitted future projections and historical usage in estimating the inventory reserve.
Property and Equipment	Property and Equipment Property and equipment, including additions and improvements, are recorded at cost less accumulated depreciation. Expenditures for general repairs and maintenance are charged to expense as incurred. When property or equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the accounts. Gains or losses from retirements and disposals are recorded as Operating income or expense. The Company evaluates the recoverability of long-lived assets when events and circumstances indicate that the assets may be impaired and the undiscounted net cash flows estimated to be generated by those assets are less than their carrying value. If the net carrying value exceeds the fair value, an impairment loss exists and is calculated based on either estimated salvage value or estimated orderly liquidation value. Depreciation is computed using the straight-line method. The estimated useful lives of the Company’s Property and equipment are as follows: Asset Category Useful Life Buildings and improvements 1 to 30 years Plant and equipment 10 years Production tooling 2 to 10 years Leasehold improvements Term of lease Information technology 1 to 5 years The Company recognized depreciation expense of $ 42,186 , $ 33,730 and $ 29,622 for the years ended December 31, 2023, 2022 and 2021 , respectively.
Tooling	Tooling The Company incurs costs related to tooling used in the manufacture of products sold to its customers. In some cases, the Company enters into contracts with its customers whereby the Company incurs the costs to design, develop and purchase tooling and is then reimbursed by the customer under a reimbursement contract. Tooling costs that will be reimbursed by customers are included in Other current assets in the accompanying consolidated balance sheets at the lower of accumulated cost or the customer reimbursable amount. As of December 31, 2023 and 2022 , the Company had $ 16,877 and $ 15,267 , respectively, of reimbursable tooling costs capitalized. Company-owned tooling is included in Property and equipment and depreciated over its expected useful life, generally two to ten years .
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets Goodwill and other intangible assets recorded in conjunction with business combinations are based on the Company’s estimate of fair value, as of the date of acquisition. Amortization of other intangible assets is computed using the straight-line method. The fair value and corresponding useful lives for acquired intangible assets are listed below as follows: Asset Category Useful Life Customer relationships 8 to 15 years Technology 5 to 12 years Product development costs 5 to 10 years Trade names Indefinite Software development costs 4 to 5 years Our business strategy largely centers on designing products based upon internally developed and purchased technology, and we protect certain technology with patents that have value to our business strategy. All costs associated with the development and issuance of new patents are expensed as incurred. Such costs are classified as Net research and development expenses in the accompanying consolidated statements of income.
Impairments of Other Intangible Assets and Goodwill	Impairments of Other Intangible Assets and Goodwill Goodwill is tested for impairment at least annually as of December 31 and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. In conducting our annual impairment assessment testing, we first perform a qualitative assessment of whether it is more likely than not that a reporting unit’s fair value is less than its carrying amount. If not, no further goodwill impairment testing is performed. If it is more likely than not that a reporting unit’s fair value is less than its carrying amount, or if we elect not to perform a qualitative assessment of a reporting unit, we then compare the fair value of the reporting unit to the related net book value. If the net book value of a reporting unit exceeds its fair value, an impairment loss is measured and recognized. The Company utilizes an income approach to estimate the fair value of a reporting unit and a market valuation approach to further support this analysis (level 3). The income approach is based on projected debt-free cash flow that is discounted to the present value using discount factors that consider the timing and risk of cash flows. We believe that this approach is appropriate because it provides a fair value estimate based on the reporting unit’s expected long-term operating cash flow performance. This approach also mitigates the impact of cyclical trends that occur in our industry. Fair value is estimated using internally developed forecasts, as well as commercial and discount rate assumptions. The discount rate used is the value-weighted average of our estimated cost of equity and of debt (“cost of capital”) derived using both known and estimated customary market metrics. Our weighted average cost of capital is adjusted to reflect risk, if necessary. Other significant assumptions include terminal value growth rates and terminal value margin rates. While there are inherent uncertainties related to the assumptions used and to management’s application of these assumptions to this analysis, we believe that the income approach provides a reasonable estimate of the fair value of a reporting unit. The Company performs its indefinite-lived intangible asset impairment assessment annually as of December 31, and between annual assessments if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. See Note 7, "Goodwill and Other Intangibles," for additional information about the goodwill impairment analysis.
Investments in Non-Consolidated Affiliates	Investments in non-consolidated affiliates During 2021, the Company’s Automotive segment invested $ 5,200 for an ownership interest in Carrar Ltd. (“Carrar”), an Israel-based technology developer of advanced thermal management systems for the electric mobility market. In June 2023, the Company made an additional investment in Carrar of $ 500 , totaling $ 5,700 invested in Carrar as of December 31, 2023 . In December 2023, we recorded a non-cash impairment charge of $ 2,900 in Other (loss) income. The Company determined that Carrar is a VIE; however, the Company does not have a controlling financial interest or have the power to direct the activities that most significantly affect the economic performance of the investment. Therefore, the Company has concluded that it is not the primary beneficiary. Gentherm’s investment in Carrar is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer, and is recorded in Other non-current assets. During 2021, the Company’s Automotive segment invested $ 2,357 for an ownership interest in Forciot Oy (“Forciot”), a Finland-based technology developer of sensors for touch, motion and force measurement. Gentherm’s investment in Forciot is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer, and is recorded in Other non-current assets. In December 2021, the Company committed to make a $ 5,000 investment in Autotech Fund III, L.P., pursuant to a limited partnership agreement. As a limited partner, the Company will periodically make capital contributions toward this total commitment amount over the expected ten-year life of the fund. The Company has made contributions totaling approximately $ 810 to the Autotech Fund III, L.P. as of December 31, 2023 . This fund focuses broadly on the automotive industry and compliments the Company’s innovation strategy.
Research and Development Expenses	Research and Development Expenses Research and development activities are expensed as incurred. Such costs and related reimbursements are classified as Net research and development expenses in the accompanying consolidated statements of income.
Leases	Leases The Company has operating leases for office, manufacturing and research and development facilities, as well as land leases for certain manufacturing facilities that are accounted for as operating leases. We also have operating leases for office equipment and automobiles. Excluding land leases, our leases have remaining lease terms ranging from less than 1 year to 8 years and may include options to extend the lease. Land leases have remaining lease terms that range from 2 to 39 years and some which specify that the end of the lease term is at the discretion of the lessee. We do not have lease arrangements with related parties. The Company determines whether a contractual arrangement is or contains a lease at inception. Leases that are operating in nature are recognized in Operating lease right-of-use assets, Current lease liabilities and Non-current lease liabilities in the accompanying consolidated balance sheets. Finance leases are included in property and equipment, net, current maturities of long-term debt, and long-term debt on the Company’s consolidated balance sheets. Lease liabilities are measured initially at the present value of the sum of the future minimum rental payments at the commencement date of the lease. Lease payments that will vary in the future due to changes in facts and circumstances are excluded from the calculation of rental payments, unless those variable payments are based on an index or rate. Rental payments are discounted using an incremental borrowing rate, unless there is a rate implicit in the lease agreement. The incremental borrowing rate is based on the Company’s credit rating, determined on a fully collateralized loan basis from information available at commencement date, and the duration of the lease term (the “reference rate”). Judgment is used to assess the importance of risk factor inputs during the computation of the Company’s credit rating. For leases at foreign subsidiaries denominated in U.S. Dollars, a risk premium associated with the borrower subsidiary’s country is added to the reference rate. For significant leases at foreign subsidiaries denominated in a foreign currency, the U.S. Dollar risk free rate with a duration similar to that of the lease term is subtracted from the reference rate and a corresponding foreign currency risk free rate with a duration similar to that of the lease term is added to the reference rate. Operating lease right-of-use assets are measured at the amount of the lease liability, adjusted for prepaid or accrued lease payments, lease incentive received, and initial direct costs incurred, as applicable. Periods covered by an option to extend the lease are initially included in the measurement of an operating lease right-of-use asset and lease liability only when it is reasonably certain we will exercise the option. Gentherm’s lease agreements do not contain residual value guarantees or impose restrictions or covenants on the Company. For all classes of underlying assets, the Company accounts for leases that contain separate lease and non-lease components as containing a single lease component. The Company does not recognize lease right-of-use assets and lease liabilities from leases with an original lease term of 12 months or less and, instead, recognizes rent payments on a straight-line basis over the lease term in the consolidated statements of income.
Income Taxes	Income Taxes The Company records income tax expense using the liability method which specifies that deferred tax assets and liabilities be measured each year based on the difference between the financial statement and tax base of assets and liabilities at the applicable enacted tax rates. A valuation allowance is provided for deferred tax assets when management considers it more likely than not that the asset will not be realized. At December 31, 2023 and 2022, a valuation allowance has been provided for certain deferred tax assets which the Company has concluded are more likely than not to not be realized. If future annual taxable income were to be significantly less than current and projected levels, there is a risk that certain of our deferred tax assets not already provided for by the valuation allowance would expire prior to utilization. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties related to income tax matters in Income tax expense.
Derivative Financial Instruments - Hedge Accounting	Derivative Financial Instruments – Hedge Accounting All derivative instruments are required to be reported on the balance sheet at fair value unless the transactions qualify and are designated as normal purchases or sales. Changes in fair value are reported currently through earnings unless they meet hedge accounting criteria. The Company’s designated hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. The Company accounts for its designated derivative financial instruments as cash flow hedges. For derivative contracts which are designated as a cash flow hedge, the effective portion of the change in the fair value of the derivative contract is recorded to Accumulated other comprehensive loss (“AOCI”) in the accompanying consolidated balance sheets. When the underlying hedge transaction is realized, the gain or loss included in AOCI is recorded into earnings in the accompanying consolidated statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. Any ineffective portion of the gain or loss is recognized in the accompanying consolidated statements of income under Cost of goods sold for foreign currency derivatives and commodity derivatives. These hedging transactions and the respective correlations meet the requirements for hedge accounting. Exposure to fluctuations in interest rates and certain commodity prices are managed by entering into swaps with various counterparties. The Company does not enter into derivative transactions for speculative or trading purposes. As part of the hedging program approval process, Gentherm identifies the specific financial risk which the derivative transaction will minimize, the appropriate hedging instrument to be used to reduce the risk and the correlation between the financial risk and the hedging instrument. Hedge positions, as well as the correlation between the transaction risks and the hedging instruments, are reviewed on an ongoing basis.
Earnings Per Share	Earnings per Share Basic earnings per share is computed by dividing net income by the weighted average number of shares of the Company's common stock, no par value ("Common Stock") outstanding during the respective period. The Company’s diluted earnings per share give effect to all potential shares of Common Stock outstanding during a period that do not have an anti-dilutive impact to the calculation. In computing the number of diluted shares outstanding, the treasury stock method is used in order to arrive at a net number of shares created upon the conversion of Common Stock equivalents.
Stock Based Compensation	Stock Based Compensation Share based payments that involve the issuance of Common Stock to employees, including grants of employee stock options, restricted stock, and time-based and performance-based restricted stock units, are recognized in the consolidated financial statements as compensation expense based upon the fair value on the date of grant. Share based payments that are satisfied only by the payment of cash, such as stock appreciation rights, are accounted for as liabilities. The liability is reported at market value of the vested portion of the underlying units. During each period, the change in the liability is recorded as compensation expense.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs") issued by the Financial Accounting Standards Board. ASUs effective in 2023 were assessed and determined to be either not applicable or are not expected to have a significant impact on the Company's consolidated financial statements.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted Segment Reporting In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures". ASU 2023-07 requires a public entity to disclose, on an annual and interim basis, significant segment expenses that are included within each reported measure of segment profit or loss and regularly reviewed by the chief operating decision maker ("CODM"), the title and position of the CODM, clarification regarding the CODM's use of multiple measures of a segment's profit or loss in assessing segment performance (this must include a measure that is consistent with the measurement principles under GAAP, but may also include additional measures of a segment's profit or loss), and a description of the composition of amounts within an "Other" segment line item. Further, ASU 2023-07 requires that all annual disclosures about a reportable segment's profit or loss and assets currently required by Topic 280 to be provided in interim periods. This update is effective for fiscals years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. ASU 2023-07 should be adopted retrospectively to all periods presented in the financial statements and early adoption is permitted. We are currently in the process of determining the impact the implementation of ASU 2023-07 will have on the Company’s financial statement disclosures. Income Taxes In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". ASU 2023-09 enhances income tax disclosures to further disaggregate the effective tax rate reconciliation and income taxes paid. This update is effective for fiscal years beginning after December 15, 2024. ASU 2023-09 should be adopted prospectively, but retrospective application is permitted. Further, early adoption is permitted. We are currently in the process of determining the impact the implementation of ASU 2023-09 will have on the Company’s financial statement disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Summary of Allowance for Doubtful Accounts	The allowance for doubtful accounts related to accounts receivable and related activity are summarized below: Year Ended December 31, 2023 2022 2021 Balance at beginning of year $ 1,220 $ 1,399 $ 1,161 Charged to costs and expenses 195 1,088 1,066 Currency translation and other 4 — ( 12 ) Deductions from reserves ( 248 ) ( 1,267 ) ( 816 ) Balance at end of year $ 1,171 $ 1,220 $ 1,399 I
Estimated Useful Lives of Property and Equipment	Depreciation is computed using the straight-line method. The estimated useful lives of the Company’s Property and equipment are as follows: Asset Category Useful Life Buildings and improvements 1 to 30 years Plant and equipment 10 years Production tooling 2 to 10 years Leasehold improvements Term of lease Information technology 1 to 5 years
Fair Value and Corresponding Useful Lives for Acquired Intangibles Assets	Amortization of other intangible assets is computed using the straight-line method. The fair value and corresponding useful lives for acquired intangible assets are listed below as follows: Asset Category Useful Life Customer relationships 8 to 15 years Technology 5 to 12 years Product development costs 5 to 10 years Trade names Indefinite Software development costs 4 to 5 years

Restructuring and Impairments (

Restructuring and Impairments (Tables)	12 Months Ended
	Dec. 31, 2023
Restructuring and Related Activities [Abstract]
Summary of Restructuring Expense by Reportable Segment	Restructuring expense by reporting segment for the years ended December 31, 2023, 2022 and 2021 was as follows: Year Ended December 31, 2023 2022 2021 Automotive $ 3,187 $ 637 $ 2,793 Medical 363 — — Corporate 1,189 — 1,064 Total $ 4,739 $ 637 $ 3,857
Summary of Restructuring Activity for All Restructuring Initiatives	The following table summarizes restructuring activity for all restructuring initiatives for the years ended December 31, 2023 and 2022: Employee Separation Costs Other Related Costs Total Balance at December 31, 2021 $ 1,494 $ — $ 1,494 Additions, charged to restructuring expenses 6 581 587 Change in estimate 50 — 50 Cash payments ( 881 ) ( 581 ) ( 1,462 ) Currency translation and other ( 81 ) — ( 81 ) Balance at December 31, 2022 $ 588 $ — $ 588 Additions, charged to restructuring expenses 3,892 993 4,885 Change in estimate ( 146 ) — ( 146 ) Cash payments ( 2,224 ) ( 878 ) ( 3,102 ) Non-cash utilization — ( 115 ) ( 115 ) Currency translation and other 40 — 40 Balance at December 31, 2023 $ 2,150 $ — $ 2,150

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2023
Alfmeier
Business Acquisition [Line Items]
Summary of Product Revenues and Operating Income	The following table provides product revenues and operating income from Alfmeier that are included in our consolidated financial statements for the year ended December 31, 2022, following the August 1, 2022 acquisition date: Year Ended December 31, 2022 Product revenues $ 98,960 Net loss ( 2,675 )
Summary of Final Purchase Consideration And Estimated Fair Values Of Assets Acquired And Liabilities Assumed	The following table summarizes the final purchase consideration and estimated fair values of assets acquired and liabilities assumed as of the acquisition date: Initial Allocation Measurement Period Adjustments Final Allocation Purchase price, consideration, net of cash acquired $ 164,887 $ 5,813 $ 170,700 Accounts receivable 24,988 ( 121 ) 24,867 Inventory 36,026 417 36,443 Prepaid expenses and other assets 20,920 ( 74 ) 20,846 Operating lease right-of-use assets 4,608 — 4,608 Property and equipment 89,942 1,242 91,184 Other intangible assets 22,668 8,791 31,459 Goodwill 43,678 ( 9,707 ) 33,971 Assumed liabilities ( 55,994 ) 975 ( 55,019 ) Deferred tax liabilities ( 21,949 ) 4,290 ( 17,659 ) Net assets acquired $ 164,887 $ 5,813 $ 170,700
Summary of Allocation of Purchase Consideration to Other Intangible Assets Acquired	The following table summarizes the allocation of the purchase consideration to the other intangible assets acquired: Preliminary Fair Value Weighted Average Life (in years) Definite-lived: Customer related $ 19,812 14 Technology 11,647 9 Total $ 31,459
Summary of Unaudited Pro Forma Information	The following unaudited pro forma information represents our product revenues and net income as if the acquisition of Alfmeier had occurred as of January 1, 2021: Year Ended December 31, 2022 2021 Product revenues $ 1,348,295 $ 1,304,505 Net Income 17,645 92,079
Dacheng
Business Acquisition [Line Items]
Summary of Product Revenues and Operating Income	The results of Dacheng's operations are reported within the Medical segment from the acquisition date. The following table provides product revenues and operating income from Dacheng that are included in our consolidated financial statements for the year ended December 31, 2022, following the July13, 2022 acquisition date: Year Ended December 31, 2022 Product revenues $ 3,499 Net Loss ( 217 )
Summary of Final Purchase Consideration And Estimated Fair Values Of Assets Acquired And Liabilities Assumed	The following table summarizes the final purchase consideration and estimated fair values of assets acquired and liabilities assumed as of the acquisition date: Initial Allocation Measurement Period Adjustments Final Allocation Purchase price, cash consideration, net of cash acquired $ 35,048 $ — $ 35,048 Accounts receivable 746 ( 124 ) 622 Inventory 1,942 ( 177 ) 1,765 Prepaid expenses and other assets 152 22 174 Operating lease right-of-use assets 841 — 841 Property and equipment 684 — 684 Other intangible assets 19,094 965 20,059 Goodwill 22,995 ( 3,464 ) 19,531 Assumed liabilities ( 2,799 ) ( 515 ) ( 3,314 ) Deferred tax liabilities ( 8,607 ) 3,293 ( 5,314 ) Net assets acquired $ 35,048 $ — $ 35,048
Summary of Allocation of Purchase Consideration to Other Intangible Assets Acquired	The following table summarizes the allocation of the purchase consideration to the other intangible assets acquired: Preliminary Fair Value Weighted Average Life (in years) Definite-lived: Customer related $ 12,837 12 Technology 4,749 12 Indefinite-lived: Tradenames 2,473 — Total $ 20,059

Details of Certain Financial _2

Details of Certain Financial Statement Components (Tables)	12 Months Ended
	Dec. 31, 2023
Financial Statement Components [Abstract]
Details of Certain Financial Statement Components	December 31, 2023 2022 Inventory: Raw materials, net $ 126,013 $ 136,217 Work in process, net 15,704 17,695 Finished goods, net 64,175 64,336 Total inventory, net $ 205,892 $ 218,248 Other current assets: Notes receivable $ 18,226 $ 12,127 Billable tooling 16,877 15,267 Income tax and other tax receivable 16,017 15,041 Short-term derivative financial instruments 10,717 6,564 Prepaid expenses 7,889 6,239 Receivables due from factor 4,422 5,490 Other 4,272 3,869 Total other current assets $ 78,420 $ 64,597 Property and equipment: Machinery and equipment $ 236,277 $ 214,342 Buildings and improvements 130,374 123,714 Information technology 41,543 39,726 Production tooling 28,033 24,839 Leasehold improvements 12,269 12,271 Construction in progress 27,461 29,023 Total property and equipment 475,957 443,915 Less: accumulated depreciation ( 230,723 ) ( 199,435 ) Total property and equipment, net $ 245,234 $ 244,480 Other current liabilities: Accrued employee liabilities $ 43,176 $ 32,031 Liabilities from discounts and rebates 22,916 26,640 Income tax and other taxes payable 19,327 14,459 Restructuring 2,150 588 Accrued warranty 3,945 2,380 Other 9,291 17,716 Total other current liabilities $ 100,805 $ 93,814

Goodwill and Other Intangibles

Goodwill and Other Intangibles (Tables)	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Changes in the Carrying Amount of Goodwill, By Reportable Segment	Changes in the carrying amount of goodwill, by reportable segment, for the years ended December 31, 2023 and 2022 were as follows: Automotive Medical Total Balance as of December 31, 2021 $ 37,329 $ 28,704 $ 66,033 Acquisition of Dacheng — 19,016 19,016 Acquisition of Alfmeier 34,494 — 34,494 Currency translation and other 1,246 ( 1,015 ) 231 Balance as of December 31, 2022 $ 73,069 $ 46,705 $ 119,774 Impairment of goodwill — ( 19,509 ) ( 19,509 ) Currency translation and other 3,627 181 3,808 Balance as of December 31, 2023 $ 76,696 $ 27,376 $ 104,073
Summary of Other Intangible Assets and Accumulated Amortization Balances	Other intangible assets and accumulated amortization balances as of December 31, 2023 and 2022 were as follows: Gross Accumulated Net Carrying Definite-lived: Customer relationships $ 115,465 $ ( 73,737 ) $ 41,728 Technology 45,861 ( 29,317 ) 16,544 Product development costs 19,434 ( 19,270 ) 164 Software development 1,007 — 1,007 Indefinite-lived: Tradenames 7,039 — 7,039 Balance as of December 31, 2023 $ 188,806 $ ( 122,324 ) $ 66,482 Gross Accumulated Net Carrying Definite-lived: Customer relationships $ 112,286 $ ( 65,748 ) $ 46,538 Technology 44,745 ( 25,709 ) 19,036 Product development costs 18,774 ( 18,456 ) 318 Software development 1,007 — 1,007 Indefinite-lived: Tradenames 7,034 — 7,034 Balance as of December 31, 2022 $ 183,846 $ ( 109,913 ) $ 73,933 As of December 31, 2022, the estimated fair value of the Medical reporting unit exceeded its carrying value by less than 10 %. During the second quarter of 2023, the Company’s Medical reporting unit did not perform in-line with forecasted results primarily driven by slower than anticipated revenue growth. As a result, an indicator of impairment was identified and the Company performed an interim quantitative assessment as of June 30, 2023. The results of this quantitative analysis indicated the carrying value of the reporting unit exceeded the fair value of the reporting unit, and accordingly an impairment expense was recorded for $ 19,509 . No further impairment was recorded as of December 31, 2023. The Company utilized an income approach to estimate the fair value of the reporting unit and a market valuation approach to further support this analysis (level 3). The income approach was based on projected debt-free cash flow that was discounted to the present value using discount factors that considered the timing and risk of cash flows. Fair value was estimated using internally developed forecasts, as well as commercial and discount rate assumptions. The discount rate used was the value-weighted average of our estimated cost of equity and of debt (“cost of capital”) derived using both known and estimated customary market metrics. Our weighted average cost of capital includes a company specific risk premium to address the risks associated with achieving the projected revenue and profitability growth rates. Other significant assumptions included terminal value growth rates and terminal value margin rates. Our ability to realize the future cash flows used in our calculations is affected by factors such as the success of strategic initiatives, changes in economic conditions, changes in our operating performance and changes in our business strategies. To further support the fair value estimate determined by the income approach, the Company utilized a market valuation approach to estimate the fair value of the Medical reporting unit. The market approach considered historical and anticipated financial metrics of the Medical reporting unit and applied valuation multiples based on recent observed transactions involving companies similar enough to the Medical reporting unit from which to draw meaningful conclusions.
Summary of Estimate of Future Amortization of Other Intangible Assets	An estimate of future amortization of other intangible assets, is as follows: 2024 $ 6,991 2025 6,977 2026 6,541 2027 6,454 2028 6,389

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Components of Lease Expense and Other Information	Components of lease expense for the years ended December 31, 2023, 2022 and 2021 were as follows: Year Ended December 31, 2023 2022 2021 Lease cost: Operating lease cost $ 9,606 $ 8,040 $ 8,227 Amortization of ROU assets - finance leases 390 168 — Interest on lease liabilities - finance leases 28 16 — Short-term lease cost 2,651 1,773 1,941 Sublease income — ( 101 ) ( 163 ) Total lease cost $ 12,675 $ 9,896 $ 10,005 Other information related to leases is as follows: Year Ended December 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 9,249 $ 10,381 Operating cash flows for finance leases 81 16 Financing cash flows for finance leases 390 164 Right-of-use lease assets obtained in exchange for lease obligations: Operating leases $ 4,704 $ 15,902 Finance leases — 1,180 December 31, 2023 December 31, 2022 Weighted average remaining lease term: Operating leases 5.6 years 5.7 years Finance leases 1.9 years 2.7 years Weighted average discount rate: Operating leases 4.96 % 4.35 % Finance leases 3.53 % 3.57 %
Summary of Operating Leases Under all Non-Cancellable Operating Leases	A summary of operating leases as of December 31, 2023, under all non-cancellable operating leases with terms exceeding one year is as follows: 2024 $ 8,533 2025 5,588 2026 3,656 2027 2,027 2028 1,798 2029 or later 5,827 Total future minimum lease payments 27,429 Less imputed interest ( 3,554 ) Total $ 23,875
Summary of Finance Leases Under all Non-Cancellable Finance Leases	A summary of finance leases as of December 31, 2023, under all non-cancellable finance leases with terms exceeding one year is as follows: 2024 $ 388 2025 152 2026 70 2027 — Total future minimum lease payments 610 Less imputed interest ( 5 ) Total $ 605

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Summary of Company's Debt	The following table summarizes the Company’s debt as of December 31, 2023 and 2022: December 31, 2023 2022 Interest Principal Interest Principal Credit Agreement: U.S. Revolving Note (U.S. Dollar denominations) 6.58 % $ 222,000 5.80 % $ 232,000 Other loans 3.90 % 233 3.89 % - 5.21 % 2,011 Finance leases 3.53 % 605 3.57 % 1,085 Total debt 222,838 235,096 Current maturities ( 621 ) ( 2,443 ) Long-term debt, less current maturities $ 222,217 $ 232,653
Principal Maturities of Debt	The scheduled principal maturities of our debt as of December 31, 2023 were as follows: U.S. Other Debt Total 2024 $ — $ 621 $ 621 2025 — 152 152 2026 — 70 70 2027 222,000 — 222,000 2028 — — — Total $ 222,000 $ 843 $ 222,843

Pension and Other Post Retire_2

Pension and Other Post Retirement Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2023
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost for Company's Defined Benefit Plans	The components of net periodic benefit cost for the Company’s defined benefit plans for the years ended December 31, 2023, 2022 and 2021 were as follows: U.S. Plan German Plan Year Ended December 31, Year Ended December 31, 2023 2022 2021 2023 2022 2021 Net periodic benefit cost: Service cost $ — $ — $ — $ — $ — $ — Interest cost 115 56 42 217 92 91 Expected return on plan assets — — — ( 115 ) ( 109 ) ( 120 ) Amortization of prior service cost and actuarial loss — 22 26 23 114 133 Net periodic benefit cost $ 115 $ 78 $ 68 $ 125 $ 97 $ 104 Assumptions: Discount rate 4.65 % 1.80 % 1.20 % 4.10 % 1.08 % 1.06 % Long-term return on assets N/A N/A N/A 3.20 % 2.90 % 2.90 %
Reconciliation of Change in Benefit Obligation, Change in Plan Assets and Balance Sheet Classification	A reconciliation of the change in benefit obligation and the change in plan assets for the years ended December 31, 2023 and 2022 is as follows: U.S. Plan German Plan As of December 31, As of December 31, 2023 2022 2023 2022 Change in projected benefit obligation: Balance at beginning of year $ 2,811 $ 3,446 $ 5,398 $ 8,102 Interest cost 115 56 217 92 Paid pension distributions ( 342 ) ( 342 ) ( 290 ) ( 281 ) Actuarial loss (gain) 18 ( 349 ) ( 89 ) ( 2,001 ) Exchange rate impact — — 170 ( 514 ) Balance at end of year $ 2,602 $ 2,811 $ 5,406 $ 5,398 Change in plan assets: Balance at beginning of year — — 3,918 4,069 Actual return on plan assets — — 98 89 Contributions — — — — Paid pension distributions — — — — Exchange rate impact — — 129 ( 240 ) Balance at end of year $ — $ — $ 4,145 $ 3,918 Underfunded Status $ ( 2,602 ) $ ( 2,811 ) $ ( 1,261 ) $ ( 1,480 ) Balance sheet classification: Other current liabilities $ ( 357 ) $ ( 342 ) $ ( 297 ) $ ( 314 ) Pension benefit obligation ( 2,245 ) ( 2,469 ) ( 964 ) ( 1,166 ) Accumulated other comprehensive loss (pre-tax): Actuarial losses 223 205 899 965 Assumptions: Discount rate 4.45 % 4.65 % 4.56 % 4.10 %
Summary of Pre-tax Amounts in AOCI Expected to Be Recognized in Net Periodic Benefit Cost	Pre-tax amounts included in AOCI that are expected to be recognized in net periodic benefit cost during the year ended December 31, 2024 are as follows: U.S Plan German Plan Actuarial losses $ — $ 20
Summary of Accumulated Benefit Obligations	The accumulated benefit obligations were as follows: U.S. Plan German Plan As of December 31, As of December 31, 2023 2022 2023 2022 Accumulated benefit obligation $ 2,602 $ 2,811 $ 5,406 $ 5,398
Schedule of Future Expected Pension Payments	The schedule of future expected pension payments is as follows: Projected Pension Year U.S Plan German Plan 2024 $ 342 $ 324 2025 342 314 2026 342 303 2027 342 292 2028 342 279 2029-2032 1,368 2,893 Total $ 3,078 $ 4,405

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Reconciliation of Changes in Accrued Warranty Costs	The following is a reconciliation of the changes in accrued warranty costs: Year Ended December 31, 2023 2022 Balance at beginning of year $ 2,380 $ 1,916 Warranty opening balance from acquired entities — 907 Warranty claims paid ( 2,252 ) ( 1,841 ) Warranty expense for products shipped during the current period 3,955 1,584 Adjustments to warranty estimates from prior periods ( 174 ) ( 274 ) Adjustments due to currency translation 36 88 Balance at end of year $ 3,945 $ 2,380

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Earnings per Share and Weighted Average Shares Outstanding Used in Calculating Basic and Diluted Earnings per Share	The following table illustrates earnings per share and the weighted average shares outstanding used in calculating basic and diluted earnings per share: Year Ended December 31, 2023 2022 2021 Net income $ 40,343 $ 24,441 $ 93,434 Basic weighted average shares of Common Stock outstanding 32,778,055 33,126,202 33,085,732 Dilutive effect of stock options, restricted stock awards and restricted stock units 288,862 376,952 423,988 Diluted weighted average shares of Common Stock outstanding 33,066,917 33,503,154 33,509,720 Basic earnings per share $ 1.23 $ 0.74 $ 2.82 Diluted earnings per share $ 1.22 $ 0.73 $ 2.79

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Information Related to Recurring Fair Value Measurement of Derivative Financial Instruments in the Consolidated Balance Sheet	Information related to the recurring fair value measurement of derivative financial instruments in the consolidated balance sheet as of December 31, 2023 is as follows: Asset Derivatives Liability Derivatives Fair Value Notional Amount Balance Sheet Fair Balance Sheet Fair Net Asset/ Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Level 2 $ 101,109 Other current assets $ 8,655 Other current liabilities $ — $ 8,655 Derivatives Not Designated as Hedging Instruments Interest rate contracts Level 2 $ 100,000 Other current assets $ 2,062 Other current liabilities $ — $ 2,062 Information related to the recurring fair value measurement of derivative financial instruments in the consolidated balance sheet as of December 31, 2022 is as follows: Asset Derivatives Liability Derivatives Fair Value Notional Amount Balance Sheet Fair Balance Sheet Fair Net Asset/ Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Level 2 $ 40,063 Other current assets $ 3,791 Other current liabilities $ — $ 3,791 Derivatives Not Designated as Hedging Instruments Interest rate contracts Level 2 $ 100,000 Other current assets $ 2,772 Other current liabilities $ — $ 2,772
Information Related to Effect of Derivative Instruments in the Consolidated Statements of Income	Information related to the effect of derivative instruments in the consolidated statements of income is as follows: Year Ended December 31, Location 2023 2022 2021 Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Cost of sales – income $ 8,630 $ 1,458 $ 1,609 Other comprehensive (loss) income 3,483 3,496 ( 1,217 ) Total foreign currency derivatives $ 12,113 $ 4,954 $ 392 Commodity derivatives Cost of sales – income $ — $ 19 $ 14 Other comprehensive (loss) income — ( 6 ) 6 Total commodity derivatives $ — $ 13 $ 20 Derivatives Not Designated as Hedging Instruments Foreign currency derivatives Foreign currency (loss) gain $ — $ ( 3,806 ) $ — Total foreign currency derivatives $ — $ ( 3,806 ) $ — Interest rate contracts Interest income (expense), net $ ( 710 ) $ 2,772 $ — Total interest rate derivatives $ ( 710 ) $ 2,772 $ —
Summary of Receivables Factored and Availability Under Receivables Factoring Agreements	Receivables factored and availability under receivables factoring agreements balances as of December 31, 2023 and 2022 were as follows: December 31, 2023 2022 Receivables factored and outstanding $ 18,532 $ 19,108 Amount available under the credit limit 5,891 5,034 Collective factoring limit $ 24,423 $ 24,142
Summary of Trade Receivables Sold and Factoring Fees Incurred	Trade receivables sold and factoring fees incurred during the years ended December 31, 2023 and 2022 were as follows: Year Ended December 31, 2023 2022 (a) Trade receivables sold $ 135,116 $ 61,482 Factoring fees incurred 800 180 (a) Represents trade receivables sold and factoring fees incurred since the acquisition of Alfmeier (acquired on August 1, 2022).

Reclassifications Out of Accu_2

Reclassifications Out of Accumulated Other Comprehensive Loss (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Schedule of Reclassification Adjustments and Other Activities Impacting Accumulated Other Comprehensive Income (Loss)	Reclassification adjustments and other activities impacting accumulated other comprehensive income (loss) during the years ended December 31, 2023, 2022 and 2021 are as follows: Defined Foreign Commodity Hedge Derivatives Foreign Total Balance at December 31, 2022 $ ( 1,067 ) $ ( 48,269 ) $ — $ 2,847 $ ( 46,489 ) Other comprehensive income before reclassifications 54 13,125 — 13,086 26,265 Income tax effect of other comprehensive income before reclassifications ( 15 ) 314 — ( 2,770 ) ( 2,471 ) Amounts reclassified from accumulated other comprehensive loss into net income 23 — — ( 9,603 ) a ( 9,580 ) Income taxes reclassified into net income ( 6 ) — — 2,121 2,115 Net current period other comprehensive income 56 13,439 — 2,834 16,329 Balance at December 31, 2023 $ ( 1,011 ) $ ( 34,830 ) $ — $ 5,681 $ ( 30,160 ) (a) The amounts reclassified from Accumulated other comprehensive loss are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instruments on our consolidated statements of income. Defined Foreign Commodity Hedge Derivatives Foreign Total Balance at December 31, 2021 $ ( 2,893 ) $ ( 34,188 ) $ 5 $ 154 $ ( 36,922 ) Other comprehensive income (loss) before reclassifications 2,341 ( 13,786 ) 13 4,954 ( 6,478 ) Income tax effect of other comprehensive income (loss) before reclassifications ( 621 ) ( 295 ) ( 3 ) ( 1,092 ) ( 2,011 ) Amounts reclassified from accumulated other comprehensive loss into net income 137 — ( 19 ) a ( 1,458 ) a ( 1,340 ) Income taxes reclassified into net income ( 31 ) — 4 289 262 Net current period other comprehensive income (loss) 1,826 ( 14,081 ) ( 5 ) 2,693 ( 9,567 ) Balance at December 31, 2022 $ ( 1,067 ) $ ( 48,269 ) $ — $ 2,847 $ ( 46,489 ) (a) The amounts reclassified from Accumulated other comprehensive loss are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instruments on our consolidated statements of income. Defined Benefit Foreign Currency Commodity Hedge Derivatives Foreign Currency Total Balance at December 31, 2020 $ ( 3,451 ) $ ( 12,637 ) $ — $ 1,106 $ ( 14,982 ) Other comprehensive income (loss) before reclassifications 512 ( 21,274 ) 20 392 ( 20,350 ) Income tax effect of other comprehensive income (loss) before reclassifications ( 71 ) ( 277 ) ( 4 ) ( 85 ) ( 437 ) Amounts reclassified from accumulated other comprehensive loss into net income $ 159 — ( 14 ) a ( 1,609 ) a ( 1,464 ) Income taxes reclassified into net income $ ( 42 ) — 3 350 311 Net current period other comprehensive income (loss) 558 ( 21,551 ) 5 ( 952 ) ( 21,940 ) Balance at December 31, 2021 $ ( 2,893 ) $ ( 34,188 ) $ 5 $ 154 $ ( 36,922 ) (a) The amounts reclassified from Accumulated other comprehensive loss are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instruments on our consolidated statements of income.

Accounting for Stock Based Co_2

Accounting for Stock Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Recognized and Unrecognized Stock-based Compensation Expense	The total recognized and unrecognized stock-based compensation expense is as follows: Stock-Based Compensation Expense 2023 2022 2021 Unrecognized Stock-Based Compensation Expense at December 31, 2023 Remaining Weighted Average Vesting Period RSUs $ 6,216 $ 5,551 $ 4,594 $ 9,124 1.84 PSUs 4,661 954 5,535 9,724 1.97 Restricted Stock 878 888 1,198 437 0.38 SARs ( 128 ) ( 794 ) 2,721 — — Stock options — — 482 — — Total Stock-Based Compensation $ 11,627 $ 6,599 $ 14,530 $ 19,285 1.87
Summary of PSU Activity	The following table summarizes PSU activity during the years ended December 31, 2023, 2022 and 2021: Unvested Performance Stock Units Relative TSR Target Weighted-Average ROIC Target Weighted-Average Adjusted EBITDA Target Shares Weighted-Average RRG Target Shares Weighted-Average Total Outstanding at December 31, 2020 157,918 $ 56.06 157,916 $ 38.58 — $ — — $ — 315,834 Granted 20,626 118.08 40,580 78.98 39,930 79.49 — — 101,136 Performance Adjustment 30,828 69.18 ( 30,830 ) 44.92 — — — — ( 2 ) Vested ( 61,656 ) 69.18 — — — — — — ( 61,656 ) Forfeited ( 16,148 ) 61.10 ( 17,374 ) 44.32 ( 2,454 ) 79.49 — ( 35,976 ) Outstanding at December 31, 2021 131,568 $ 62.09 150,292 $ 47.52 37,476 $ 79.49 — $ — 319,336 Granted 21,324 103.31 42,640 68.63 42,640 68.63 — — 106,604 Performance Adjustment 45,004 57.46 ( 2,258 ) 41.61 — — — — 42,746 Vested ( 90,371 ) 57.46 ( 43,106 ) 41.61 — — — — ( 133,477 ) Forfeited ( 4,724 ) 68.67 ( 6,493 ) 56.87 ( 3,543 ) 75.10 — — ( 14,760 ) Outstanding at December 31, 2022 102,801 $ 65.20 141,075 $ 55.18 76,573 $ 73.66 — $ — 320,449 Granted 30,622 89.87 30,622 59.91 61,255 59.91 30,622 59.91 153,121 Performance Adjustment — — ( 59,928 ) 33.90 — — — — ( 59,928 ) Vested ( 59,928 ) 49.25 — — — — — — ( 59,928 ) Forfeited ( 8,494 ) 75.67 ( 11,618 ) 55.94 ( 7,836 ) 70.95 ( 789 ) 59.91 ( 28,737 ) Outstanding at December 31, 2023 65,001 $ 101.15 100,151 $ 69.55 129,992 $ 67.34 29,833 $ 59.91 324,977
Restricted Stock Activity	The following table summarizes restricted stock activity during the years ended December 31, 2023, 2022 and 2021: Unvested Restricted Stock Shares Weighted-Average Outstanding at December 31, 2020 34,906 $ 39.82 Granted 13,742 70.18 Vested ( 37,272 ) 41.70 Forfeited — — Outstanding at December 31, 2021 11,376 $ 70.33 Granted 13,600 73.54 Vested ( 11,376 ) 70.33 Forfeited — — Outstanding at December 31, 2022 13,600 $ 73.54 Granted 17,923 56.96 Vested ( 11,900 ) 73.54 Forfeited ( 1,700 ) 73.54 Outstanding at December 31, 2023 17,923 $ 56.96
SARs Activity	The following table summarizes SARs activity during the years ended December 31, 2023, 2022 and 2021: Stock Appreciation Rights Shares Weighted-Average Weighted-Average Aggregate Outstanding at December 31, 2020 171,600 $ 40.60 2.44 $ 4,224 Granted — — Exercised ( 116,000 ) 40.34 Forfeited — — Outstanding at December 31, 2021 55,600 $ 41.15 1.28 $ 2,544 Granted — — Exercised ( 40,850 ) 42.27 Forfeited — — Outstanding at December 31, 2022 14,750 $ 38.05 1.15 $ 402 Granted — — Exercised ( 12,500 ) 38.05 Forfeited — — Outstanding at December 31, 2023 2,250 $ 38.05 0.15 $ 32 Exercisable at December 31, 2023 2,250 $ 38.05 0.15 $ 32
Summary of Stock Option Activity	The following table summarizes stock option activity during the years ended December 31, 2023, 2022 and 2021: Options Shares Weighted-Average Weighted-Average Aggregate Outstanding at December 31, 2020 428,000 $ 37.61 3.20 $ 11,815 Granted — — Exercised ( 215,250 ) 38.46 Forfeited ( 6,000 ) 38.05 Outstanding at December 31, 2021 206,750 $ 36.72 2.60 $ 10,375 Granted — — Exercised ( 44,116 ) 37.87 Forfeited — — Outstanding at December 31, 2022 162,634 $ 36.41 2.68 $ 8,212 Granted — — Exercised ( 6,450 ) 40.79 Forfeited ( 16,500 ) 41.59 Outstanding at December 31, 2023 139,684 $ 35.59 0.90 $ 2,342 Exercisable at December 31, 2023 139,684 $ 35.59 0.90 $ 2,342
RSU
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted Stock Activity	The following table summarizes RSU activity during the years ended December 31, 2023, 2022 and 2021: Unvested Restricted Stock Units Time Vesting Weighted-Average Outstanding at December 31, 2020 208,905 $ 37.26 Granted 93,539 79.79 Vested ( 88,296 ) 38.49 Forfeited ( 20,522 ) 48.76 Outstanding at December 31, 2021 193,626 $ 56.02 Granted 117,507 66.86 Vested ( 95,692 ) 49.85 Forfeited ( 13,863 ) 70.52 Outstanding at December 31, 2022 201,578 $ 64.27 Granted 136,964 58.68 Vested ( 82,695 ) 59.43 Forfeited ( 23,986 ) 59.47 Outstanding at December 31, 2023 231,861 $ 63.19

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Earnings Before Income Taxes	The income tax provisions were calculated based upon the following components of earnings before income tax for the years ended December 31, 2023, 2022 and 2021: Year Ended December 31, 2023 2022 2021 Earnings (loss) before income tax: Domestic $ ( 37,222 ) $ ( 34,211 ) $ ( 4,547 ) Foreign 92,176 72,593 118,399 Earnings before income tax $ 54,954 $ 38,382 $ 113,852
Provision for Income Taxes	The components of the provision for income taxes for the years ended December 31, 2023, 2022 and 2021 are summarized as follows: Year Ended December 31, 2023 2022 2021 Current income tax expense: Federal $ 3,510 $ 3,006 $ 1,944 State and local 414 650 234 Foreign 23,759 17,607 18,390 Total current income tax expense 27,683 21,263 20,568 Deferred income tax (benefit) expense: Federal ( 7,495 ) ( 5,971 ) ( 4,400 ) State and local 444 ( 213 ) ( 91 ) Foreign ( 6,021 ) ( 1,138 ) 4,341 Total deferred (benefit) income tax expense ( 13,072 ) ( 7,322 ) ( 150 ) Total income tax expense $ 14,611 $ 13,941 $ 20,418
Deferred Tax Assets and Deferred Tax Liabilities	The deferred tax assets and deferred tax liabilities and related valuation allowance were comprised of the following as of December 31, 2023 and 2022: December 31, 2023 2022 Deferred tax assets: Net operating losses $ 44,053 $ 43,296 Intangible assets 4,314 4,417 Research and development credits 7,127 7,835 Property and equipment 4,800 6,983 Valuation reserves and accrued liabilities 11,221 8,388 Capitalized Research and Development Costs 23,658 19,087 Stock compensation 3,227 3,051 Defined benefit obligation 1,691 1,265 Inventory 181 6,762 Other credits 8,946 10,296 Other 9,154 790 Total deferred tax asset 118,372 112,170 Valuation allowance ( 35,888 ) ( 36,671 ) Deferred tax liabilities: Unrealized foreign currency exchange gains — ( 2,413 ) Undistributed profits of subsidiary ( 4,609 ) ( 5,981 ) Property and equipment ( 12,627 ) ( 15,423 ) Other ( 1,550 ) ( 3,056 ) Total deferred tax liability ( 18,786 ) ( 26,873 ) Net deferred tax asset $ 63,698 $ 48,626
Reconciliations Between Statutory Federal Income Tax Rate and Effective Rate	Reconciliations between the statutory Federal income tax rate and the effective rate of income tax expense for the years ended December 31, 2023, 2022 and 2021 are as follows: Year Ended December 31, 2023 2022 2021 Statutory Federal income tax rate 21.0 % 21.0 % 21.0 % Increase (decrease) resulting from: Change in valuation allowance ( 3.1 )% 6.4 % ( 1.2 )% Effect of different tax rates of foreign jurisdictions 0.9 % ( 4.9 )% ( 5.2 )% Tax credits & deductions related to R&D ( 8.5 )% ( 10.1 )% ( 2.3 )% Goodwill impairment 4.1 % — — Non-deductible expenses 6.8 % 14.9 % 1.7 % Non-deductible expenses related to acquisitions — 7.0 % — Other foreign, state and local taxes 3.5 % 0.7 % 1.6 % Tax impact of foreign income 3.6 % 4.2 % 3.6 % Stock option compensation — ( 3.8 )% ( 2.0 )% Prior year adjustments 0.7 % 1.7 % ( 0.7 )% Other ( 2.4 )% ( 0.8 )% 1.4 % Effective rate 26.6 % 36.3 % 17.9 %
Net Operating Loss Carryforwards	The Company has Net Operating Loss (“NOL”) carryforwards as follows: Jurisdiction Amount as of December 31, 2023 Years of Expiration U.S. state income tax $ 51,235 2024 - 2042 Foreign $ 296,334 Never
Reconciliation of Unrecognized Tax Benefits	The reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Year Ended December 31, 2023 2022 2021 Balance at beginning of year $ 6,185 $ 5,665 $ 4,967 Additions based on tax position related to current year 87 972 1,105 Additions based on tax position related to prior year 347 433 160 Reductions from settlements and statute of limitation expiration ( 1,266 ) ( 610 ) $ ( 312 ) Effect of foreign currency translation 133 ( 275 ) ( 255 ) Balance at end of year $ 5,486 $ 6,185 $ 5,665

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2023
Segment Reporting [Abstract]
Segment Information about Reported Product Revenues, Depreciation and Amortization and Operating Income (Loss)	The tables below present segment information about the reported product revenues and operating income of the Company for years ended December 31, 2023, 2022 and 2021. Automotive Medical Corporate Total 2023: Product revenues $ 1,422,952 $ 46,124 $ — $ 1,469,076 Depreciation and amortization 45,845 3,654 1,449 50,948 Operating income (loss) 185,956 ( 22,234 ) ( 86,283 ) 77,439 2022: Product revenues $ 1,161,616 $ 43,040 $ — $ 1,204,656 Depreciation and amortization 39,815 3,344 1,235 44,394 Operating income (loss) 118,433 ( 4,029 ) ( 66,097 ) 48,307 2021: Product revenues $ 1,004,633 $ 41,517 $ — $ 1,046,150 Depreciation and amortization 35,389 2,460 931 38,780 Operating income (loss) 162,994 ( 1,829 ) ( 46,159 ) 115,006
Segment Information About Reported Segment Product Revenues by Product Category	Automotive and Medical segment product revenues by product category for each of the years ended December 31, 2023, 2022 and 2021 are as follows: Year Ended December 31, 2023 2022 2021 Climate Control Seat $ 482,665 $ 426,046 $ 393,816 Seat Heaters 308,588 283,970 270,054 Steering Wheel Heaters 153,943 120,949 102,496 Lumbar and Massage Comfort Solutions (a) 144,923 56,980 — Valve Systems (a) 106,262 41,980 — Automotive Cables 79,993 76,962 84,114 Battery Performance Solutions 75,484 71,907 69,594 Electronics 40,387 44,106 51,648 Other Automotive 30,707 38,716 32,911 Subtotal Automotive segment 1,422,952 1,161,616 1,004,633 Medical segment (a) 46,124 43,040 41,517 Total Company $ 1,469,076 $ 1,204,656 $ 1,046,150 (a) Includes product revenues from acquisitions since their respective acquisition dates (see Note 4).
Product Revenues Information by Geographic Area	Revenue (based on shipment destination) by geographic area for each of the years ended December 31, 2023, 2022 and 2021 is as follows: Year Ended December 31, 2023 2022 2021 United States $ 537,096 $ 472,468 $ 404,466 China 221,512 183,419 142,816 South Korea 115,854 94,937 93,516 Germany 102,383 75,367 66,929 Czech Republic 69,714 49,293 43,931 Japan 60,879 57,718 63,527 Romania 53,982 47,532 51,367 Mexico 45,733 23,233 18,194 Slovakia 44,946 34,686 30,004 Finland 39,632 33,627 29,325 Other 177,345 132,376 102,075 Total Non-U.S. 931,980 732,188 641,684 Total Company $ 1,469,076 $ 1,204,656 $ 1,046,150
Percentage of Total Product Revenues Generated from Customers	The table below lists the percentage of total product revenues generated from sales to customers which contributed 10% or more to the Company’s total consolidated product revenue for the years ended December 31, 2023, 2022 and 2021: Year Ended December 31, 2023 2022 2021 Lear 15 % 16 % 15 % Adient 13 % 15 % 15 %
Schedule of Property and Equipment, Net by Geographic Area	Property and equipment, net, for each of the geographic areas in which the Company operates as of December 31, 2023 and 2022 is as follows: December 31, Property and equipment, net 2023 2022 Germany $ 46,586 $ 47,342 China 45,429 43,162 Mexico 39,943 31,597 United States 37,413 41,034 North Macedonia 27,675 27,808 Vietnam 21,664 19,808 Czech Republic 11,126 11,381 Hungary 9,097 11,736 Ukraine 5,986 5,077 Other 315 5,535 Total $ 245,234 $ 244,480

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands	1 Months Ended	12 Months Ended
	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($) Segment	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Basis Of Presentation And Accounting Policies [Line Items]
Number of reportable segments | Segment		2
capitalized costs to obtain contract		$ 7,305	$ 2,239
Amortization of capitalized costs into product revenues		179	78
Cash and cash equivalents		149,673	153,891
Allowance for doubtful accounts		1,171	1,220	$ 1,399	$ 1,161
Depreciation expense		42,186	33,730	29,622
Investment amount		5,700		5,200
Additional investment made	$ 500
Non-cash impairment charges		$ 2,900
Operating lease, description		The Company has operating leases for office, manufacturing and research and development facilities, as well as land leases for certain manufacturing facilities that are accounted for as operating leases. We also have operating leases for office equipment and automobiles.
Operating lease, existence of option to extend		true
Operating lease, options to extend		Excluding land leases, our leases have remaining lease terms ranging from less than 1 year to 8 years and may include options to extend the lease.
Forciot Oy | Gentherm Automotive Segment
Basis Of Presentation And Accounting Policies [Line Items]
Investment amount				2,357
Autotech Fund III, L.P.
Basis Of Presentation And Accounting Policies [Line Items]
Investment commitment		$ 810		$ 5,000
Capital contribution description		As a limited partner, the Company will periodically make capital contributions toward this total commitment amount over the expected ten-year life of the fund.
Production Tooling
Basis Of Presentation And Accounting Policies [Line Items]
Reimbursable tooling capitalized within prepaid expenses and other current assets		$ 16,877	$ 15,267
Concentration of Credit Risk | Accounts receivable | Lear
Basis Of Presentation And Accounting Policies [Line Items]
Concentration risk percentage		17%	17%
Concentration of Credit Risk | Accounts receivable | Adient
Basis Of Presentation And Accounting Policies [Line Items]
Concentration risk percentage		19%	18%
Foreign Jurisdictions
Basis Of Presentation And Accounting Policies [Line Items]
Cash and cash equivalents		$ 125,251	$ 108,620
Minimum
Basis Of Presentation And Accounting Policies [Line Items]
Expected period of costs to be realized to recognize assets		1 year
Operating lease, term of contract		1 year
Minimum | Production Tooling
Basis Of Presentation And Accounting Policies [Line Items]
Property plant and equipment, estimated useful life		2 years
Minimum | Ground
Basis Of Presentation And Accounting Policies [Line Items]
Operating lease, term of contract		2 years
Maximum
Basis Of Presentation And Accounting Policies [Line Items]
Original maturities of highly liquid investments		90 days
Operating lease, term of contract		8 years
Maximum | Production Tooling
Basis Of Presentation And Accounting Policies [Line Items]
Property plant and equipment, estimated useful life		10 years
Maximum | Ground
Basis Of Presentation And Accounting Policies [Line Items]
Operating lease, term of contract		39 years
Entities Ownership Interest
Basis Of Presentation And Accounting Policies [Line Items]
Ownership interest		20%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]
Balance at beginning of year	$ 1,220	$ 1,399	$ 1,161
Charged to costs and expenses	195	1,088	1,066
Currency translation and other	4		(12)
Deductions from reserves	(248)	(1,267)	(816)
Balance at end of year	$ 1,171	$ 1,220	$ 1,399

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Detail)	Dec. 31, 2023
Plant and Equipment
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	10 years
Leasehold Improvements
Property Plant And Equipment [Line Items]
Leasehold improvements	us-gaap:UsefulLifeTermOfLeaseMember
Minimum | Buildings and Improvements
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	1 year
Minimum | Production Tooling
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	2 years
Minimum | Information Technology
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	1 year
Maximum | Buildings and Improvements
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	30 years
Maximum | Production Tooling
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	10 years
Maximum | Information Technology
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	5 years

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Fair Value and Corresponding Useful Lives for Acquired Intangibles Assets (Detail)	12 Months Ended
	Dec. 31, 2023
Customer Related | Minimum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	8 years
Customer Related | Maximum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	15 years
Technology | Minimum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	5 years
Technology | Maximum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	12 years
Software Development Costs | Minimum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	4 years
Software Development Costs | Maximum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	5 years
Product Development Costs | Minimum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	5 years
Product Development Costs | Maximum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	10 years

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) - USD ($) $ in Thousands	Aug. 01, 2022	Jul. 13, 2022
Alfmeier
Business Acquisition [Line Items]
Acquisition date	Aug. 01, 2022
Percentage of equity interests acquired	100%
Total consideration	$ 170,700
Dacheng
Business Acquisition [Line Items]
Acquisition date		Jul. 13, 2022
Percentage of equity interests acquired		100%
Total consideration		$ 35,048
Contingent payments		$ 500

Acquisitions - Summary of Produ

Acquisitions - Summary of Product Revenues and Operating Income (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Product revenues	$ 1,469,076	$ 1,204,656	$ 1,046,150
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Operating income	$ 77,439	$ 48,307	$ 115,006
Alfmeier
Business Acquisition [Line Items]
Product revenues		$ 98,960
Type of Revenue [Extensible List]		us-gaap:ProductMember
Net Income (Loss)		$ (2,675)
Dacheng
Business Acquisition [Line Items]
Product revenues		$ 3,499
Type of Revenue [Extensible List]		us-gaap:ProductMember
Net Income (Loss)		$ (217)

Acquisitions - Summary of Final

Acquisitions - Summary of Final Purchase Consideration And Estimated Fair Values Of Assets Acquired And Liabilities Assumed (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Aug. 01, 2022	Jul. 13, 2022	Dec. 31, 2023
Business Acquisition [Line Items]
Goodwill	$ 119,774			$ 104,073
Alfmeier
Business Acquisition [Line Items]
Purchase price, cash consideration, net of cash acquired	170,700
Accounts receivable	24,867
Inventory	36,443
Prepaid expenses and other assets	20,846
Operating lease right-of-use assets	4,608
Property and equipment	91,184
Other intangible assets	31,459	$ 31,459
Goodwill	33,971
Assumed liabilities	(55,019)
Deferred tax liabilities	(17,659)
Net assets acquired	170,700
Alfmeier | Initial Allocation
Business Acquisition [Line Items]
Purchase price, cash consideration, net of cash acquired		164,887
Accounts receivable		24,988
Inventory		36,026
Prepaid expenses and other assets		20,920
Operating lease right-of-use assets		4,608
Property and equipment		89,942
Other intangible assets		22,668
Goodwill		43,678
Assumed liabilities		(55,994)
Deferred tax liabilities		(21,949)
Net assets acquired		164,887
Alfmeier | Measurement Period Adjustments
Business Acquisition [Line Items]
Purchase price, cash consideration, net of cash acquired		5,813
Accounts receivable		(121)
Inventory		417
Prepaid expenses and other assets		(74)
Property and equipment		1,242
Other intangible assets		8,791
Goodwill		(9,707)
Assumed liabilities		975
Deferred tax liabilities		4,290
Net assets acquired		$ 5,813
Dacheng
Business Acquisition [Line Items]
Purchase price, cash consideration, net of cash acquired	35,048
Accounts receivable	622
Inventory	1,765
Prepaid expenses and other assets	174
Operating lease right-of-use assets	841
Property and equipment	684
Other intangible assets	20,059		$ 20,059
Goodwill	19,531
Assumed liabilities	(3,314)
Deferred tax liabilities	(5,314)
Net assets acquired	$ 35,048
Dacheng | Initial Allocation
Business Acquisition [Line Items]
Purchase price, cash consideration, net of cash acquired			35,048
Accounts receivable			746
Inventory			1,942
Prepaid expenses and other assets			152
Operating lease right-of-use assets			841
Property and equipment			684
Other intangible assets			19,094
Goodwill			22,995
Assumed liabilities			(2,799)
Deferred tax liabilities			(8,607)
Net assets acquired			35,048
Dacheng | Measurement Period Adjustments
Business Acquisition [Line Items]
Accounts receivable			(124)
Inventory			(177)
Prepaid expenses and other assets			22
Other intangible assets			965
Goodwill			(3,464)
Assumed liabilities			(515)
Deferred tax liabilities			$ 3,293

Acquisitions - Summary of Alloc

Acquisitions - Summary of Allocation of Purchase Consideration to Other Intangible Assets Acquired (Detail) - USD ($) $ in Thousands			12 Months Ended
	Aug. 01, 2022	Jul. 13, 2022	Dec. 31, 2023	Dec. 31, 2022
Alfmeier
Business Acquisition [Line Items]
Preliminary Fair Value, Total	$ 31,459			$ 31,459
Alfmeier | Customer Related
Business Acquisition [Line Items]
Preliminary Fair Value, Definite-lived	$ 19,812
Weighted Average Life (in years)	14 years		14 years
Alfmeier | Technology
Business Acquisition [Line Items]
Preliminary Fair Value, Definite-lived	$ 11,647
Weighted Average Life (in years)	9 years		9 years
Dacheng
Business Acquisition [Line Items]
Preliminary Fair Value, Total		$ 20,059		$ 20,059
Dacheng | Tradenames
Business Acquisition [Line Items]
Preliminary Fair Value, Indefinite-lived		2,473
Dacheng | Customer Related
Business Acquisition [Line Items]
Preliminary Fair Value, Definite-lived		$ 12,837
Weighted Average Life (in years)		12 years	12 years
Dacheng | Technology
Business Acquisition [Line Items]
Preliminary Fair Value, Definite-lived		$ 4,749
Weighted Average Life (in years)		12 years	12 years

Acquisitions - Summary of Unaud

Acquisitions - Summary of Unaudited Pro Forma Information (Detail) - Alfmeier - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Product revenues	$ 1,348,295	$ 1,304,505
Net Income	$ 17,645	$ 92,079

Restructuring and Impairments -

Restructuring and Impairments - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended	12 Months Ended
	Sep. 19, 2023	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Restructuring Cost And Reserve [Line Items]
Restructuring expenses			$ 4,739	$ 637	$ 3,857
Cash payments for restructuring expenses			3,102	1,462
Non-cash impairment charges			2,900
Impairment of goodwill			19,509
Medical Segments
Restructuring Cost And Reserve [Line Items]
Impairment of goodwill		$ 19,509
Property and Equipment
Restructuring Cost And Reserve [Line Items]
Non-cash impairment charges				690
Intangible Assets
Restructuring Cost And Reserve [Line Items]
Non-cash impairment charges				5,601
Inventory
Restructuring Cost And Reserve [Line Items]
Non-cash impairment charges			6,064	9,378
2023 Manufacturing Footprint Rationalization
Restructuring Cost And Reserve [Line Items]
Non cash expenses for accelerated depreciation and impairment of fixed assets	$ 1,000
2023 Manufacturing Footprint Rationalization | Maximum
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	16,000
Cash payments for restructuring expenses	15,000
Restructuring charges for capital expenditures	8,000
2023 Manufacturing Footprint Rationalization | Minimum
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	12,000
Cash payments for restructuring expenses	11,000
Restructuring charges for capital expenditures	7,000
Employee Separation Costs
Restructuring Cost And Reserve [Line Items]
Cash payments for restructuring expenses			2,224	881
Employee Separation Costs | Other Restructuring Activities
Restructuring Cost And Reserve [Line Items]
Restructuring expenses			3,208	56	2,192
Employee Separation Costs | 2023 Manufacturing Footprint Rationalization
Restructuring Cost And Reserve [Line Items]
Restructuring expenses			538
Other Restructuring
Restructuring Cost And Reserve [Line Items]
Cash payments for restructuring expenses			878	581
Other Restructuring | Other Restructuring Activities
Restructuring Cost And Reserve [Line Items]
Restructuring expenses			834	$ 581	$ 1,665
Other Restructuring | 2023 Manufacturing Footprint Rationalization | Maximum
Restructuring Cost And Reserve [Line Items]
Future restructuring expenses expected	3,000
Other Restructuring | 2023 Manufacturing Footprint Rationalization | Minimum
Restructuring Cost And Reserve [Line Items]
Future restructuring expenses expected	2,000
Other Costs | 2023 Manufacturing Footprint Rationalization
Restructuring Cost And Reserve [Line Items]
Restructuring expenses			$ 159
Employee Severance Retention and Termination Costs | 2023 Manufacturing Footprint Rationalization | Maximum
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	4,000
Employee Severance Retention and Termination Costs | 2023 Manufacturing Footprint Rationalization | Minimum
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	$ 2,000

Restructuring and Impairments_2

Restructuring and Impairments - Summary of Restructuring Expense by Reportable Segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	$ 4,739	$ 637	$ 3,857
Operating Segments | Automotive Segments
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	3,187	$ 637	2,793
Operating Segments | Medical Segments
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	363
Operating Segments | Corporate Segments
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	$ 1,189		$ 1,064

Restructuring and Impairments_3

Restructuring and Impairments - Summary of Restructuring Activity for All Restructuring Initiatives (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Restructuring Cost And Reserve [Line Items]
Balance, beginning of period	$ 588	$ 1,494
Additions, charged to restructuring expenses	4,885	587
Change in estimate	(146)	50
Cash payments	(3,102)	(1,462)
Non-cash utilization	(115)
Currency translation and other	40	(81)
Balance, end of period	2,150	588
Employee Separation Costs
Restructuring Cost And Reserve [Line Items]
Balance, beginning of period	588	1,494
Additions, charged to restructuring expenses	3,892	6
Change in estimate	(146)	50
Cash payments	(2,224)	(881)
Currency translation and other	40	(81)
Balance, end of period	2,150	588
Other Restructuring
Restructuring Cost And Reserve [Line Items]
Additions, charged to restructuring expenses	993	581
Cash payments	(878)	$ (581)
Non-cash utilization	$ (115)

Details of Certain Financial _3

Details of Certain Financial Statement Components (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Inventory:
Raw materials, net	$ 126,013	$ 136,217
Work in process, net	15,704	17,695
Finished goods, net	64,175	64,336
Total inventory, net	205,892	218,248
Other current assets:
Billable tooling	16,877	15,267
Income tax and other tax receivable	16,017	15,041
Short-term derivative financial instruments	10,717	6,564
Prepaid expenses	7,889	6,239
Other	4,272	3,869
Total other current assets	78,420	64,597
Property and equipment:
Machinery and equipment	236,277	214,342
Buildings and improvements	130,374	123,714
Information technology	41,543	39,726
Production tooling	28,033	24,839
Leasehold improvements	12,269	12,271
Construction in progress	27,461	29,023
Total property and equipment	475,957	443,915
Less: accumulated depreciation	(230,723)	(199,435)
Total property and equipment, net	245,234	244,480
Other current liabilities:
Accrued employee liabilities	43,176	32,031
Liabilities from discounts and rebates	22,916	26,640
Income tax and other taxes payable	19,327	14,459
Restructuring	2,150	588
Accrued warranty	3,945	2,380	$ 1,916
Other	9,291	17,716
Total other current liabilities	100,805	93,814
Related Party
Other current assets:
Notes receivable	18,226	12,127
Receivables due from factor	$ 4,422	$ 5,490

Goodwill and Other Intangible_2

Goodwill and Other Intangibles - Summary of Changes in the Carrying Amount of Goodwill, By Reportable Segment (Detail) - USD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Goodwill [Line Items]
Balance, beginning of period		$ 119,774,000	$ 119,774,000
Impairment of goodwill			(19,509,000)
Balance, end of period	$ 104,073,000		104,073,000	$ 119,774,000
Operating Segments
Goodwill [Line Items]
Balance, beginning of period		119,774,000	119,774,000	66,033,000
Impairment of goodwill			(19,509,000)
Currency translation and other			3,808,000	231,000
Balance, end of period	104,073,000		104,073,000	119,774,000
Automotive Segments | Operating Segments
Goodwill [Line Items]
Balance, beginning of period		73,069,000	73,069,000	37,329,000
Currency translation and other			3,627,000	1,246,000
Balance, end of period	76,696,000		76,696,000	73,069,000
Medical Segments | Operating Segments
Goodwill [Line Items]
Balance, beginning of period		46,705,000	46,705,000	28,704,000
Impairment of goodwill	0	(19,509,000)	(19,509,000)
Currency translation and other			181,000	(1,015,000)
Balance, end of period	$ 27,376,000		27,376,000	46,705,000
Dacheng [Member]
Goodwill [Line Items]
Balance, beginning of period		19,531,000	19,531,000
Balance, end of period				19,531,000
Dacheng [Member] | Operating Segments
Goodwill [Line Items]
Acquisition				19,016,000
Dacheng [Member] | Medical Segments | Operating Segments
Goodwill [Line Items]
Acquisition				19,016,000
Alfmeier [Member]
Goodwill [Line Items]
Balance, beginning of period		$ 33,971,000	$ 33,971,000
Balance, end of period				33,971,000
Alfmeier [Member] | Operating Segments
Goodwill [Line Items]
Acquisition				34,494,000
Alfmeier [Member] | Automotive Segments | Operating Segments
Goodwill [Line Items]
Acquisition				$ 34,494,000

Goodwill and Other Intangible_3

Goodwill and Other Intangibles - Summary of Other Intangible Assets and Accumulated Amortization Balances (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Intangible Assets [Line Items]
Gross Carrying Value	$ 188,806	$ 183,846
Accumulated Amortization	(122,324)	(109,913)
Net Carrying Value	66,482	73,933
Customer Relationship
Intangible Assets [Line Items]
Gross Carrying Value	115,465	112,286
Accumulated Amortization	(73,737)	(65,748)
Net Carrying Value	41,728	46,538
Technology
Intangible Assets [Line Items]
Gross Carrying Value	45,861	44,745
Accumulated Amortization	(29,317)	(25,709)
Net Carrying Value	16,544	19,036
Product Development Costs
Intangible Assets [Line Items]
Gross Carrying Value	19,434	18,774
Accumulated Amortization	(19,270)	(18,456)
Net Carrying Value	164	318
Software Development
Intangible Assets [Line Items]
Gross Carrying Value	1,007	1,007
Net Carrying Value	1,007	1,007
Tradenames
Intangible Assets [Line Items]
Gross Carrying Value	7,039	7,034
Net Carrying Value	$ 7,039	$ 7,034

Goodwill and Other Intangible_4

Goodwill and Other Intangibles - Additional Information (Detail) - USD ($)			6 Months Ended		12 Months Ended
	Aug. 01, 2022	Jul. 13, 2022	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Goodwill And Other Intangible Assets [Line Items]
Carrying value percentage			10%		10%
Intangible assets			$ 66,482,000		$ 66,482,000	$ 73,933,000
Other intangible assets			8,290,000		8,290,000	9,018,000	$ 8,821,000
Impairment of goodwill					19,509,000
Operating Segments
Goodwill And Other Intangible Assets [Line Items]
Impairment of goodwill					19,509,000
Operating Segments | Medical Segments
Goodwill And Other Intangible Assets [Line Items]
Impairment of goodwill			0	$ 19,509,000	19,509,000
Technology
Goodwill And Other Intangible Assets [Line Items]
Intangible assets			16,544,000		16,544,000	19,036,000
Customer Relationship
Goodwill And Other Intangible Assets [Line Items]
Intangible assets			41,728,000		41,728,000	46,538,000
Impairment of intangible asset						$ 5,601,000
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]						Impairment of Intangible Assets (Excluding Goodwill)
Other intangible impairment charges						$ 5,601,000
Dacheng [Member] | Technology
Goodwill And Other Intangible Assets [Line Items]
Intangible assets			4,749,000		$ 4,749,000
Weighted Average Life (in years)		12 years			12 years
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life		12 years			12 years
Dacheng [Member] | Customer Relationship
Goodwill And Other Intangible Assets [Line Items]
Intangible assets			12,837,000		$ 12,837,000
Weighted Average Life (in years)		12 years			12 years
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life		12 years			12 years
Alfmeier [Member] | Technology
Goodwill And Other Intangible Assets [Line Items]
Intangible assets			11,647,000		$ 11,647,000
Weighted Average Life (in years)	9 years				9 years
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	9 years				9 years
Alfmeier [Member] | Customer Relationship
Goodwill And Other Intangible Assets [Line Items]
Intangible assets			19,812,000		$ 19,812,000
Weighted Average Life (in years)	14 years				14 years
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	14 years				14 years
Trade Names [Member] | Dacheng [Member]
Goodwill And Other Intangible Assets [Line Items]
Intangible assets			$ 2,473,000		$ 2,473,000

Goodwill and Other Intangible_5

Goodwill and Other Intangibles - Summary of Estimate of Future Amortization of Other Intangible Assets (Detail) $ in Thousands	Dec. 31, 2023 USD ($)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2024	$ 6,991
2025	6,977
2026	6,541
2027	6,454
2028	$ 6,389

Leases - Components of Lease Ex

Leases - Components of Lease Expense and Other Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Lease cost:
Operating lease cost	$ 9,606	$ 8,040	$ 8,227
Amortization of ROU assets - finance leases	390	168
Interest on lease liabilities - finance leases	28	16
Short-term lease cost	2,651	1,773	1,941
Sublease income		(101)	(163)
Total lease cost	12,675	9,896	$ 10,005
Operating cash flows for operating leases	9,249	10,381
Operating cash flows for finance leases	81	16
Financing cash flows for finance leases	390	164
Right-of-use lease assets obtained in exchange for lease obligations, Operating leases	$ 4,704	15,902
Right-of-use lease assets obtained in exchange for lease obligations, Finance leases		$ 1,180
Weighted-average remaining lease term, Operating leases	5 years 7 months 6 days	5 years 8 months 12 days
Weighted-average remaining lease term, Finance leases	1 year 10 months 24 days	2 years 8 months 12 days
Weighted-average discount rate, Operating leases	4.96%	4.35%
Weighted-average discount rate, Finance leases	3.53%	3.57%

Leases - Summary of Operating L

Leases - Summary of Operating Leases Under all Non-Cancellable Operating Leases (Detail) $ in Thousands	Dec. 31, 2023 USD ($)
Leases [Abstract]
2024	$ 8,533
2025	5,588
2026	3,656
2027	2,027
2028	1,798
2029 or later	5,827
Total future minimum lease payments	27,429
Less imputed interest	(3,554)
Total	$ 23,875

Leases - Summary of Finance Lea

Leases - Summary of Finance Leases Under all Non-Cancellable Finance Leases (Detail) $ in Thousands	Dec. 31, 2023 USD ($)
Leases [Abstract]
2024	$ 388
2025	152
2026	70
Total future minimum lease payments	610
Less imputed interest	$ (5)
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Total
Total	$ 605

Summary of Company's Debt (Deta

Summary of Company's Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Total debt	$ 222,838	$ 235,096
Current maturities	(621)	(2,443)
Long-term debt, less current maturities	$ 222,217	$ 232,653
U.S. Revolving Note (U.S. Dollar Denominations)
Debt Instrument [Line Items]
Interest Rate	6.58%	5.80%
Total debt	$ 222,000	$ 232,000
Other Loans
Debt Instrument [Line Items]
Interest Rate	3.90%
Total debt	$ 233	$ 2,011
Other Loans | Minimum
Debt Instrument [Line Items]
Interest Rate		3.89%
Other Loans | Maximum
Debt Instrument [Line Items]
Interest Rate		5.21%
Finance Leases
Debt Instrument [Line Items]
Interest Rate	3.53%	3.57%
Total debt	$ 605	$ 1,085

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)				12 Months Ended
	Jun. 10, 2027	Jun. 27, 2024	Jun. 10, 2022	Dec. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Maximum percentage of stock of non US subsidiaries pledge to secure obligation				66%
Unamortized deferred debt issuance costs written off				$ 144,000
Second Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Remaining borrowing capacity				$ 278,000,000
Second Amended and Restated Credit Agreement | Federal Funds Rate
Debt Instrument [Line Items]
Interest rate				0.50%
Second Amended and Restated Credit Agreement | SOFR Rate
Debt Instrument [Line Items]
Interest rate				1%
Term SOFR Rate Loans | Second Amended and Restated Credit Agreement | Minimum
Debt Instrument [Line Items]
Interest rate				1.125%
Term SOFR Rate Loans | Second Amended and Restated Credit Agreement | Maximum
Debt Instrument [Line Items]
Interest rate				2.125%
Base Rate Loans | Second Amended and Restated Credit Agreement | Minimum
Debt Instrument [Line Items]
Interest rate				0.125%
Base Rate Loans | Second Amended and Restated Credit Agreement | Maximum
Debt Instrument [Line Items]
Interest rate				1.125%
Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity increase subject to specified conditions			$ 200,000,000
Revolving Credit Facility | Second Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity			500,000,000
Increase in maximum borrowing capacity			25,000,000
Debt issuance cost			1,520,000
Revolving Credit Facility | Second Amended and Restated Credit Agreement | Minimum
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage				0.175%
Revolving Credit Facility | Second Amended and Restated Credit Agreement | Maximum
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage				0.30%
Revolving Credit Facility | Letters of Credit
Debt Instrument [Line Items]
Line of credit, outstanding amount				$ 0	$ 0
Revolving Credit Facility | Swing Line Loans
Debt Instrument [Line Items]
Maximum borrowing capacity			50,000,000
Standby Letters of Credit | Second Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 15,000,000
Scenario Forecast | Revolving Credit Facility | Second Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Debt maturity date	Jun. 10, 2027
Scenario Forecast | Revolving Credit Facility | Revolving Note (U.S. Dollar)
Debt Instrument [Line Items]
Debt maturity date		Jun. 27, 2024

Principal Maturities of Debt (D

Principal Maturities of Debt (Detail) $ in Thousands	Dec. 31, 2023 USD ($)
Debt Instrument [Line Items]
Debt maturing in 2024	$ 621
Debt maturing in 2025	152
Debt maturing in 2026	70
Debt maturing in 2027	222,000
Total	222,843
US and Euro Denominated Revolving Note
Debt Instrument [Line Items]
Debt maturing in 2027	222,000
Total	222,000
Other Debt
Debt Instrument [Line Items]
Debt maturing in 2024	621
Debt maturing in 2025	152
Debt maturing in 2026	70
Total	$ 843

Pension and Other Post Retire_3

Pension and Other Post Retirement Benefit Plans - Components of Net Periodic Benefit Cost for Company's Defined Benefit Plans (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
United States
Net periodic benefit cost:
Interest cost	$ 115	$ 56	$ 42
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, General and Administrative Expense	Selling, General and Administrative Expense	Selling, General and Administrative Expense
Amortization of prior service cost and actuarial loss		$ 22	$ 26
Net periodic benefit cost	$ 115	$ 78	$ 68
Assumptions:
Discount rate	4.65%	1.80%	1.20%
German Plan
Net periodic benefit cost:
Interest cost	$ 217	$ 92	$ 91
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, General and Administrative Expense	Selling, General and Administrative Expense	Selling, General and Administrative Expense
Expected return on plan assets	$ (115)	$ (109)	$ (120)
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax	Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax	Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax
Amortization of prior service cost and actuarial loss	$ 23	$ 114	$ 133
Net periodic benefit cost	$ 125	$ 97	$ 104
Assumptions:
Discount rate	4.10%	1.08%	1.06%
Long-term return on assets	3.20%	2.90%	2.90%

Pension and Other Post Retire_4

Pension and Other Post Retirement Benefit Plans - Reconciliation of Change in Benefit Obligation, Change in Plan Assets and Balance Sheet Classification (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Balance sheet classification:
Pension benefit obligation	$ (3,209)	$ (3,638)
United States
Change in projected benefit obligation:
Balance at beginning of year	2,811	3,446
Interest cost	115	56	$ 42
Paid pension distributions	(342)	(342)
Actuarial loss (gain)	18	(349)
Balance at end of year	2,602	2,811	3,446
Change in plan assets:
Underfunded Status	(2,602)	(2,811)
Balance sheet classification:
Other current liabilities	(357)	(342)
Pension benefit obligation	(2,245)	(2,469)
Accumulated other comprehensive loss (pre-tax):
Actuarial losses	$ 223	$ 205
Discount rate	4.45%	4.65%
German Plan
Change in projected benefit obligation:
Balance at beginning of year	$ 5,398	$ 8,102
Interest cost	217	92	91
Paid pension distributions	(290)	(281)
Actuarial loss (gain)	(89)	(2,001)
Exchange rate impact	170	(514)
Balance at end of year	5,406	5,398	8,102
Change in plan assets:
Balance at beginning of year	3,918	4,069
Actual return on plan assets	98	89
Exchange rate impact	129	(240)
Balance at end of year	4,145	3,918	$ 4,069
Underfunded Status	(1,261)	(1,480)
Balance sheet classification:
Other current liabilities	(297)	(314)
Pension benefit obligation	(964)	(1,166)
Accumulated other comprehensive loss (pre-tax):
Actuarial losses	$ 899	$ 965
Discount rate	4.56%	4.10%

Pension and Other Post Retire_5

Pension and Other Post Retirement Benefit Plans - Summary of Pre-tax Amounts in AOCI Expected to Be Recognized in Net Periodic Benefit Cost (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
United States
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses		$ 223	$ 205
German Plan
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses		$ 899	$ 965
German Plan | Scenario Forecast
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	$ 20

Pension and Other Post Retire_6

Pension and Other Post Retirement Benefit Plans - Summary of Accumulated Benefit Obligations (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
United States
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligation	$ 2,602	$ 2,811
German Plan
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligation	$ 5,406	$ 5,398

Pension and Other Post Retire_7

Pension and Other Post Retirement Benefit Plans - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
401(k) Plan
Defined Benefit Plan Disclosure [Line Items]
Cost recognized for contributions to defined contribution plan	$ 2,344,000	$ 1,984,000	$ 1,724,000
United States
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, expected employer contribution in next fiscal year	0
German Plan
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, expected employer contribution in next fiscal year	$ 0

Pension and Other Post Retire_8

Pension and Other Post Retirement Benefit Plans - Schedule of Future Expected Pension Payments (Detail) $ in Thousands	Dec. 31, 2023 USD ($)
United States
Defined Benefit Plan Disclosure [Line Items]
2024	$ 342
2025	342
2026	342
2027	342
2028	342
2029-2032	1,368
Total projected pension benefit payments	3,078
German Plan
Defined Benefit Plan Disclosure [Line Items]
2024	324
2025	314
2026	303
2027	292
2028	279
2029-2032	2,893
Total projected pension benefit payments	$ 4,405

Commitments and Contingencies -

Commitments and Contingencies - Reconciliation of Changes in Accrued Warranty Costs (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Loss Contingency [Abstract]
Balance at beginning of year	$ 2,380	$ 1,916
Warranty opening balance from acquired entities		907
Warranty claims paid	(2,252)	(1,841)
Warranty expense for products shipped during the current period	3,955	1,584
Adjustments to warranty estimates from prior periods	(174)	(274)
Adjustments due to currency translation	36	88
Balance at end of year	$ 3,945	$ 2,380

Commitments and Contingencies_2

Commitments and Contingencies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2023
Labor Agreements
Loss Contingencies [Line Items]
Percentage of workforce as members of industrial trade unions	33%

Earnings Per Share (Detail)

Earnings Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Earnings Per Share [Abstract]
Net income	$ 40,343	$ 24,441	$ 93,434
Basic weighted average shares of Common Stock outstanding	32,778,055	33,126,202	33,085,732
Dilutive effect of stock options, restricted share awards and restricted stock units	288,862	376,952	423,988
Diluted weighted average shares of Common Stock outstanding	33,066,917	33,503,154	33,509,720
Basic earnings per share	$ 1.23	$ 0.74	$ 2.82
Diluted earnings per share	$ 1.22	$ 0.73	$ 2.79

Financial Instruments - Additio

Financial Instruments - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022		Dec. 31, 2021	Sep. 30, 2022	Jun. 30, 2022
Derivative [Line Items]
Trade receivables	$ 135,116,000	$ 61,482,000	[1]
Factoring fees	800,000	180,000	[1]
Factoring receivables not yet paid	18,532,000	19,108,000
Collective limit under factoring arrangements	24,423,000	24,142,000
Interest Rate Swap
Derivative [Line Items]
Hedge Ineffectiveness Incurred	$ 0	0
Floating to Fixed interest Rate Swap
Derivative [Line Items]
Notional Value						$ 100,000,000
Maturity date	Jul. 31, 2025
Foreign Currency Derivatives
Derivative [Line Items]
Gain (loss) on derivatives	$ 12,113,000	4,954,000		$ 392,000
Foreign Currency Derivatives | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Gain (loss) on derivatives		(3,806,000)
Foreign Currency Derivatives | Derivatives Not Designated as Hedging Instruments | Foreign Currency (Loss) Gain
Derivative [Line Items]
Gain (loss) on derivatives		$ (3,806,000)
Alfmeier | Foreign Currency Derivatives | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Notional Value					$ 128,319,000	$ 128,319,000
[1] Represents trade receivables sold and factoring fees incurred since the acquisition of Alfmeier (acquired on August 1, 2022).

Information Related to Recurrin

Information Related to Recurring Fair Value Measurement of Derivative Financial Instruments in the Consolidated Balance Sheet (Detail) - Fair Value, Inputs, Level 2 - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Foreign Currency Derivatives | Designated as Hedging Instrument
Derivatives Fair Value [Line Items]
Notional Amount	$ 101,109	$ 40,063
Net Asset/ (Liabilities)	8,655	3,791
Foreign Currency Derivatives | Designated as Hedging Instrument | Other Current Assets
Derivatives Fair Value [Line Items]
Asset Derivatives, Fair Value	8,655	3,791
Interest Rate Contracts | Derivatives Not Designated as Hedging Instruments
Derivatives Fair Value [Line Items]
Notional Amount	100,000	100,000
Net Asset/ (Liabilities)	2,062	2,772
Interest Rate Contracts | Derivatives Not Designated as Hedging Instruments | Other Current Assets
Derivatives Fair Value [Line Items]
Asset Derivatives, Fair Value	$ 2,062	$ 2,772

Information Related to Effect o

Information Related to Effect of Derivative Instruments in the Consolidated Statements of Income (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives	$ 12,113	$ 4,954	$ 392
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax
Commodity Hedges
Derivative Instruments Gain Loss [Line Items]
Total commodity derivatives		$ 13	$ 20
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]		Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax
Other comprehensive (loss) income | Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives	$ 3,483	$ 3,496	$ (1,217)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax
Other comprehensive (loss) income | Commodity Hedges
Derivative Instruments Gain Loss [Line Items]
Total commodity derivatives		$ (6)	$ 6
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]		Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax
Derivatives Not Designated as Hedging Instruments | Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives		$ (3,806)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]		Gain (Loss), Foreign Currency Transaction, before Tax
Derivatives Not Designated as Hedging Instruments | Interest Rate Contracts
Derivative Instruments Gain Loss [Line Items]
Total interest rate derivatives	$ (710)	$ 2,772
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Income (Expense), Net	Interest Income (Expense), Net
Cost of sales | Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives	$ 8,630	$ 1,458	$ 1,609
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of Goods and Services Sold	Cost of Goods and Services Sold	Cost of Goods and Services Sold
Cost of sales | Commodity Hedges
Derivative Instruments Gain Loss [Line Items]
Total commodity derivatives		$ 19	$ 14
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]		Cost of Goods and Services Sold	Cost of Goods and Services Sold
Foreign Currency (Loss) Gain | Derivatives Not Designated as Hedging Instruments | Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives		$ (3,806)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]		Gain (Loss), Foreign Currency Transaction, before Tax
Interest Income (Expense), Net | Derivatives Not Designated as Hedging Instruments | Interest Rate Contracts
Derivative Instruments Gain Loss [Line Items]
Total interest rate derivatives	$ (710)	$ 2,772
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Income (Expense), Net	Interest Income (Expense), Net

Financial Instruments - Summary

Financial Instruments - Summary of Receivables Factored and Availability Under Receivables Factoring Agreements (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Receivables factored and outstanding	$ 18,532	$ 19,108
Amount available under the credit limit	5,891	5,034
Maximum Limits for Accounts Receivable Factoring Arrangements, Total	$ 24,423	$ 24,142

Financial Instruments - Summa_2

Financial Instruments - Summary of Trade Receivables Sold and Factoring Fees Incurred (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	[1]
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Trade receivables sold	$ 135,116	$ 61,482
Factoring fees incurred	$ 800	$ 180
[1] Represents trade receivables sold and factoring fees incurred since the acquisition of Alfmeier (acquired on August 1, 2022).

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Recurring Basis
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Financial assets, fair value	$ 0	$ 0
Financial liabilities, fair value	0	0
Fair Value, Nonrecurring Basis
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Financial assets, fair value	0	0
Financial liabilities, fair value	$ 0	$ 0

Equity - Additional Information

Equity - Additional Information (Detail) - USD ($) $ in Thousands			12 Months Ended
	Nov. 02, 2023	Nov. 01, 2023	Dec. 31, 2023	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2022
Class Of Stock [Line Items]
Common Stock, shares authorized			55,000,000			55,000,000
Preferred stock, shares authorized			4,991,000
Common Stock, shares issued			31,542,001			33,202,082
Common Stock, shares outstanding			31,542,001			33,202,082
Preferred stock, shares issued			0
Preferred stock, shares outstanding			0
Cash paid to repurchased shares			$ 91,094	$ 20,000
ASR Agreement
Class Of Stock [Line Items]
Initial repurchase, shares	1,220,000
Initial repurchase, percentage	80%
ASR Agreement | Bank of America
Class Of Stock [Line Items]
Cash paid to repurchased shares	$ 60,000
2020 Stock Repurchase Program
Class Of Stock [Line Items]
Cash paid to repurchased shares			92,510
Remaining authorized repurchase amount			$ 37,491
Stock repurchase program period					3 years
Stock repurchase program expiration date		Jun. 30, 2024			Dec. 15, 2023
2020 Stock Repurchase Program | ASR Agreement
Class Of Stock [Line Items]
Share repurchase authorized aggregate amount		$ 60,000
Maximum
Class Of Stock [Line Items]
Shares issued			59,991,000
Maximum | 2020 Stock Repurchase Program
Class Of Stock [Line Items]
Stock repurchase program, authorized to repurchase amount					150,000

Schedule of Reclassification Ad

Schedule of Reclassification Adjustments and Other Activities Impacting Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance	$ (46,489)		$ (36,922)		$ (14,982)
Other comprehensive income (loss) before reclassifications	26,265		(6,478)		(20,350)
Income tax effect of other comprehensive income (loss) before reclassifications	(2,471)		(2,011)		(437)
Amounts reclassified from accumulated other comprehensive loss into net income	(9,580)		(1,340)		(1,464)
Income taxes reclassified into net income	2,115		262		311
Other comprehensive income (loss), net of tax	16,329		(9,567)		(21,940)
Ending Balance	(30,160)		(46,489)		(36,922)
Defined Benefit Pension Plans
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance	(1,067)		(2,893)		(3,451)
Other comprehensive income (loss) before reclassifications	54		2,341		512
Income tax effect of other comprehensive income (loss) before reclassifications	(15)		(621)		(71)
Amounts reclassified from accumulated other comprehensive loss into net income	23		137		159
Income taxes reclassified into net income	(6)		(31)		(42)
Other comprehensive income (loss), net of tax	56		1,826		558
Ending Balance	(1,011)		(1,067)		(2,893)
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance	(48,269)		(34,188)		(12,637)
Other comprehensive income (loss) before reclassifications	13,125		(13,786)		(21,274)
Income tax effect of other comprehensive income (loss) before reclassifications	314		(295)		(277)
Other comprehensive income (loss), net of tax	13,439		(14,081)		(21,551)
Ending Balance	(34,830)		(48,269)		(34,188)
Commodity Hedge Derivatives
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance			5
Other comprehensive income (loss) before reclassifications			13		20
Income tax effect of other comprehensive income (loss) before reclassifications			(3)		(4)
Amounts reclassified from accumulated other comprehensive loss into net income			(19)	[1]	(14)	[2]
Income taxes reclassified into net income			4		3
Other comprehensive income (loss), net of tax			(5)		5
Ending Balance					5
Foreign Currency Hedge Derivatives
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance	2,847		154		1,106
Other comprehensive income (loss) before reclassifications	13,086		4,954		392
Income tax effect of other comprehensive income (loss) before reclassifications	(2,770)		(1,092)		(85)
Amounts reclassified from accumulated other comprehensive loss into net income	(9,603)	[3]	(1,458)	[1]	(1,609)	[2]
Income taxes reclassified into net income	2,121		289		350
Other comprehensive income (loss), net of tax	2,834		2,693		(952)
Ending Balance	$ 5,681		$ 2,847		$ 154
[1] The amounts reclassified from Accumulated other comprehensive loss are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instruments on our consolidated statements of income. The amounts reclassified from Accumulated other comprehensive loss are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instruments on our consolidated statements of income. The amounts reclassified from Accumulated other comprehensive loss are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instruments on our consolidated statements of income.

Accounting for Stock Based Co_3

Accounting for Stock Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	May 18, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Performance based restricted stock units outstanding	17,923	13,600	11,376	34,906
Awards vesting period	1 year 10 months 13 days
Shareholder Return Award Performance Measurement Period	3 years
Deferred tax benefit (expense)	$ 1,794	$ (444)	$ 2,725
Granted, Shares	0	0	0	0	0	0
Total intrinsic value of options exercised	$ 201	$ 1,582	$ 8,269
Total fair value of restricted stock vested	$ 875	$ 800	$ 1,554
Performance Based Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Performance based restricted stock units outstanding	324,977	320,449	319,336	315,834
Awards vesting period	1 year 11 months 19 days
Awards vesting condition	Company’s achievement of one of four separate performance metrics: a target return on invested capital ratio (“ROIC”), as defined in the award agreement, for a specified fiscal year; a target three-year cumulative Adjusted EBITDA (“Adjusted EBITDA”), as defined in the award agreement; the Company’s relative total shareholder return (“TSR”), as defined in the award agreement, during a specific three-year measurement period; and a target relative revenue growth relative to light vehicle production in the Company's relevant markets ("RRG"), as defined in the award agreement, during a specific three-year measurement period.
Stock option achieving minimum threshold	50%
Stock option achieving maximum threshold	200%
Total intrinsic value of stock units vested	$ 2,951	$ 6,986	$ 4,265
ROIC
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Awards vesting period	3 years
RSU
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Awards vesting period	1 year 10 months 2 days
Total intrinsic value of stock units vested	$ 4,915	$ 4,774	$ 3,398
Stock Appreciation Rights (SARs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted, Shares	0	0	0	0	0	0
Total intrinsic value of options exercised	$ 242	$ 1,348	$ 4,301
Employee and Consultants | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation, requisite service period	2 years
Employee and Consultants | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation, requisite service period	4 years
Director
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation, requisite service period	1 year
2023 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares authorized for grant	3,683,330
Number of shares authorized for grant							3,730,000

Accounting for Stock Based Co_4

Accounting for Stock Based Compensation - Summary of Recognized and Unrecognized Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense	$ 11,627	$ 6,599	$ 14,530
Unrecognized Stock-Based Compensation Expense	$ 19,285
Remaining Weighted Average Vesting Period	1 year 10 months 13 days
RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense	$ 6,216	5,551	4,594
Unrecognized Stock-Based Compensation Expense	$ 9,124
Remaining Weighted Average Vesting Period	1 year 10 months 2 days
PSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense	$ 4,661	954	5,535
Unrecognized Stock-Based Compensation Expense	$ 9,724
Remaining Weighted Average Vesting Period	1 year 11 months 19 days
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense	$ 878	888	1,198
Unrecognized Stock-Based Compensation Expense	$ 437
Remaining Weighted Average Vesting Period	4 months 17 days
SARs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense	$ (128)	$ (794)	2,721
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense			$ 482

Accounting for Stock Based Co_5

Accounting for Stock Based Compensation - Summarizes RSU Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	13,600	11,376	34,906
Granted, Shares	17,923	13,600	13,742
Vested, Shares	(11,900)	(11,376)	(37,272)
Forfeited, Shares	(1,700)
Outstanding at end of period, Shares	17,923	13,600	11,376
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 73.54	$ 70.33	$ 39.82
Granted, Weighted-Average Grant Date Fair Value	56.96	73.54	70.18
Vested, Weighted-Average Grant Date Fair Value	73.54	70.33	41.7
Forfeited, Weighted-Average Grant Date Fair Value	73.54
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 56.96	$ 73.54	$ 70.33
RSU | Time Vesting Shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	201,578	193,626	208,905
Granted, Shares	136,964	117,507	93,539
Vested, Shares	(82,695)	(95,692)	(88,296)
Forfeited, Shares	(23,986)	(13,863)	(20,522)
Outstanding at end of period, Shares	231,861	201,578	193,626
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 64.27	$ 56.02	$ 37.26
Granted, Weighted-Average Grant Date Fair Value	58.68	66.86	79.79
Vested, Weighted-Average Grant Date Fair Value	59.43	49.85	38.49
Forfeited, Weighted-Average Grant Date Fair Value	59.47	70.52	48.76
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 63.19	$ 64.27	$ 56.02

Accounting for Stock Based Co_6

Accounting for Stock Based Compensation - Summarizes PSU Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	13,600	11,376	34,906
Granted, Shares	17,923	13,600	13,742
Vested, Shares	(11,900)	(11,376)	(37,272)
Forfeited, Shares	(1,700)
Outstanding at end of period, Shares	17,923	13,600	11,376
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 73.54	$ 70.33	$ 39.82
Granted, Weighted-Average Grant Date Fair Value	56.96	73.54	70.18
Vested, Weighted-Average Grant Date Fair Value	73.54	70.33	41.7
Forfeited, Weighted-Average Grant Date Fair Value	73.54
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 56.96	$ 73.54	$ 70.33
Performance Based Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	320,449	319,336	315,834
Granted, Shares	153,121	106,604	101,136
Performance Adjustment, Shares	(59,928)	42,746	(2)
Vested, Shares	(59,928)	(133,477)	(61,656)
Forfeited, Shares	(28,737)	(14,760)	(35,976)
Outstanding at end of period, Shares	324,977	320,449	319,336
Performance Based Units | Relative TSR Target Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	102,801	131,568	157,918
Granted, Shares	30,622	21,324	20,626
Performance Adjustment, Shares		45,004	30,828
Vested, Shares	(59,928)	(90,371)	(61,656)
Forfeited, Shares	(8,494)	(4,724)	(16,148)
Outstanding at end of period, Shares	65,001	102,801	131,568
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 65.2	$ 62.09	$ 56.06
Granted, Weighted-Average Grant Date Fair Value	89.87	103.31	118.08
Performance Adjustment, Weighted-Average Grant Date Fair Value		57.46	69.18
Vested, Weighted-Average Grant Date Fair Value	49.25	57.46	69.18
Forfeited, Weighted-Average Grant Date Fair Value	75.67	68.67	61.1
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 101.15	$ 65.2	$ 62.09
Performance Based Units | ROIC Target Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	141,075	150,292	157,916
Granted, Shares	30,622	42,640	40,580
Performance Adjustment, Shares	(59,928)	(2,258)	(30,830)
Vested, Shares		(43,106)
Forfeited, Shares	(11,618)	(6,493)	(17,374)
Outstanding at end of period, Shares	100,151	141,075	150,292
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 55.18	$ 47.52	$ 38.58
Granted, Weighted-Average Grant Date Fair Value	59.91	68.63	78.98
Performance Adjustment, Weighted-Average Grant Date Fair Value	33.9	41.61	44.92
Vested, Weighted-Average Grant Date Fair Value		41.61
Forfeited, Weighted-Average Grant Date Fair Value	55.94	56.87	44.32
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 69.55	$ 55.18	$ 47.52
Performance Based Units | Adjusted EBITDA Target Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	76,573	37,476
Granted, Shares	61,255	42,640	39,930
Forfeited, Shares	(7,836)	(3,543)	(2,454)
Outstanding at end of period, Shares	129,992	76,573	37,476
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 73.66	$ 79.49
Granted, Weighted-Average Grant Date Fair Value	59.91	68.63	$ 79.49
Forfeited, Weighted-Average Grant Date Fair Value	70.95	75.1	79.49
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 67.34	$ 73.66	$ 79.49
Performance Based Units | RRG Target Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted, Shares	30,622
Forfeited, Shares	(789)
Outstanding at end of period, Shares	29,833
Granted, Weighted-Average Grant Date Fair Value	$ 59.91
Forfeited, Weighted-Average Grant Date Fair Value	59.91
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 59.91

Accounting for Stock Based Co_7

Accounting for Stock Based Compensation - Summarizes Restricted Stock Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]
Outstanding at beginning of period, Shares	13,600	11,376	34,906
Granted, Shares	17,923	13,600	13,742
Vested, Shares	(11,900)	(11,376)	(37,272)
Forfeited, Shares	(1,700)
Outstanding at end of period, Shares	17,923	13,600	11,376
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 73.54	$ 70.33	$ 39.82
Granted, Weighted-Average Grant Date Fair Value	56.96	73.54	70.18
Vested, Weighted-Average Grant Date Fair Value	73.54	70.33	41.7
Forfeited, Weighted-Average Grant Date Fair Value	73.54
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 56.96	$ 73.54	$ 70.33

Accounting for Stock Based Co_8

Accounting for Stock Based Compensation - Summarizes SARs Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options Outstanding, beginning balance, Shares	162,634	206,750	428,000
Granted, Shares	0	0	0	0	0	0
Exercised, Shares	(6,450)	(44,116)	(215,250)
Forfeited, Shares	(16,500)		(6,000)
Stock Options Outstanding, ending balance, Shares	139,684	162,634	206,750	428,000
Exercisable, Ending Balance	139,684
Stock Options Outstanding, beginning balance, Weighted-Average Exercise Price	$ 36.41	$ 36.72	$ 37.61
Exercised, Weighted-Average Exercise Price	40.79	37.87	38.46
Forfeited, Weighted-Average Exercise Price	41.59		38.05
Stock Options Outstanding, ending balance, Weighted-Average Exercise Price	35.59	$ 36.41	$ 36.72	$ 37.61
Exercisable, Weighted Average Exercise Price	$ 35.59
Stock Options Outstanding, Weighted-Average Remaining Contractual Term	10 months 24 days	2 years 8 months 4 days	2 years 7 months 6 days	3 years 2 months 12 days
Exercisable, Weighted-Average Remaining Contractual Term	10 months 24 days
Outstanding, Aggregate Intrinsic Value	$ 2,342	$ 8,212	$ 10,375	$ 11,815
Exercisable, Aggregate Intrinsic Value	$ 2,342
Stock Appreciation Rights (SARs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options Outstanding, beginning balance, Shares	14,750	55,600	171,600
Granted, Shares	0	0	0	0	0	0
Exercised, Shares	(12,500)	(40,850)	(116,000)
Stock Options Outstanding, ending balance, Shares	2,250	14,750	55,600	171,600
Exercisable, Ending Balance	2,250
Stock Options Outstanding, beginning balance, Weighted-Average Exercise Price	$ 38.05	$ 41.15	$ 40.6
Exercised, Weighted-Average Exercise Price	38.05	42.27	40.34
Stock Options Outstanding, ending balance, Weighted-Average Exercise Price	38.05	$ 38.05	$ 41.15	$ 40.6
Exercisable, Weighted Average Exercise Price	$ 38.05
Stock Options Outstanding, Weighted-Average Remaining Contractual Term	1 month 24 days	1 year 1 month 24 days	1 year 3 months 10 days	2 years 5 months 8 days
Exercisable, Weighted-Average Remaining Contractual Term	1 month 24 days
Outstanding, Aggregate Intrinsic Value	$ 32	$ 402	$ 2,544	$ 4,224
Exercisable, Aggregate Intrinsic Value	$ 32

Accounting for Stock Based Co_9

Accounting for Stock Based Compensation - Summarizes Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-Based Payment Arrangement [Abstract]
Stock Options Outstanding, beginning balance, Shares	162,634	206,750	428,000
Granted, Shares	0	0	0	0	0	0
Exercised, Shares	(6,450)	(44,116)	(215,250)
Forfeited, Shares	(16,500)		(6,000)
Stock Options Outstanding, ending balance, Shares	139,684	162,634	206,750	428,000
Stock Options Exercisable, Shares	139,684
Stock Options Outstanding, beginning balance, Weighted-Average Exercise Price	$ 36.41	$ 36.72	$ 37.61
Exercised, Weighted-Average Exercise Price	40.79	37.87	38.46
Forfeited, Weighted-Average Exercise Price	41.59		38.05
Stock Options Outstanding, ending balance, Weighted-Average Exercise Price	35.59	$ 36.41	$ 36.72	$ 37.61
Exercisable, Weighted-Average Exercise Price	$ 35.59
Stock Options Outstanding, Weighted-Average Remaining Contractual Term	10 months 24 days	2 years 8 months 4 days	2 years 7 months 6 days	3 years 2 months 12 days
Exercisable, Weighted-Average Remaining Contractual Term	10 months 24 days
Stock Options Outstanding, Aggregate Intrinsic Value	$ 2,342	$ 8,212	$ 10,375	$ 11,815
Exercisable, Aggregate Intrinsic Value	$ 2,342

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Taxes [Line Items]
Undistributed earnings offsetting with dividend received deduction percent	100%
Valuation allowance	$ 35,888	$ 36,671
Total unrecognized tax benefits	$ 5,486	6,185	$ 5,665	$ 4,967
U.S. State | Earliest Tax Year
Income Taxes [Line Items]
Operating loss carryforward, year of expiration	2024
U.S. State | Latest Tax Year
Income Taxes [Line Items]
Operating loss carryforward, year of expiration	2042
Non-U.S. Subsidiaries
Income Taxes [Line Items]
Operating loss carryforward, amount	$ 296,334
Net operating loss carryforward, year of expiration	no expiration date
Valuation allowance	$ 16,413
Foreign Jurisdictions
Income Taxes [Line Items]
Income tax holiday, description	The Company currently benefits from tax holidays in various non-U.S. jurisdictions with expiration dates from 2024 – 2025
Income tax holiday, income in foreign jurisdictions	$ 8,185	$ 2,414	$ 4,721

Income Taxes - Earnings Before

Income Taxes - Earnings Before Income Taxes and Tax Provisions - (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Earnings (loss) before income tax:
Domestic	$ (37,222)	$ (34,211)	$ (4,547)
Foreign	92,176	72,593	118,399
Earnings before income tax	$ 54,954	$ 38,382	$ 113,852

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Current income tax expense:
Federal	$ 3,510	$ 3,006	$ 1,944
State and local	414	650	234
Foreign	23,759	17,607	18,390
Total current income tax expense	27,683	21,263	20,568
Deferred income tax (benefit) expense:
Federal	(7,495)	(5,971)	(4,400)
State and local	444	(213)	(91)
Foreign	(6,021)	(1,138)	4,341
Total deferred (benefit) income tax expense	(13,072)	(7,322)	(150)
Total income tax expense	$ 14,611	$ 13,941	$ 20,418

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets and Deferred Tax Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets:
Net operating losses	$ 44,053	$ 43,296
Intangible assets	4,314	4,417
Research and development credits	7,127	7,835
Property and equipment	4,800	6,983
Valuation reserves and accrued liabilities	11,221	8,388
Capitalized Research and Development Costs	23,658	19,087
Stock compensation	3,227	3,051
Defined benefit obligation	1,691	1,265
Inventory	181	6,762
Other credits	8,946	10,296
Other	9,154	790
Total deferred tax asset	118,372	112,170
Valuation allowance	(35,888)	(36,671)
Deferred tax liabilities:
Unrealized foreign currency exchange gains		(2,413)
Undistributed profits of subsidiary	(4,609)	(5,981)
Property and equipment	(12,627)	(15,423)
Other	(1,550)	(3,056)
Total deferred tax liability	(18,786)	(26,873)
Net deferred tax asset	$ 63,698	$ 48,626

Income Taxes - Reconciliations

Income Taxes - Reconciliations Between Statutory Federal Income Tax Rate and Effective Rate (Detail)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Statutory Federal income tax rate	21%	21%	21%
Increase (decrease) resulting from:
Change in valuation allowance	(3.10%)	6.40%	(1.20%)
Effect of different tax rates of foreign jurisdictions	0.90%	(4.90%)	(5.20%)
Tax credits & deductions related to R&D	(8.50%)	(10.10%)	(2.30%)
Goodwill impairment	4.10%
Non-deductible expenses	6.80%	14.90%	1.70%
Non-deductible expenses related to acquisitions		7%
Other foreign, state and local taxes	3.50%	0.70%	1.60%
Tax impact of foreign income	3.60%	4.20%	3.60%
Stock Option Compensation		(3.80%)	(2.00%)
Prior year adjustments	0.70%	1.70%	(0.70%)
Other	(2.40%)	(0.80%)	1.40%
Effective rate	26.60%	36.30%	17.90%

Income Taxes - Net Operating Lo

Income Taxes - Net Operating Loss Carryforwards (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
U.S. state income tax
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, amount	$ 51,235
U.S. state income tax | Minimum
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, year of expiration	2024
U.S. state income tax | Maximum
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, year of expiration	2042
Foreign, Never
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, amount	$ 296,334
Operating loss carryforward, year of expiration	Never

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Balance at beginning of year	$ 6,185	$ 5,665	$ 4,967
Additions based on tax position related to current year	87	972	1,105
Additions based on tax position related to prior year	347	433	160
Reductions from settlements and statute of limitation expiration	(1,266)	(610)	(312)
Effect of foreign currency translation	(133)	(275)	(255)
Balance at end of year	$ 5,486	$ 6,185	$ 5,665

Segment Reporting - Segment Inf

Segment Reporting - Segment Information about Reported Product Revenues, Depreciation and Amortization and Operating Income (Loss) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Product revenues	$ 1,469,076	$ 1,204,656	$ 1,046,150
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Depreciation and amortization	$ 50,948	$ 44,394	$ 38,780
Operating income (loss)	77,439	48,307	115,006
Automotive Segments
Segment Reporting Information [Line Items]
Product revenues	$ 1,422,952	$ 1,161,616	$ 1,004,633
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Depreciation and amortization	$ 45,845	$ 39,815	$ 35,389
Operating income (loss)	185,956	118,433	162,994
Medical Segments
Segment Reporting Information [Line Items]
Product revenues	$ 46,124	$ 43,040	$ 41,517
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Depreciation and amortization	$ 3,654	$ 3,344	$ 2,460
Operating income (loss)	$ (22,234)	$ (4,029)	$ (1,829)
Corporate Segments
Segment Reporting Information [Line Items]
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Depreciation and amortization	$ 1,449	$ 1,235	$ 931
Operating income (loss)	$ (86,283)	$ (66,097)	$ (46,159)

Segment Reporting - Segment I_2

Segment Reporting - Segment Information About Reported Segment Product Revenues by Product Category (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Product revenues		$ 1,469,076	$ 1,204,656	$ 1,046,150
Automotive Segments
Segment Reporting Information [Line Items]
Product revenues		1,422,952	1,161,616	1,004,633
Automotive Segments | Climate Control Seat
Segment Reporting Information [Line Items]
Product revenues		482,665	426,046	393,816
Automotive Segments | Seat Heaters
Segment Reporting Information [Line Items]
Product revenues		308,588	283,970	270,054
Automotive Segments | Steering Wheel Heaters
Segment Reporting Information [Line Items]
Product revenues		153,943	120,949	102,496
Automotive Segments | Lumbar and Massage Comfort Solutions
Segment Reporting Information [Line Items]
Product revenues	[1]	144,923	56,980
Automotive Segments | Valve Systems
Segment Reporting Information [Line Items]
Product revenues	[1]	106,262	41,980
Automotive Segments | Automotive Cables
Segment Reporting Information [Line Items]
Product revenues		79,993	76,962	84,114
Automotive Segments | Battery Performance Solutions
Segment Reporting Information [Line Items]
Product revenues		75,484	71,907	69,594
Automotive Segments | Electronics
Segment Reporting Information [Line Items]
Product revenues		40,387	44,106	51,648
Automotive Segments | Other Automotive
Segment Reporting Information [Line Items]
Product revenues		30,707	38,716	32,911
Industrial Segments | Medical
Segment Reporting Information [Line Items]
Product revenues	[1]	$ 46,124	$ 43,040	$ 41,517
[1] Includes product revenues from acquisitions since their respective acquisition dates (see Note 4).

Segment Reporting (Detail)

Segment Reporting (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Product revenues	$ 1,469,076	$ 1,204,656	$ 1,046,150
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
United States
Segment Reporting Information [Line Items]
Product revenues	$ 537,096	$ 472,468	$ 404,466
China
Segment Reporting Information [Line Items]
Product revenues	221,512	183,419	142,816
South Korea
Segment Reporting Information [Line Items]
Product revenues	115,854	94,937	93,516
Germany
Segment Reporting Information [Line Items]
Product revenues	102,383	75,367	66,929
Czech Republic
Segment Reporting Information [Line Items]
Product revenues	69,714	49,293	43,931
Japan
Segment Reporting Information [Line Items]
Product revenues	60,879	57,718	63,527
Romania
Segment Reporting Information [Line Items]
Product revenues	53,982	47,532	51,367
Mexico
Segment Reporting Information [Line Items]
Product revenues	45,733	23,233	18,194
Slovakia
Segment Reporting Information [Line Items]
Product revenues	44,946	34,686	30,004
Finland
Segment Reporting Information [Line Items]
Product revenues	39,632	33,627	29,325
Other
Segment Reporting Information [Line Items]
Product revenues	177,345	132,376	102,075
Non U.S.
Segment Reporting Information [Line Items]
Product revenues	$ 931,980	$ 732,188	$ 641,684

Segment Reporting - Percentage

Segment Reporting - Percentage of Total Product Revenues Generated from Customers (Detail) - Sales Revenue, Net - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Lear
Segment Reporting Information [Line Items]
Total product revenues in percentage	15%	16%	15%
Adient
Segment Reporting Information [Line Items]
Total product revenues in percentage	13%	15%	15%

Segment Reporting - Segment Rep

Segment Reporting - Segment Reporting About Property and Equipment, Net by Geographic Areas (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Property and equipment, net	$ 245,234	$ 244,480
Germany
Segment Reporting Information [Line Items]
Property and equipment, net	46,586	47,342
China
Segment Reporting Information [Line Items]
Property and equipment, net	45,429	43,162
Mexico
Segment Reporting Information [Line Items]
Property and equipment, net	39,943	31,597
United States
Segment Reporting Information [Line Items]
Property and equipment, net	37,413	41,034
North Macedonia
Segment Reporting Information [Line Items]
Property and equipment, net	27,675	27,808
Vietnam
Segment Reporting Information [Line Items]
Property and equipment, net	21,664	19,808
Czech Republic
Segment Reporting Information [Line Items]
Property and equipment, net	11,126	11,381
Ukraine
Segment Reporting Information [Line Items]
Property and equipment, net	5,986	5,077
Hungary
Segment Reporting Information [Line Items]
Property and equipment, net	9,097	11,736
Other
Segment Reporting Information [Line Items]
Property and equipment, net	$ 315	$ 5,535

Valuation and Qualifying Acco_2

Valuation and Qualifying Accounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Allowance for Deferred Income Tax Assets
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	$ 36,671	$ 16,090	$ 17,197
Charged to Costs and Expenses	(1,746)	2,482	357
Other Activity	963	18,099	(102)
Deductions from Reserves			(1,362)
Balance at End of Period	35,888	36,671	16,090
Reserve for Inventory
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	19,246	6,014	7,141
Charged to Costs and Expenses	6,867	15,923	2,499
Other Activity	3,876	(133)	(134)
Deductions from Reserves	(1,972)	(2,558)	(3,492)
Balance at End of Period	$ 28,017	$ 19,246	$ 6,014